protocolSection
dict | hasResults
bool 2
classes | documentSection
dict |
|---|---|---|
{
"armsInterventionsModule": {
"interventions": [
{
"name": "transcranial magnetic stimulation"
}
]
},
"conditionsModule": {
"conditions": [
"Healthy"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The project examines electroencephalography, MRI, and behavioral measures indexing flexibility (critical state dynamics) in the brain when healthy young adults do demanding cognitive tasks, and in response to transcranial magnetic stimulation."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "CROSSOVER",
"interventionModelDescription": "The study will involve three sessions of within-subject, crossover, double-blind transcranial magnetic stimulation with either 1) active intermittent theta burst stimulation, 2) active continuous theta burst stimulation or 3) sham intermittent or continuous theta burst stimulation.",
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": "Participants numbers will be assigned three blinded codes which are linked with either sham, active continuous, or active intermittent theta burst stimulation in the stimulator protocol. The investigator will enter the code to initiate the corresponding stimulator protocol, but will not know which protocol is active.Half of participants will be assigned a sham code corresponding to sham continuous theta burst stimulation and half will be assigned a sham code corresponding to sham intermittent theta burst stimulation. So, for any given session, either continuous or intermittent theta burst stimulation will be used, but it will be unclear whether the stimulation is active or sham.",
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "BASIC_SCIENCE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 60,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "45 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Brain Criticality, Oculomotor Control, and Cognitive Effort",
"nctId": "NCT06344559",
"orgStudyIdInfo": {
"id": "2023001006",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Critical dynamics - immediate effects of cTBS versus sham stimulation"
},
{
"measure": "Functional E/I balance - immediate effects of cTBS versus sham stimulation"
},
{
"measure": "Avalanche branching ratio - immediate effects of cTBS versus sham stimulation"
},
{
"measure": "Critical dynamics - immediate effects of iTBS versus sham stimulation"
},
{
"measure": "Functional E/I balance - immediate effects of iTBS versus sham stimulation"
},
{
"measure": "Avalanche branching ratio - immediate effects of iTBS versus sham stimulation"
},
{
"measure": "Memory-guided saccade accuracy - effects of cTBS versus sham stimulation"
},
{
"measure": "Memory-guided saccade accuracy - effects of iTBS versus sham stimulation"
},
{
"measure": "Anti-saccade accuracy - effects of cTBS versus sham stimulation"
},
{
"measure": "Anti-saccade accuracy - effects of iTBS versus sham stimulation"
},
{
"measure": "Subjective effort discounting - cTBS versus sham stimulation"
},
{
"measure": "Subjective effort discounting - iTBS versus sham stimulation"
},
{
"measure": "Subjective effort rating - cTBS versus sham stimulation"
},
{
"measure": "Subjective effort rating - iTBS versus sham stimulation"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Rutgers, The State University of New Jersey"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-06-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-12-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | {
"largeDocumentModule": {
"largeDocs": [
{
"date": "2024-03-17",
"filename": "Prot_000.pdf",
"hasIcf": false,
"hasProtocol": true,
"hasSap": false,
"label": "Study Protocol",
"size": 1099938,
"typeAbbrev": "Prot",
"uploadDate": "2024-03-27T17:23"
},
{
"date": "2023-07-30",
"filename": "ICF_001.pdf",
"hasIcf": true,
"hasProtocol": false,
"hasSap": false,
"label": "Informed Consent Form",
"size": 711815,
"typeAbbrev": "ICF",
"uploadDate": "2024-03-27T17:01"
}
]
}
} |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Metabolomics"
}
]
},
"conditionsModule": {
"conditions": [
"Critical Illness",
"Refeeding Syndrome",
"Hypophosphatemia"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Prague",
"contacts": null,
"country": "Czechia",
"facility": "University Hospital Královské Vinohrady",
"geoPoint": {
"lat": 50.08804,
"lon": 14.42076
},
"state": null,
"status": null,
"zip": null
},
{
"city": "Foggia",
"contacts": null,
"country": "Italy",
"facility": "University Hospital Policlinico of Foggia",
"geoPoint": {
"lat": 41.45845,
"lon": 15.55188
},
"state": null,
"status": null,
"zip": null
},
{
"city": "Huddinge",
"contacts": [
{
"email": "[email protected]",
"name": "Martin Sundström Rehal, MD PhD",
"phone": "+46-8-12381507",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Olav Rooyackers, PhD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Sweden",
"facility": "Karolinska University Hospital",
"geoPoint": {
"lat": 59.23705,
"lon": 17.98192
},
"state": "Stockholm",
"status": null,
"zip": "14186"
},
{
"city": "Stockholm",
"contacts": [
{
"email": "[email protected]",
"name": "Jonas Blixt, MD PhD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Sweden",
"facility": "Karolinska Universitetssjukhuset Solna",
"geoPoint": {
"lat": 59.33258,
"lon": 18.0649
},
"state": null,
"status": null,
"zip": null
},
{
"city": "Stockholm",
"contacts": [
{
"email": "[email protected]",
"name": "Rebecka Rubenson Wahlin, MD PhD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Sweden",
"facility": "Södersjukhuset",
"geoPoint": {
"lat": 59.33258,
"lon": 18.0649
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The overall aim of the study is to improve understanding of refeeding syndrome (RFS) in patients admitted to the intensive care unit (ICU) using metabolomics. Patients are included as part of a prospective multicenter observational study on phosphate disorders in the ICU. Blood samples are collected day 1-7 of ICU stay. Samples from patients who develop refeeding hypophosphatemia and matched controls without hypophosphatemia are analysed for metabolomics and proteomics. Untargeted analyses will be performed to identify the affected metabolic pathways. The investigators will also perform AUROC analyses to identify potential biomarkers for early detection of RFS."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CONTROL",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 500,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Metabolic Pathway Analysis in Intensive Care Unit Patients With Refeeding Syndrome",
"nctId": "NCT06344546",
"orgStudyIdInfo": {
"id": "K 2023-10247",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Metabolomics"
}
],
"secondaryOutcomes": [
{
"measure": "Metabolomics"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Karolinska University Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-06"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-06"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "JMKX003142 Injection"
},
{
"name": "Placebo"
}
]
},
"conditionsModule": {
"conditions": [
"Healthy Adult"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Beijing",
"contacts": [
{
"email": null,
"name": "Haiyan Li",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Haiyan Li, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Dongyang Liu, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "China",
"facility": "Peking University Third Hospital",
"geoPoint": {
"lat": 39.9075,
"lon": 116.39723
},
"state": "Beijing",
"status": null,
"zip": "100191"
}
]
},
"descriptionModule": {
"briefSummary": "To Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003142 Injection Administered Randomly, Double-blind, Placebo-controlled, Single-ascending Dose and Multiple-ascending Doses in Chinese Healthy Adult Subjects"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 78,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "45 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Study of JMKX003142 Injection in Chinese Healthy Subjects",
"nctId": "NCT06344533",
"orgStudyIdInfo": {
"id": "JMKX003142iv-101",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Number of the Adverse Events that are related to the single dose treatment"
},
{
"measure": "Number of the Adverse Events that are related to the multiple dose treatment"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Zhejiang Hangyu Pharmaceutical Co., Ltd"
}
],
"leadSponsor": {
"class": "INDUSTRY",
"name": "Jemincare"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-05-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-01-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-10"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "pektoralis minor shortnes"
},
{
"name": "Group in which the Pectoralis Minor stretching exercise was performed in a sham manner"
},
{
"name": "The group in which Pectoralis Minor stretching exercise was not applied"
}
]
},
"conditionsModule": {
"conditions": [
"The Study Will Not be Based on Any Disease",
"Ability to Swim 100m Independent Freestyle",
"Be Between the Ages of 9-16",
"Continuing Running as Part of a Sports Club"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Üsküdar",
"contacts": null,
"country": "Turkey",
"facility": "Galatasaray Ergün Gürsoy Olympic Swimming Pool",
"geoPoint": {
"lat": 41.02252,
"lon": 29.02369
},
"state": "Nuhkuyusu",
"status": null,
"zip": "34662"
}
]
},
"descriptionModule": {
"briefSummary": "Swimming is one of the sports branches that includes many factors such as aerobic and anaerobic endurance, strength, flexibility, speed, quickness, rhythm, coordination as well as sportive performance and technical skills.Athletes must have a high level of fitness, strength, coordination, agility, speed and motor control to perform at an elite level with minimal injury risk.Repetitive upper extremity movements imposed by freestyle swimming may lead to changes in muscle length and tension by paving the way for postural misalignment in adolescent swimmers.As can be seen in the studies, young swimmers who are preparing for the competition have postural disorders and injuries related to use, such as decreased posture, shoulder joint range of motion and subacromial distance.Pectoralis minor stretching exercise to be performed in swimmers is aimed to improve swimming performance and prevent possible postural disorders by contributing to the increase of maximal shoulder muscle strength as well as correcting the incorrectly developed posture in children."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "three groups as intervention, exercises group non- exercises group and scham",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "HEALTH_SERVICES_RESEARCH",
"timePerspective": null
},
"enrollmentInfo": {
"count": 91,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "16 Years",
"minimumAge": "9 Years",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Pectoralis Minor Shorthening and Swimming Performance",
"nctId": "NCT06344520",
"orgStudyIdInfo": {
"id": "IsiU",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Speed Tests"
},
{
"measure": "Apley test"
},
{
"measure": "Round Shoulder"
},
{
"measure": "Anthropometric Measurement:"
},
{
"measure": "Posture analysis: (ANNEX2)"
},
{
"measure": "Anthropometric Measurement 2"
},
{
"measure": "Y Balance Test"
},
{
"measure": "Eurofit Test Battery"
},
{
"measure": "Eurofit Test Battery 2"
},
{
"measure": "Eurofit Test Battery 3"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Istinye University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-10-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-08-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-12-29"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": null,
"conditionsModule": {
"conditions": [
"Pancreas Neoplasm",
"Cancer of Pancreas",
"Pancreatitis",
"Neuroendocrine Tumors"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Milan",
"contacts": [
{
"email": "[email protected]",
"name": "Matteo Tacelli, MD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Italy",
"facility": "IRCCS San Raffaele Hospital",
"geoPoint": {
"lat": 45.46427,
"lon": 9.18951
},
"state": null,
"status": "RECRUITING",
"zip": "20132"
}
]
},
"descriptionModule": {
"briefSummary": "The aim of the TAILOR-EUS study (Iconographic Registry of Bilio-Pancreatic Endoscopic Ultrasound Procedures) is to establish a clinical registry comprising images and videos generated during endoscopic procedures conducted for the investigation of pancreatic diseases (PD). The study will compile historical, pathological, and imaging data from approximately 12,000 patients (2,000 retrospectively and 10,000 prospectively) who underwent endoscopic ultrasound procedures for inflammatory pancreatic conditions (e.g., acute, recurrent, chronic pancreatitis), autoimmune bilio-pancreatic diseases (e.g., autoimmune pancreatitis), neoplastic bilio-pancreatic conditions, and screenings for individuals at high risk of developing such diseases at the Bilio-Pancreatic Endoscopy and Endoscopic Ultrasound Unit of the IRCCS San Raffaele Hospital between 2000 and 2027.Participants have undergone or will undergo the standard diagnostic pathway appropriate for their conditions as part of routine clinical practice. All instrumental examinations and endoscopic ultrasound procedures are integral to the standard diagnostic and therapeutic approach for pancreatic diseases."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "OTHER"
},
"enrollmentInfo": {
"count": 12000,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "TAILOR-EUS",
"briefTitle": "Iconographic Registry of Pancreatobiliary Endoscopy Procedures",
"nctId": "NCT06344507",
"orgStudyIdInfo": {
"id": "TAILOR-EUS",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Registry for images and videos"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "IRCCS San Raffaele"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-03-28"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Arch EchoTM Intracardiac Ultrasound catheter and ultrasound system"
},
{
"name": "SOUNDSTAR 3D Diagnostic Ultrasound catheter and ACUSON P500 system"
}
]
},
"conditionsModule": {
"conditions": [
"Structural Heart Diseases",
"Atrial Septal Defect",
"Patent Foramen Ovale",
"Arrhythmias, Cardiac",
"Atrial Fibrillation",
"Supraventricular Tachycardia",
"Valve Disease, Heart"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Beijing",
"contacts": [
{
"email": "[email protected]",
"name": "Deyong Long, MD, PhD",
"phone": "64412431",
"phoneExt": "0086010",
"role": "CONTACT"
},
{
"email": null,
"name": "Ribo Tang, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "China",
"facility": "Beijing Anzhen Hospital, Capital Medical University",
"geoPoint": {
"lat": 39.9075,
"lon": 116.39723
},
"state": "Bejing",
"status": null,
"zip": "100011"
},
{
"city": "Changzhou",
"contacts": [
{
"email": "[email protected]",
"name": "Ling Yang, MD",
"phone": "68873108",
"phoneExt": "00860519",
"role": "CONTACT"
},
{
"email": null,
"name": "Ling Yang, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Bo Qian, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "China",
"facility": "The First People's Hospital of Changzhou",
"geoPoint": {
"lat": 31.77359,
"lon": 119.95401
},
"state": "Jiangsu",
"status": null,
"zip": "213004"
},
{
"city": "Changchun",
"contacts": [
{
"email": "[email protected]",
"name": "Shuyan Li, MD, PhD",
"phone": "88782222",
"phoneExt": "00860431",
"role": "CONTACT"
},
{
"email": null,
"name": "Shuyan Li, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Hongbo Meng",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "China",
"facility": "The First Hospital Of Jilin University",
"geoPoint": {
"lat": 43.88,
"lon": 125.32278
},
"state": "Jilin",
"status": null,
"zip": "130021"
},
{
"city": "Shanghai",
"contacts": [
{
"email": null,
"name": "Songwen Chen, MD, PhD",
"phone": "18017638339",
"phoneExt": "0086",
"role": "CONTACT"
},
{
"email": null,
"name": "Songwen Chen, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Juan Sun",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "China",
"facility": "Shanghai General Hospital",
"geoPoint": {
"lat": 31.22222,
"lon": 121.45806
},
"state": "Shanghai",
"status": null,
"zip": "200081"
}
]
},
"descriptionModule": {
"briefSummary": "The INTELICE trial is a prospective, multicenter, 1:1 randomized controlled non-inferiority study. It aims to compare a novel intracardiac echography (ICE) catheter and combined ultrasound system with existing commercial ones. The evaluation will be conducted on patients undergoing planned intracardiac interventional process."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "OTHER",
"timePerspective": null
},
"enrollmentInfo": {
"count": 130,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "90 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "INTELICE",
"briefTitle": "Cardiac Interventional ICE Imaging Trial",
"nctId": "NCT06344494",
"orgStudyIdInfo": {
"id": "INTELICE-CTP-2401",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Device performance"
}
],
"primaryOutcomes": [
{
"measure": "Image quality"
}
],
"secondaryOutcomes": [
{
"measure": "Image quality"
},
{
"measure": "Procedure success"
},
{
"measure": "Technical success"
},
{
"measure": "Procedure time"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "ICE Intelligent Healthcare Co., Ltd"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-05"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-04"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-05"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Surgical (Hyalex Cartilage Knee Implant)"
}
]
},
"conditionsModule": {
"conditions": [
"Cartilage Injury"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Łódź",
"contacts": [
{
"email": "[email protected]",
"name": "Klaudia Marchewa",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Marcin Domzalski, M.D.",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Poland",
"facility": "SPORTO",
"geoPoint": {
"lat": 51.75,
"lon": 19.46667
},
"state": null,
"status": "RECRUITING",
"zip": "09-038"
}
]
},
"descriptionModule": {
"briefSummary": "The Hyalex First-in-Human Study is a prospective, multicenter, open-label, single-arm, 2-phase, first-in-human study to evaluate the safety and technical performance of the HYALEX Knee Cartilage System for replacement of loss of articular cartilage and bone of the knee femoral condyles in symptomatic patients who require surgical treatment."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 15,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "21 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The Hyalex First-in-Human Study",
"nctId": "NCT06344481",
"orgStudyIdInfo": {
"id": "CL-00003",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Freedom from implant rejection and infection."
},
{
"measure": "Change in the Knee Injury & Osteoarthritis Outcome Score (KOOS) from baseline at 12 months."
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Hyalex Orthopaedics, Inc."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-09"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-12"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-09"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-07"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Early Mobilization"
}
]
},
"conditionsModule": {
"conditions": [
"Early Mobilization",
"Sleep Quality",
"Critical Care",
"Nursing Caries"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Istanbul",
"contacts": null,
"country": "Turkey",
"facility": "İstanbul University-Cerrahpaşa Cerrahpaşa School of Medicine",
"geoPoint": {
"lat": 41.01384,
"lon": 28.94966
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this is randomized controlled study to examine the effect of early mobilization on sleep, physiological parameters, and length of stay in the intensive care unit (ICU).The hypothesis are:Hypothesis I: Early mobilization positively affects the sleep quality of patients.Hypothesis II: Early mobilization positively affects the physiological parameters of patients (respiratory rate, heart rate, blood pressure, body temperature, pain).Hypothesis III: Early mobilization shortens the length of stay of patients in the intensive care unit (ICU).Early mobilization will begin in the experimental group after sedation is discontinued within the first 12 hours and its effects disappear. In early mobilization, in the evaluation of in-bed mobilization, physiological parameters (respiratory rate, sPO 2, heart rate, blood pressure, body temperature, pain) will be evaluated and recorded in the supine, semi-fowler position. In out-of-bed mobilization, the patient's physiological parameters (respiratory rate, sPO 2, heart rate, blood pressure, body temperature, pain) will be determined and recorded before mobilization and when the head is in a 45˚ upward position. Surgical wounds and dressing areas, if any, are protected, drains are identified, care is taken not to remove equipment such as urinary catheters or nasogastric tubes, when the patient is seated on the edge of the bed with the help of a nurse, when he/she is stood up next to the bed with the support of the nurse, when he/she is made to sit in a chair next to the bed and when he/she is in a chair. While sitting, 1st minute, 5th minute, 10th minute respiratory rate, sPO2, heart rate, blood pressure, body temperature values and pain levels will be recorded and these data will be evaluated on their own. During mobilization, if the patient develops chest pain, arrhythmia, hypertension (systolic pressure\\>160 mmHg), or hypotension (systolic pressure\\<90 mmHg), tachypnea, or hypoxia, a break will be taken and the physician will be consulted. The same procedures will be repeated during the mobilization of the patient in the first 24-36 hours and the necessary records will be made by the researcher.Control Group:After admission to the Cardiovascular Surgery ICU, the type, purpose and implementation process of the study will be explained to the patients, and a routine/standard postoperative mobilization procedure will be applied to the patients in the control group. Accordingly, patients will be mobilized in the first 24 hours after surgery, and in the evaluation of in-bed mobilization, their physiological parameters (respiratory rate, sPO 2, heart rate, blood pressure, body temperature, pain) will be evaluated and recorded in the supine, semi-fowler position. In out-of-bed mobilization, the patient's physiological parameters (respiratory rate, sPO 2, heart rate, blood pressure, body temperature, pain) will be determined and recorded before mobilization and when the head is in a 45˚ upward position. Again, arterial blood gas monitoring of the patients in the control group will be performed at maximum 4-hour intervals, and respiratory parameters will be frequently evaluated and recorded."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 82,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The Effect of Early Mobilization on Sleep, Physiological Parameters, and Length of Stay in ICU",
"nctId": "NCT06344468",
"orgStudyIdInfo": {
"id": "531393",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The length of stay of patients in the intensive care unit"
}
],
"secondaryOutcomes": [
{
"measure": "The Richards-Campbell Sleep Questionnaire (RCSQ)"
},
{
"measure": "The Glasgow Coma Scale (GCS)"
},
{
"measure": "Physiological Parameter - for the experimental group"
},
{
"measure": "Physiological Parameter - for the control group"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Istanbul University - Cerrahpasa (IUC)"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-03-04"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-06-05"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-04-12"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "School Retention and Completion Incentive Savings via Modified Iowa Gambling Task A"
},
{
"name": "Iowa Gambling Task"
},
{
"name": "School Retention and Completion Incentive Savings via Modified Iowa Gambling Task B"
}
]
},
"conditionsModule": {
"conditions": [
"Delay Discounting"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The goal of this randomized clinical trial is to investigate how the Stay-and-Complete School Incentive Savings, part of the Pé-de-Meia Program, affects decision-making among low-income high school students, particularly their tendency towards delay discounting. This concept describes the preference for immediate gratifications over larger future rewards. The main questions it seeks to answer are:Can exposure to the specific educational stimuli of the Pé-de-Meia Program alter students' propensity for delay discounting? How do different levels of delay discounting influence students' decision-making regarding their studies and the utilization of the program's incentives?Participants will:Engage in a modified version of the Iowa Gambling Task (IGT), a computerized game that simulates decision-making under uncertainty, adapted to reflect the stimuli and choices related to the Pé-de-Meia Program.Complete questionnaires that measure their propensity for delay discounting and gather demographic and socioeconomic information.Researchers will compare the outcomes among groups of students exposed to different types of stimuli (aligned with the program's objectives, contrasting, and a control group without modifications) to see if the specific financial and educational incentives of the Pé-de-Meia Program influence how students value immediate rewards compared to future benefits. This study is expected to contribute to the improvement of public educational policies, encouraging school retention and promoting the educational success of low-income adolescents."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": null,
"whoMasked": [
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 120,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "24 Years",
"minimumAge": "14 Years",
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Influence of Educational Stimuli From the Pé-de-Meia Program on Delay Discounting Propensity",
"nctId": "NCT06344455",
"orgStudyIdInfo": {
"id": "RCT Delay Discounting",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Delay Discounting 1"
},
{
"measure": "Delay Discounting 2"
}
],
"secondaryOutcomes": [
{
"measure": "decision-making performance under risk and uncertainty"
},
{
"measure": "loss aversion"
},
{
"measure": "Loss Frequency-Based Decision Strategy"
},
{
"measure": "Learning"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Federal Institute of Education, Science and Technology of the State of Mato Grosso"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-07-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-12-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Arginine vasopressin"
},
{
"name": "Norepinephrine"
}
]
},
"conditionsModule": {
"conditions": [
"Acute Kidney Injury Post Liver Transplantation"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Paris",
"contacts": [
{
"email": "[email protected]",
"name": "Nabila PIZZI",
"phone": "01 40 05 49 83",
"phoneExt": "+33",
"role": "CONTACT"
},
{
"email": null,
"name": "Jaques DURANTEAU, Pr",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "France",
"facility": "URC Lariboisière-Fernand Widal-saint Louis",
"geoPoint": {
"lat": 48.85341,
"lon": 2.3488
},
"state": null,
"status": null,
"zip": "75010"
}
]
},
"descriptionModule": {
"briefSummary": "Liver transplantation (LT) is a high-risk surgery for hemodynamic instability and haemorrhagic shock with a high-risk of acute kidney injury (AKI). Indeed, the incidence of post-transplant AKI exceeds 50% in some series with 15% of patients requiring renal replacement therapy. Acute kidney injury after LT is a predisposing factor for chronic renal failure which is independently associated with higher morbidity and mortality.Arginine vasopressin (AVP), an essential stress hormone released in response to hypotension, binds to AVPR1a to promote vasoconstriction. Furthermore, it may have nephroprotective effects with a preferential vasoconstriction of the post-glomerular arteriole resulting in increased glomerular filtrationThe hypothesis of the present work is that low-dose arginine-vasopressin supplementation reduce posttransplant AKI in liver transplantation."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Prospective, national multicentre, double-blinded, randomized ,controlled superiority trial with two parallel arms",
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": "All the clinical teams involved intraoperatively (anaesthetists, nurse anaesthetists and surgeons) and postoperatively (doctors and nurses who will take care of the patient postoperatively) and the families will ignore the allocation of treatments for the duration of the trial,except the nurse in charge of preparing the infusions ,She will ensure respect for the blind",
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 304,
"type": "ESTIMATED"
},
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)",
"nctId": "NCT06344442",
"orgStudyIdInfo": {
"id": "APHP220827",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The primary objective is to compare the effect of intraoperative low-dose supplementation of AVP vs norepinephrine infusions on post-transplant Acute Kidney Injury after liver transplantation."
}
],
"secondaryOutcomes": [
{
"measure": "To compare into the two arms the number of packed red blood cellsand fresh frozen plasma transfused"
},
{
"measure": "To compare into the two arms the number of the Number of AKI KDIGO 1"
},
{
"measure": "To compare into the two arms the Number of AKI KDIGO 2"
},
{
"measure": "To compare into the Number of AKI KDIGO 3"
},
{
"measure": "The need for renal replacement for replacement therapy (RRT) in ICU"
},
{
"measure": "The number of patients remaining on dialysis at the end of the study"
},
{
"measure": "Average intraoperative norepinephrine concentrations"
},
{
"measure": "Average intraoperative concentrations of other vasopressors and inotropes (Adrenalin, Dobutamine)"
},
{
"measure": "Number of platelets transfused intraoperatively"
},
{
"measure": "Amount of vascular filling solutions intraoperatively"
},
{
"measure": "Sequential Organ Failure Assessment (SOFA score)"
},
{
"measure": "Number of days alive outside intensive care unit"
},
{
"measure": "Mortality"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Assistance Publique - Hôpitaux de Paris"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-06-05"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-06-05"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-05"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Stellest Lenses"
},
{
"name": "Stellest Lenses+0.05% atropine"
},
{
"name": "Single vision Lenses+0.05% atropine"
}
]
},
"conditionsModule": {
"conditions": [
"Myopia"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Kaohsiung",
"contacts": [
{
"email": null,
"name": "Pei-Chang Wu",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Pei-Chang Wu",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Taiwan",
"facility": "Kaohsiung Chang Gung Memorial Hospital",
"geoPoint": {
"lat": 22.61626,
"lon": 120.31333
},
"state": null,
"status": "RECRUITING",
"zip": "833401"
}
]
},
"descriptionModule": {
"briefSummary": "The prevalence of myopia is increasing globally, especially in Asian countries. 70-80% of the young population suffers from myopia, and almost 20% have high myopia. High myopia can easily lead to blinding diseases, including retinal detachment, macular degeneration, and glaucoma. In Taiwan, according to a survey by the National Health Administration, the proportion of myopia among Grade 1 students has exceeded 81%.There are many ways to control myopia progression. High concentrations of atropine have been reported highly effective in the control of the myopia progression. However the accompanied side effects such as photophobia and near blurred vision. Recent research shows that low-concentration atropine can achieve similar control effect and more acceptable with much minimal side effect compared to high concentration of atropine.Multiple animal experiments have confirmed that giving retinal myopia defocus signals can effectively decrease the growth of the eye, thereby inhibiting the progression of myopia. Therefore, regarding lens design, myopic defocus does play an important role in myopia control, including orthokeratology lenses, multifocal soft contact lenses, and peripheral defocus lenses.Stellest, a myopia control lens based on the myopia defocus theory, is equipped with highly aspheric lenslet technology. In a recent study, compared with single vision lenses, Stellest significantly slowed down the myopia progression reaching 67% and retard axial elongation reaching 64% The purpose of this study is to explore the effectiveness of Stellest Lenses in controlling myopia in Taiwanese children and whether Stellest Lenses combined with low-concentration atropine eye drops can increase the effect of myopia control."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 100,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "12 Years",
"minimumAge": "6 Years",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Stellest Lenses and Low-concentration Atropine Myopia Control Among Children",
"nctId": "NCT06344429",
"orgStudyIdInfo": {
"id": "STL_CT_0001",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Spherical equivalent refraction power"
},
{
"measure": "Axial length"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Essilor-Polylite Taiwan Co., Ltd."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-08-20"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-04"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-08-20"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-08-20"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Use of ReX to dispense and monitor solid oral medication therapy."
}
]
},
"conditionsModule": {
"conditions": [
"Any Solid Oral Medication"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Cincinnati",
"contacts": null,
"country": "United States",
"facility": "OHC",
"geoPoint": {
"lat": 39.12713,
"lon": -84.51435
},
"state": "Ohio",
"status": null,
"zip": "45242"
}
]
},
"descriptionModule": {
"briefSummary": "Primary Objective:• To assess the persistence of ReX technology platform use, measured by the percentage (%) of participants who used ReX: 1) throughout the study period and 2) before the treatment discontinuation.Secondary Objective:• To evaluate the impact of the ReX technology platform on ribo treatment duration and ribo dose taking adherence as compared to control group."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "SEQUENTIAL",
"interventionModelDescription": "Study groups",
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": "A minimum of 50 and a maximum of 200 patient charts are expected to be reviewed for the control study group.",
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 200,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform",
"nctId": "NCT06344416",
"orgStudyIdInfo": {
"id": "RXG-001-2024-CLP (Rex-002)",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Outcome MeasureReX Platform Study Group"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Dosentrx Ltd."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-01-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-03-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-30"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "analgesic"
},
{
"name": "Tender point infiltration"
}
]
},
"conditionsModule": {
"conditions": [
"Herpes Zoster",
"Local Infiltration",
"Acute Pain"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Beijing",
"contacts": [
{
"email": "[email protected]",
"name": "Luo Fang, M.D",
"phone": "+86 13611326978",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "China",
"facility": "Beijing Tiantan Hospital",
"geoPoint": {
"lat": 39.9075,
"lon": 116.39723
},
"state": "Beijing",
"status": "RECRUITING",
"zip": "100070"
}
]
},
"descriptionModule": {
"briefSummary": "Herpes zoster (HZ) is a skin infection disease which cause severe zoster-associated pain (ZAP) along sensory nerve in the corresponding segment. Evidence for the efficacy of existing local therapies for acute/subacute ZAP is limited. The hypothesis is that patients with acute/subacute ZAP treated with TPIs with local anesthetic and steroids under the basis of standard treatment will show better clinical outcomes compared with subjects treated with standard antiviral medicine treatment only."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "CROSSOVER",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 136,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Clinical Efficacy and Safety of Tender Point Infiltration (TPI) for Acute and Subacute Zoster Associated Pain",
"nctId": "NCT06344403",
"orgStudyIdInfo": {
"id": "KY2024-045-02",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The presence of postherpetic neuralgia using VAS score"
}
],
"secondaryOutcomes": [
{
"measure": "visual analogue scale score at each time point"
},
{
"measure": "Proportion of patients receiving repeated TPIs and block points"
},
{
"measure": "Consumption of oral drugs at each time point"
},
{
"measure": "The presence of PHN 3 and month 6 post treatment"
},
{
"measure": "Patient satisfaction scores on the 5-point Likert scale"
},
{
"measure": "Quality of life on the Scores on the WHOQOL-BREF"
},
{
"measure": "Adverse reactions through study completion"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Beijing Tiantan Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-03-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-10-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Pentoxifylline"
}
]
},
"conditionsModule": {
"conditions": [
"Cognitive Impairment"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Shijiazhuang",
"contacts": [
{
"email": "[email protected]",
"name": "Jiaying Rong",
"phone": "15241876265",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "China",
"facility": "BHan",
"geoPoint": {
"lat": 38.04139,
"lon": 114.47861
},
"state": null,
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "Pentoxifylline can improve cognitive impairment after ischemic stroke, possibly by improving the level of cerebral blood flow, affecting the content of blood oxygen and metabolic substances in the brain, and then playing a protective role in the transmission of nerve electrical signals, and ultimately improving cognitive function. The patients with cognitive impairment and non-dementia PSCIND after ischemic stroke were randomly divided into two groups. In addition to the basic drugs of ischemic stroke, the patients were given pentothemine sustained release tablets and blank control respectively to observe the effects of pentothemine on cognitive function and neuronal electrical signals in the patients with ischemic PSCIND. It is expected to explore the possible internal biological mechanism by using transcranial Doppler, oxygen-dependent functional magnetic resonance imaging and craniocerebral magnetic resonance pop analysis. Finally, statistical correlation analysis was used to elucidate the specific mechanism of pentoxifylline in improving cognitive function of non-dementia patients with cognitive impairment after ischemic stroke."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 200,
"type": "ESTIMATED"
},
"phases": [
"PHASE1",
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "40 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke",
"nctId": "NCT06344390",
"orgStudyIdInfo": {
"id": "20210327",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Pentoxifylline can improve cognitive impairment after ischemic stroke"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "The First Hospital of Hebei Medical University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-10-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-10"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Betaine"
},
{
"name": "Placebo"
}
]
},
"conditionsModule": {
"conditions": [
"Overweight and Obesity"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Poznań",
"contacts": [
{
"email": "[email protected]",
"name": "Agata Chmurzynska",
"phone": "+48 618466181",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Agata Chmurzynska",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Emilia Zawieja",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Monika Młodzik-Czyżewska",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Paweł Juszczak",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "Poland",
"facility": "Poznan University of Life Sciences",
"geoPoint": {
"lat": 52.40692,
"lon": 16.92993
},
"state": null,
"status": null,
"zip": "60-637"
}
]
},
"descriptionModule": {
"briefSummary": "Obesity represents a serious global health issue with significant consequences, including an increased risk of chronic diseases. Statistics indicate a growing trend of obesity, highlighting the need to seek methods that improve fat tissue metabolism and reduce obesity-related complications. Previous research on animals has shown that betaine, a substance engaged in one-carbon metabolism, may enhance fat oxidation and lower adipose tissue. Therefore, the aim of the research will be to assess the impact of 8-week betaine supplementation on body composition and lipid metabolism markers, as well as expression of genes related to lipid metabolism, in a group of adult women with abdominal obesity.This study is designed in a placebo-controlled, double-blinded, randomized fashion. The participants will be overweight or obese pre-menopausal females. Upon enrollment, participants will be randomly assigned to one of two parallel groups: betaine (3g/d) or placebo. The supplementation period will last for 8 weeks. There will be three study meetings: T1 before supplementation, T2 after 4 weeks of supplementation, and T3 after 8 weeks of supplementation. Blood will be drawn and body composition measured, and adipose tissue biopsy taken at meetings T1 and T3. The T2 meeting will involve only body composition measurement. Study outcomes will include body mass and composition (including body fat percent), lipid profile, and the expression of genes related to lipid metabolism in adipose tissue and peripheral blood mononuclear cells."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "BASIC_SCIENCE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 60,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "45 Years",
"minimumAge": "18 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Betaine Supplementation and Lipid Metabolism in Overweight and Obese Pre-menopausal Women",
"nctId": "NCT06344377",
"orgStudyIdInfo": {
"id": "BETadiposeWOMEN",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Body composition"
},
{
"measure": "Body mass"
},
{
"measure": "Waist and hips circumference"
},
{
"measure": "Lipid profile"
},
{
"measure": "Gene expression"
}
],
"secondaryOutcomes": [
{
"measure": "Liver function test"
},
{
"measure": "Dietary intake"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Poznan University of Life Sciences"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-12-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-05"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-12-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-21"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)"
}
]
},
"conditionsModule": {
"conditions": [
"Metabolic Dysfunction-associated Steatotic Liver Disease"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "New York",
"contacts": [
{
"email": "[email protected]",
"name": "Meena Bansal, MD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Icahn School of Medicine at Mount Sinai",
"geoPoint": {
"lat": 40.71427,
"lon": -74.00597
},
"state": "New York",
"status": null,
"zip": "10029"
},
{
"city": "Sha Tin",
"contacts": [
{
"email": "[email protected]",
"name": "Vincent Wong, PhD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Hong Kong",
"facility": "The Chinese University of Hong Kong",
"geoPoint": {
"lat": 22.38333,
"lon": 114.18333
},
"state": null,
"status": null,
"zip": null
},
{
"city": "Barcelona",
"contacts": [
{
"email": "[email protected]",
"name": "Isabel Graupera, PhD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Spain",
"facility": "Fundació de Recerca Clinic Barcelona",
"geoPoint": {
"lat": 41.38879,
"lon": 2.15899
},
"state": null,
"status": null,
"zip": null
},
{
"city": "Sevilla",
"contacts": [
{
"email": "[email protected]",
"name": "Manuel R Gómez, PhD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Spain",
"facility": "University of Seville",
"geoPoint": {
"lat": 37.38283,
"lon": -5.97317
},
"state": null,
"status": null,
"zip": "41004"
},
{
"city": "Edinburgh",
"contacts": [
{
"email": "[email protected]",
"name": "Jonathan Fallowfield, PhD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Timothy Kendall, PhD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United Kingdom",
"facility": "University of Edinburgh",
"geoPoint": {
"lat": 55.95206,
"lon": -3.19648
},
"state": "Scotland",
"status": null,
"zip": null
},
{
"city": "Edinburgh",
"contacts": [
{
"email": "[email protected]",
"name": "Quentin Anstee, PhD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Jo Boyle",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United Kingdom",
"facility": "University of Edinburgh",
"geoPoint": {
"lat": 55.95206,
"lon": -3.19648
},
"state": "Scotland",
"status": null,
"zip": null
},
{
"city": "London",
"contacts": [
{
"email": "[email protected]",
"name": "Pinelopi Manousou, PhD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United Kingdom",
"facility": "Imperial College London",
"geoPoint": {
"lat": 51.50853,
"lon": -0.12574
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The aim of this multi-center, retrospective epidemiologic study is to confirm the prognostic performance of the Digital Pathology (DP) FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS), derived from standard digital pathology liver biopsy images, in predicting clinical hepatic decompensation events in patients with metabolic dysfunction-associated steatohepatitis (MASH)."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "RETROSPECTIVE"
},
"enrollmentInfo": {
"count": 2000,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "DPAILO-1",
"briefTitle": "Digital Pathology and AI for Liver Outcomes in MASLD",
"nctId": "NCT06344364",
"orgStudyIdInfo": {
"id": "PHN 1-080-23",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Performance of Hepatic Decompensation Event predictive value of the FibroNest Ph-FCS"
}
],
"secondaryOutcomes": [
{
"measure": "Performance of Hepatic Decompensation Event predictive value of the FIB-4 biomarker, a non-invasive test"
},
{
"measure": "Performance of Hepatic Decompensation Event predictive value of the elastography (Fibroscan) biomarker, a non-invasive test"
},
{
"measure": "Performance of Hepatic Decompensation Event predictive value of the FibroNest Parenchymal Tissue Adjusted Phenotypic Fibrosis Composite Score (Pt-Ph-FCS)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Chinese University of Hong Kong"
},
{
"name": "University of Edinburgh"
},
{
"name": "University of Seville"
},
{
"name": "Imperial College London"
},
{
"name": "Icahn School of Medicine at Mount Sinai"
},
{
"name": "Fundacio Clinic Barcelona"
}
],
"leadSponsor": {
"class": "INDUSTRY",
"name": "PharmaNest, Inc"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-08"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "TQB3006 tablets"
}
]
},
"conditionsModule": {
"conditions": [
"Advanced Malignant Neoplasm"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Harbin",
"contacts": [
{
"email": "[email protected]",
"name": "Tongsen Zheng, Doctor",
"phone": "15134569619",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "China",
"facility": "Harbin Medical University Cancer Hospital",
"geoPoint": {
"lat": 45.75,
"lon": 126.65
},
"state": "Heilongjiang",
"status": "RECRUITING",
"zip": "150000"
}
]
},
"descriptionModule": {
"briefSummary": "This study includes two stage: dose escalation and dose extension, with a single dose and a multiple dose study. This is a single-center, open, non-randomized, single arm, study to evaluate the safety, tolerability and pharmacokinetics of TQB3006 tables in patients with advanced malignant cancer."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 93,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer",
"nctId": "NCT06344351",
"orgStudyIdInfo": {
"id": "TQB3006-I-01",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Dose limiting toxicity (DLT)"
},
{
"measure": "Maximum tolerated dose (MTD)"
},
{
"measure": "Recommended phase II dose (RP2D)"
}
],
"secondaryOutcomes": [
{
"measure": "Adverse events (AE)"
},
{
"measure": "Serious adverse events (SAE)"
},
{
"measure": "Time to reach maximum plasma concentration (Tmax)"
},
{
"measure": "Peak concentration (Cmax)"
},
{
"measure": "Half-life (t1/2)"
},
{
"measure": "Area under the concentration-time curve (AUC [0-infinity])"
},
{
"measure": "Area under the concentration-time curve (AUC [0-t])"
},
{
"measure": "Apparent clearance (CL/F)"
},
{
"measure": "Apparent volume of distribution (Vd/F)"
},
{
"measure": "Objective response rate (ORR)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Chia Tai Tianqing Pharmaceutical Group Co., Ltd."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-08"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-26"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-03"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-25"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "tDCS stimulation"
},
{
"name": "TDCS sham-stimulation"
}
]
},
"conditionsModule": {
"conditions": [
"Refractory Status Epilepticus"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Beijing",
"contacts": [
{
"email": "[email protected]",
"name": "Weibi Chen",
"phone": "+8615010255903",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "China",
"facility": "Xuanwu Hospital, Capital Medical University",
"geoPoint": {
"lat": 39.9075,
"lon": 116.39723
},
"state": "Beijing",
"status": "RECRUITING",
"zip": "100053"
}
]
},
"descriptionModule": {
"briefSummary": "The purpose of the study is to assess the efficacy and safety of targeting tDCS stimulation for treatment of Refractory status epilepticus"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "The patients who meet the eligibility requirements will be randomized in a 1:1 ratio to undergo targeting tDCS stimulation (up to 10 times) or sham stimulation",
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 32,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "14 Years",
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "tDCS",
"briefTitle": "Application of tDCS Stimulation in Controlling Refractory Status Epilepticus",
"nctId": "NCT06344338",
"orgStudyIdInfo": {
"id": "Z211100002921030",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Number of participants with status epilepticus termination between tDCS treatment group and tDCS sham--stimulation group as assessed by Salzburg Consensus Criteria for Non-Convulsive Status Epilepticus"
}
],
"secondaryOutcomes": [
{
"measure": "Number of participants with treatment-related adverse events between tDCS treatment group and tDCS sham--stimulation group"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Xuanwu Hospital, Beijing"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-03-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-31"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "fospropofol"
}
]
},
"conditionsModule": {
"conditions": [
"Elective Surgery"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Wuhan",
"contacts": [
{
"email": "[email protected]",
"name": "Aijun Xu, Dr.",
"phone": "+8618627784217",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "China",
"facility": "Tongji hospital",
"geoPoint": {
"lat": 30.58333,
"lon": 114.26667
},
"state": "Hubei",
"status": null,
"zip": "430030"
}
]
},
"descriptionModule": {
"briefSummary": "Exploring the 90% effective dose (ED90) of fospropofol disodium in induction and maintenance of anesthesia in adults of different ages, providing more clinical evidence for the application of fospropofol disodium in clinical anesthesia"
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 330,
"type": "ESTIMATED"
},
"phases": [
"PHASE4"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "ED90 of Fospropofol Disodium in Induction and Maintenance of Anesthesia",
"nctId": "NCT06344325",
"orgStudyIdInfo": {
"id": "EDPP",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Sedation score"
}
],
"secondaryOutcomes": [
{
"measure": "Postoperative adverse reactions"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Tongji Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-03-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-03-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Yangxue Qingnao Granules"
}
]
},
"conditionsModule": {
"conditions": [
"Stroke, Acute Ischemic"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Beijing",
"contacts": null,
"country": "China",
"facility": "Peking University Third Hospital",
"geoPoint": {
"lat": 39.9075,
"lon": 116.39723
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "Evaluate the effectiveness of Yangxue Qingnao Granules in preventing post thrombolytic hemorrhage transformation in patients with acute cerebral infarction, and explore its possible mechanism"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 60,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "50 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Effectiveness of Yangxue Qingnao Granules in Preventing Post Thrombolytic Hemorrhage Transformation in Patients With Acute Cerebral Infarction",
"nctId": "NCT06344312",
"orgStudyIdInfo": {
"id": "M2023551",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The proportion of subjects with mRS score ≤ 1 on the 90th day of treatment"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Peking University Third Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-06-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "ACTIVE_NOT_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-01-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-01-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "potential predictors"
}
]
},
"conditionsModule": {
"conditions": [
"Pancreatic Ductal Adenocarcinoma"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Shanghai",
"contacts": null,
"country": "China",
"facility": "Huadong Hospital affiliated to Fudan University",
"geoPoint": {
"lat": 31.22222,
"lon": 121.45806
},
"state": null,
"status": null,
"zip": "200040"
}
]
},
"descriptionModule": {
"briefSummary": "More and more older adults are diagnosed with pancreatic ductal adenocarcinoma (PDAC), but the rate of surgical resection in patients with resectable tumour is still low. Clinical workers need to take more attention to oncologic care in this group. It's significant to explore potential predictors for impacting elderly patients chose to abandon surgical resection."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CONTROL",
"primaryPurpose": null,
"timePerspective": "RETROSPECTIVE"
},
"enrollmentInfo": {
"count": 5302,
"type": "ACTUAL"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "100 Years",
"minimumAge": "75 Years",
"sex": "ALL",
"stdAges": [
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Predictors for Low Rates of Surgical Resection in Elderly Patients With Resectable Pancreatic Ductal Adenocarcinoma",
"nctId": "NCT06344299",
"orgStudyIdInfo": {
"id": "HuaDong Hosiptal of FUDAN",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "ORs of potential predictors"
}
],
"secondaryOutcomes": [
{
"measure": "Overall survival (OS)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Fudan University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-09-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-06-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-01-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Minimal enteral nutrition"
},
{
"name": "Distilled water"
}
]
},
"conditionsModule": {
"conditions": [
"Hypoxic-Ischemic Encephalopathy"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Istanbul",
"contacts": null,
"country": "Turkey",
"facility": "IstanbulTRH",
"geoPoint": {
"lat": 41.01384,
"lon": 28.94966
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this clinical trial is to evaluate the effects of minimal enteral nutrition (MEN) on mesenteric blood flow and oxygenation with Doppler USG and Near Infrared Spectroscopy (NIRS) during therapeutic hypo¬thermia (TH) in babies with hypoxic ischemic encephalopathy. The main question it aims to answer is:1- How do the mesenteric blood flow and oxygenation get affected with MEN during TH? Participants will be either fed with MEN during TH or given placebo."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "An enteral intake of breast milk with a volume of 10-20 mL/kg/day was defined as minimal enteral feeding. Minimal enteral feeding was initiated at postnatal 24 hours with breast milk via an orogastric tube. A total daily intake of 120 ml/kg/day was defined as full enteral feeding.The babies were randomized into two groups based on whether they received MEN during TH. While the babies fed with MEN during TH constituted the study group, the control group was composed of the babies who were given the same amount of distilled water according to the same protocol. Two groups were compared in terms of demographic characteristics, clinical outcomes, NIRS and Doppler measurements.",
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": "The feeding materials were prepared inside an opaque syringe and serially numbered by Total Parenteral Nutrition Department in our institution. The investigators who made all measurements, examinations and collected data, and the nurses of the babies were blinded. All of the infants in the study group were fed with breast milk during the trial.",
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 60,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "1 Day",
"minimumAge": "0 Days",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The Effects of Minimal Enteral Nutrition on Mesenteric Blood Flow and Oxygenation in Neonates With HIE",
"nctId": "NCT06344286",
"orgStudyIdInfo": {
"id": "IstanbulTRH-DArman-002",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Cerebral and mesenteric blood flow velocities and oxygenation"
},
{
"measure": "Cerebral and mesenteric rSO2 values"
}
],
"secondaryOutcomes": [
{
"measure": "Development of NEC"
},
{
"measure": "Feeding intolerance"
},
{
"measure": "Time to full enteral feeding"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER_GOV",
"name": "Istanbul Training and Research Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2022-10-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2022-08-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2020-09-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "ROM exercises"
}
]
},
"conditionsModule": {
"conditions": [
"Hemodialysis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Düzce",
"contacts": null,
"country": "Turkey",
"facility": "Duzce University",
"geoPoint": {
"lat": 40.83889,
"lon": 31.16389
},
"state": null,
"status": null,
"zip": "81000"
}
]
},
"descriptionModule": {
"briefSummary": "Range of motion (ROM) is a term used to describe the amount of motion in each joint in our body. Every joint in the body has a normal range of motion. Maintaining the normal opening of the joints is achieved through movement. ROM exercises reduce contractures and are very important in terms of helping to preserve muscle movements. ROM exercises are an inexpensive method that can be applied in any environment, either as a group or individually, covering all muscle-joint groups. Individuals with disabilities can perform ROM exercises individually or receive support from healthcare professionals. It provides support to venous return by increasing muscle strength in patients who are immobilized for a long time.Based on this information, the aim of our study is to investigate the effect of lower extremity ROM exercises during hemodialysis on hypotension, fatigue and hemodialysis comfort.The patients will be divided into the intervention group (n=32) in which 20 minutes of ROM exercise was applied and the control group (n=32) in which routine nursing care was given. For the sample calculation of the study, G power analysis was performed, type 1 error was 0.05; type 2 error 0.20; With a power of 0.80, a minimum sample size of 64 people for the experimental and control groups. The case group will be given lower extremity ROM exercises for a total of two weeks. Each individual in the case group will have lower extremity ROM exercises, each of which will last 20 minutes, at the beginning of the session and at the beginning of the hour until the end of the session. \"Piper's Fatigue Scale\" and Hemodialysis Comfort Scale\" in the data collection form will be applied again at the end of the 1st and 2nd weeks after the sessions have started. The vital signs of the individual will be followed and recorded at each session."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "The patients will be divided into the intervention group (n=32) in which 20 minutes of ROM exercise was applied and the control group (n=32) in which routine nursing care was given. For the sample calculation of the study, G power analysis was performed, type 1 error was 0.05; type 2 error 0.20; With a power of 0.80, a minimum sample size of 64 people for the experimental and control groups. The case group will be given lower extremity ROM exercises for a total of two weeks. Each individual in the case group will have lower extremity ROM exercises, each of which will last 20 minutes, at the beginning of the session and at the beginning of the hour until the end of the session. \"Piper's Fatigue Scale\" and Hemodialysis Comfort Scale\" in the data collection form will be applied again at the end of the 1st and 2nd weeks after the sessions have started. The vital signs of the individual will be followed and recorded at each session.",
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": "You are completely free to participate in the research or not. Not participating in this research will certainly not affect the service you receive. You have the right to withdraw from the study at any time by giving notice; you may also be excluded from the study by the investigator, if deemed necessary, provided that no harm is done to your medical condition.If you participate in the research, you will not be charged or paid any fees for the expenses to be made in the study. In addition, at the end of the research, your information will only serve scientific purposes without revealing your identity.",
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 70,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The Effect of Lower Extremity ROM Exercises on Hypotension, Fatigue, and Hemodialysis Comfort in Individuals",
"nctId": "NCT06344273",
"orgStudyIdInfo": {
"id": "Burcu01",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "follow-up form"
},
{
"measure": "Piper Fatigue Scale"
},
{
"measure": "comfort condition"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Duzce University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-10-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-08-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-07-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "human Neural Stem Cells (hNSC)"
},
{
"name": "Saline (Placebo)"
}
]
},
"conditionsModule": {
"conditions": [
"Amyotrophic Lateral Sclerosis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "San Giovanni Rotondo",
"contacts": null,
"country": "Italy",
"facility": "Casa Sollievo Della Sofferenza IRCCS",
"geoPoint": {
"lat": 41.70643,
"lon": 15.7277
},
"state": "Foggia",
"status": "NOT_YET_RECRUITING",
"zip": "71013"
},
{
"city": "Novara",
"contacts": [
{
"email": "[email protected]",
"name": "Letizia Mazzini, MD",
"phone": "+39 0321 3733962",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Italy",
"facility": "Centro SLA Azienda Ospedaliera Università Maggiore della Carità",
"geoPoint": {
"lat": 45.44694,
"lon": 8.62118
},
"state": null,
"status": "RECRUITING",
"zip": "28100"
},
{
"city": "Padua",
"contacts": [
{
"email": "[email protected]",
"name": "Gianni Sorarù, MD",
"phone": "+39049-8213645/646",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Italy",
"facility": "Azienda Ospedaliera di Padova",
"geoPoint": {
"lat": 45.40797,
"lon": 11.88586
},
"state": null,
"status": "NOT_YET_RECRUITING",
"zip": "35128"
},
{
"city": "Palermo",
"contacts": [
{
"email": "[email protected]",
"name": "Vincenzo La Bella, MD",
"phone": "+39 091 6555158",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Italy",
"facility": "Azienza Ospedaliera Universitaria - Policlinico \"P. Giaccone\" Università degli Studi di Palermo",
"geoPoint": {
"lat": 38.13205,
"lon": 13.33561
},
"state": null,
"status": "NOT_YET_RECRUITING",
"zip": "90129"
}
]
},
"descriptionModule": {
"briefSummary": "A Not for Profit Phase II Study to Evaluate Safety, Efficacy and Biomarkers secondary endpoints of Human Neural Stem cell intracerebroventricular transplantation in amyotrophic lateral sclerosis patients: a randomized, placebo controlled, triple blind study.This is an approximate 24-months study (PHASE B) consisting, per patient, of a 30-day screening period, 12-month enrollment and follow up period. A preliminary 3+3 dose-escalation open-label phase (PHASE A) will be performed in order to test the toxicity of the two proposed cell doses. The study will be stopped when all the subjects included in the treatment period complete the study visits. The study uses an ATMP, for that reason all the patients follow up will be prosecuted long life."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "This is an approximate 24-months triple-blinded, randomized, controlled vs placebo, in three arms study (PHASE B). A preliminary 3+3 dose-escalation open-label phase (PHASE A) will be performed in order to test the toxicity of the two proposed cell doses.In the phase B three arms will be: 1) hNSCs 20 milion cells 2) hNSCs 40 milion cells 3) Saline (comparator)",
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": "In order to blind also the statistician that will analyse the results the protocol has been designed as a triple-blinded protocol. This means that both the researchers, which include neurologist, neurosurgeon and biologist, as well as the patients and the statisticians are unaware of whether the participant received the treatment or the placebo (only IMP Manufacturer QP is unblinded since release the cell drug to the use in the surgery room)",
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 30,
"type": "ESTIMATED"
},
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "STEMALS",
"briefTitle": "Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis (STEMALS)",
"nctId": "NCT06344260",
"orgStudyIdInfo": {
"id": "hNSCALSII",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Safety of treatment"
}
],
"secondaryOutcomes": [
{
"measure": "Biological Endpoints"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Ministry of Health, Italy"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Casa Sollievo della Sofferenza IRCCS"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-09"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-03"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-01-25"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "RAS inhibitors：Losartan®️/Valsartan®️"
},
{
"name": "dapagliflozin：Forxiga®️"
},
{
"name": "simagliptin：Forxiga®️"
}
]
},
"conditionsModule": {
"conditions": [
"Obesity",
"Chronic Kidney Diseases"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Shanghai",
"contacts": [
{
"email": "[email protected]",
"name": "wei jin",
"phone": "+8615026696535",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "China",
"facility": "Renji Hospital Affiliated to Shanghai JIAO TONG University school of medicine",
"geoPoint": {
"lat": 31.22222,
"lon": 121.45806
},
"state": "Shanghai",
"status": "RECRUITING",
"zip": "200127"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this clinical trial is to exploring the changes in 24-hour urinary protein and renal function in obese patients with kidney disease after the application of sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon like peptide-1 receptor agonists (GLP-1RA).Eligible patients were randomly and non-blindly allocated to four groups in a 1:1:1:1 ratio.The first group is the optimized treatment group, and patients in this group maintain the maximum dose/maximum tolerated dose of RAS blocker therapy.The second group is the optimized treatment + SGLT2i group. Participants in this group are titrated to the target dose (10 mg qd) in combination with dapagliflozin on the basis of optimized treatment.The third group is the optimized treatment + GLP-1RA group. Participants in this group will be titrated to the target dose (1mg qw) in combination with semaglutide on the basis of optimized treatment.The last group is the optimized treatment + SGLT2i + GLP-1RA treatment group, that is, based on the optimized treatment, combined with dapagliflozin titrated to the target dose (10 mg qd) and semaglutide titrated to the target dose (1 mg qw)."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 48,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease",
"nctId": "NCT06344247",
"orgStudyIdInfo": {
"id": "IIT-2023-0253",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Change of 24-hour urine protein quantification"
}
],
"secondaryOutcomes": [
{
"measure": "Decline in glomerular filtration rate"
},
{
"measure": "Changes in BMI"
},
{
"measure": "changes in fasting blood glucose"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "RenJi Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-09-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-09-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "End-inspiratory Maneuvers"
}
]
},
"conditionsModule": {
"conditions": [
"Respiratory Disease",
"Artificial Respiration"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Bari",
"contacts": [
{
"email": "[email protected]",
"name": "Salvatore Grasso, MD, Professor",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Francesco Murgolo, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Domenico Luca Grieco, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Italy",
"facility": "Azienda ospedaliero-universitaria consorziale policlinico di Bari",
"geoPoint": {
"lat": 41.11148,
"lon": 16.8554
},
"state": null,
"status": "RECRUITING",
"zip": "70124"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this observational study is to evaluate whether the airway occlusion pressure recorded during a sudden end-expiratory breath-hold (ΔPocc) is correlated with esophageal swing in pressure and the reliability of P0.1, driving pressure, plateau pressure, pressure-muscle index, and diaphragm ultrasound as noninvasive estimates of inspiratory effort and lung distension in hypoxemic patients undergoing NIV.The main questions this trial aims to answer are:- Primary Outcome: whether the airway occlusion pressure recorded during a sudden end-expiratory breath-hold (ΔPocc) is correlated with esophageal swing in pressure and the reliability of various noninvasive estimates of inspiratory effort and lung distension in hypoxemic patients undergoing NIV.Secondary outcomes will include:* Statistic metric of association between P0.1, ΔP, PMI and ΔPes* Statistic metric of association between P0.1, ΔPocc, ΔP, PMI and PaO2/FiO2 ratio* Statistic metric of association between P0.1, ΔPocc, ΔP, PMI and tidal volume* Statistic metric of association between P0.1, ΔPocc, ΔP, PMI and DTF%* Statistic metric of association between P0.1, ΔPocc, ΔP, PMI and Ex/DTF%* Statistic metric of association between P0.1, ΔPocc, ΔP, PMI and respiratory rate, VAS dyspnea and VAS discomfort.Participants will undergo the following tasks and treatments:* Complete written informed consent before enrollment.* Post-extubation noninvasive ventilation via nose-to-mouth and full-face masks.* Monitoring of esophageal pressure (in all patients the catheter will be placed before extubation, according to clinical judgment, and its correct position will be verified through a positive pressure occlusion test)* Continuous recording of airway pressure, flow, and esophageal pressure (Pes), using a dedicated pneumotachograph and pressure transducer.* Sudden end-inspiratory and end-expiratory occlusion maneuvers, to measure plateau pressure (Pplat) and end-expiratory airway occlusion pressure (ΔPocc), respectively.* Collection of hemodynamic and arterial blood-gas parameters, performed according to clinical judgment, along with assessments of dyspnea and discomfort using a modified visual analogue scale (VAS).* Diaphragm ultrasound during occlusion maneuvers, measuring diaphragm displacement, diaphragm thickening fraction (DTF%), and diaphragmatic excursion (Ex) under various conditions."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 60,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "INSPIRE",
"briefTitle": "Non-invasive Assessment of Inspiratory Effort and Tidal Distension During Non-invasive Ventilation (INSPIRE)",
"nctId": "NCT06344234",
"orgStudyIdInfo": {
"id": "0049191",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Reliability of various noninvasive estimates of inspiratory effort and lung distension in hypoxemic patients undergoing NIV"
}
],
"primaryOutcomes": [
{
"measure": "Statistic metric of association between ΔPocc and ΔPes"
}
],
"secondaryOutcomes": [
{
"measure": "Statistic metric of association between P0.1, ΔP, PMI and ΔPes"
},
{
"measure": "Statistic metric of association between P0.1, ΔPocc, ΔP, PMI and PaO2/FiO2 ratio"
},
{
"measure": "Statistic metric of association between P0.1, ΔPocc, ΔP, PMI and tidal volume"
},
{
"measure": "Statistic metric of association between P0.1, ΔPocc, ΔP, PMI and DTF%"
},
{
"measure": "Statistic metric of association between P0.1, ΔPocc, ΔP, PMI and Ex/DTF%"
},
{
"measure": "Statistic metric of association between P0.1, ΔPocc, ΔP, PMI and respiratory rate, VAS dyspnea and VAS discomfort"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University of Bari"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-06-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-05-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-11-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Dextrain Manipulandum and haptic feedback device"
}
]
},
"conditionsModule": {
"conditions": [
"Stroke",
"Upper Extremity Paresis",
"Manual Dexterity",
"Sensory Integration Dysfunction",
"Vibration; Disorder"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The aim of this comparative and reliability study is to highlight a deficit in the use of vibrotactile sensory feedback (haptic effect) in the planning and execution of fine manual dexterity movements after stroke. The investigators will include 3 groups of subjects, 1 group of young healthy subjects, 1 of older subjects matched in age and sex to the group of chronic stroke patients. Participants will take part in clinical tests of fine motor skills and sensitivity and will use a device to assess the key components of manual dexterity, to which vibrotactile sensors will be added. If they so wish, participants will be able to take part in a transcranial magnetic stimulation (TMS) study to assess the facilitation of cortical excitability due to the haptic effect."
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "DIAGNOSTIC",
"timePerspective": null
},
"enrollmentInfo": {
"count": 90,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "HapticS",
"briefTitle": "Post-stroke Haptic Feedback Use Deficit: A Comparative and Reliability Study",
"nctId": "NCT06344221",
"orgStudyIdInfo": {
"id": "2023-A00954-41",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Assessing haptic effect during a dexterity exercise with and without sensory feedback: finger independence"
}
],
"secondaryOutcomes": [
{
"measure": "Assessing haptic effect during another dexterity exercise with and without sensory feedback: the force control of the index"
},
{
"measure": "Assessing haptic effect during another dexterity exercise with and without sensory feedback: the rhythm capacity"
},
{
"measure": "Correlation between clinical assessment and haptic measure"
},
{
"measure": "Assessment of the feasibility of the haptic measures"
},
{
"measure": "Assessment of the benefits of the haptic measures"
},
{
"measure": "Study the test re-test reliability of the haptic device by comparing the haptic effect on dexterity assessed at the beginning and end of the session by the same evaluator"
},
{
"measure": "Assessment of the impact of age on the dexterity performances (Finger independence, force control of the index and rhythm capacity)"
},
{
"measure": "Measurement of the manual dexterity facilitation between tactile (haptic device with vibrations on the fingers) and auditory feedback (sounds during the dexterity tasks)"
},
{
"measure": "Transcranial magnetic stimulation (TMS)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Brain & Spine Institute (ICM)"
},
{
"name": "Centre Hospitalier Régional d'Orléans"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Centre Hospitalier St Anne"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-07-15"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-07-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-15"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": null,
"conditionsModule": {
"conditions": [
"Head and Neck Cancer"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Milan",
"contacts": [
{
"email": "[email protected]",
"name": "maria Cossu Rocca, MD",
"phone": "00390294372900",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Italy",
"facility": "European Institute of Oncology",
"geoPoint": {
"lat": 45.46427,
"lon": 9.18951
},
"state": "MI",
"status": "RECRUITING",
"zip": "20141"
}
]
},
"descriptionModule": {
"briefSummary": "Predicting toxicity in elderly patients with head and neck cancer:validating a disease-oriented toxicity predictive tool and integrating it with avail-able screening tools for better outcomes."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 3,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "99 Years",
"minimumAge": "70 Years",
"sex": "ALL",
"stdAges": [
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "PREtoxEL",
"briefTitle": "Predicting Toxicity in Elderly Patients With Head and Neck Cancer",
"nctId": "NCT06344208",
"orgStudyIdInfo": {
"id": "IEO 1647",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Predicting toxicity in elderly patients with head and neck cancer"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "European Institute of Oncology"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-03-15"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Valacyclovir 500 mg"
},
{
"name": "Naproxen Sodium 550mg"
}
]
},
"conditionsModule": {
"conditions": [
"Acute Apical Abscess"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Karachi",
"contacts": [
{
"email": "[email protected]",
"name": "Dr. Yumna Shaheen Ali",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Pakistan",
"facility": "Dr. Yumna Shaheen Ali",
"geoPoint": {
"lat": 24.8608,
"lon": 67.0104
},
"state": "Sindh",
"status": "RECRUITING",
"zip": "75290"
}
]
},
"descriptionModule": {
"briefSummary": "This study is aimed to evaluate the efficacy of valacyclovir in reducing postoperative pain following emergency chamber opening for acute apical abscess .There will be 82 participants, (41 in each group) Group A will receive Valacyclovir Group B will receive standard treatment i.e. Naproxen Sodium. Pain level will be assessed by using Numeric rating scale for 6 days"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 82,
"type": "ESTIMATED"
},
"phases": [
"PHASE4"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "Antiviral",
"briefTitle": "Valacyclovir Monotherapy in Pain Management of Acute Periapical Abscesses After Emergency Chamber Opening",
"nctId": "NCT06344195",
"orgStudyIdInfo": {
"id": "2517",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Changes in pain score using Numeric Rating Scale (NRS)"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Dow University of Health Sciences"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-05"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-10"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-04"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-27"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Step Up and Down Test"
}
]
},
"conditionsModule": {
"conditions": [
"Total Knee Arthroplasty"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Izmir",
"contacts": null,
"country": "Turkey",
"facility": "Dokuz Eylul University",
"geoPoint": {
"lat": 38.41273,
"lon": 27.13838
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The aim of the study is to measure the validity and reliability of the StUD test in patients with TKA. Forty-seven patients with primary TKA included in this study. The test-retest reliability of the StUD test was measured with 1-hour interval. Validity was assessed that the 30s Chair Stand Test (30sCS), the Hospital for Special Surgery score (HSS) and Short Form-12 Quality Life Questionnaire (SF-12) were used as comparator instruments."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "CROSS_SECTIONAL"
},
"enrollmentInfo": {
"count": 47,
"type": "ACTUAL"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "85 Years",
"minimumAge": "40 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Reliability, Concurrent Validity and Minimal Detectable Change of the Step Up and Down Test in Patients With Total Knee Arthroplasty",
"nctId": "NCT06344182",
"orgStudyIdInfo": {
"id": "STarkan",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Hospital for Special Surgery (HSS) Knee Score"
},
{
"measure": "12-Item Short-Form Health Survey"
}
],
"primaryOutcomes": [
{
"measure": "Step Up and Down Test"
}
],
"secondaryOutcomes": [
{
"measure": "30 Seconds Chair Stand Test"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Dokuz Eylul University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2021-05-15"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2021-05-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2021-02-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Sebacoyl Dinalbuphine Ester"
},
{
"name": "Morphine"
}
]
},
"conditionsModule": {
"conditions": [
"Postsurgical Pain",
"Cesarean Section",
"Chronic Post-surgical Pain"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Inadequate postoperative pain management can lead to physical and psychological distress in patients as well as impact surgical wound healing and increase the risk of developing postoperative delirium and cardiopulmonary and thromboembolic events. Severe postoperative pain may also result in the development of chronic post-surgical pain (CPSP), which in turn can lead to prolonged use of opioids and increased health-care costs. A descriptive survey study in 60 postpartum women who received cesarean section suggested that the presence of postoperative pain significantly reduced the willingness of breastfeeding and infant care. The incidence of CPSP after cesarean delivery has been reported to vary from 1% to 18% up to 1 year after operation. Intrathecal morphine (ITM) injection is considered as the standard pain management strategy for post-cesarean pain. However, the overall analgesic effect of ITM is about 8-12h and it is associated with pruritus, nausea/vomiting, urinary retention, constipation, mental status change, and respiratory depression. Therefore, the development of a safe, conveniently operated, and long-lasting analgesic strategy, which serves as background pain control modality up to several days after cesarean section should provide clinically beneficial advantages in the management of acute postoperative pain and prevention of CPSP in postpartum women. Naldebain® is prodrug of nalbuphine, which was approved by the Taiwan FDA in 2017. Naldebain® is rapidly hydrolyzed by tissue of plasma esterase to release nalbuphine. The bioavailability of nalbuphine following intramuscular injection Naldebain® was 85.4%, and it took approximately 6 days for the complete release of Naldebain® into the blood circulation. Therefore, a single parenteral injection of Naldebain® could provide long lasting analgesic effect in several phase II trials. However, Naldebain® has not been tested in the pain control after cesarean section. Therefore, this PI-initiated prospective, randomized, open-label, non-inferiority trial aims to investigate the clinical efficacy of Naldebain® in management of acute postoperative pain in term parturient who receive elective cesarean section to provide analgesic effect that is not inferior to the standard ITM and prevent the development of CPSP."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Randomized, open-label, non-inferiority trial",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 120,
"type": "ESTIMATED"
},
"phases": [
"PHASE2",
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "20 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Dinalbuphine Ester (Naldebain) for Pain Management After Cesarean Section",
"nctId": "NCT06344169",
"orgStudyIdInfo": {
"id": "DTCRD112(2)-I-15",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Intensity of surgical pain after operation as assessed by visual analogue scale"
},
{
"measure": "Rescue doses of analgesics administered after operation"
}
],
"secondaryOutcomes": [
{
"measure": "Incidence of chronic post-surgical pain"
},
{
"measure": "Satisfaction of living after surgery as assessed by the HRQoL short-form (SF)-12"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Dalin Tzu Chi General Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-06-14"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-22"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-03-14"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-15"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy"
}
]
},
"conditionsModule": {
"conditions": [
"Pancreatic Cancer",
"Adjuvant Therapy"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Chengdu",
"contacts": [
{
"email": "[email protected]",
"name": "Zhong Wu, MD",
"phone": "028-85422851",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Zhong Wu",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "China",
"facility": "West China Hospital, Sichuan University",
"geoPoint": {
"lat": 30.66667,
"lon": 104.06667
},
"state": "Sichuan",
"status": "RECRUITING",
"zip": "610000"
}
]
},
"descriptionModule": {
"briefSummary": "The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in postoperative adjuvant treatment of Pancreatic Cancer"
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 43,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer",
"nctId": "NCT06344156",
"orgStudyIdInfo": {
"id": "PDAC-Neoantigen",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "18-month RFS"
},
{
"measure": "Incidence of Treatment-Related Adverse Events [Safety and Tolerability]"
}
],
"secondaryOutcomes": [
{
"measure": "18-month OS"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Sichuan University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-04-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-04-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Various labs and imaging tests"
}
]
},
"conditionsModule": {
"conditions": [
"Mild Autonomous Cortisol Secretion (MACS)"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Cleveland",
"contacts": [
{
"email": "[email protected]",
"name": "Maya Boyd",
"phone": "216-444-4919",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "[email protected] Jenkins",
"phone": "216-445-4791",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "The Cleveland Clinic Foundation",
"geoPoint": {
"lat": 41.4995,
"lon": -81.69541
},
"state": "Ohio",
"status": null,
"zip": "44195"
}
]
},
"descriptionModule": {
"briefSummary": "The aim of the proposed study is to estimate the incidence of Mild Autonomous Cortisol Secretion (MACS) in patients with Adrenal Incidentaloma (AI) and evaluate the available diagnostic tests to determine the most sensitive and specific combination of tests for assessing MACS from adrenal adenoma for prediction of the phenotype associated with cortisol excess. As well as following the patients for 4 years and see if anything changes."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_ONLY",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 20,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "MACS",
"briefTitle": "Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma",
"nctId": "NCT06344143",
"orgStudyIdInfo": {
"id": "24-324",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Evaluate best diagnostic test(s)"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Recordati Rare Diseases"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "The Cleveland Clinic"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2030-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-26"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2029-11-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-07-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Radiation Therapy"
}
]
},
"conditionsModule": {
"conditions": [
"Astrocytoma",
"Glioma",
"Recurrent Glioblastoma"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Bethesda",
"contacts": [
{
"email": null,
"name": "National Cancer Institute Referral Office",
"phone": "888-624-1937",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "National Institutes of Health Clinical Center",
"geoPoint": {
"lat": 38.98067,
"lon": -77.10026
},
"state": "Maryland",
"status": null,
"zip": "20892"
}
]
},
"descriptionModule": {
"briefSummary": "Background:Glioblastoma (GBM) is a cancer of the brain. Current survival rates for people with GBM are poor; survival ranges from 5.2 months to 39 months. Most tumors come back within months or years after treatment, and when they do, they are worse: Overall survival drops to less than 10 months. No standard treatment exists for people whose GBM has returned after radiation therapy.Objective:To find a safe schedule for using radiation to treat GBM tumors that returned after initial radiation treatment.Eligibility:People aged 18 years and older with grade 4 GBM that returned after initial radiation treatment.Design:Participants will be screened. They will have a physical exam with blood tests. A sample of tumor tissue may be collected.Participants will undergo re-irradiation planning: They will wear a plastic mask over their head during imaging scans. These scans will pinpoint the exact location of the tumor. This spot will be the target of the radiation treatments.Participants will undergo radiation treatment 4 times per week. Some people will have this treatment for 3 weeks, some for 2 weeks, and some for 1 week. Blood tests and other exams will be repeated at each visit.Participants will complete questionnaires about their physical and mental health. They will answer these questions before starting radiation treatment; once a week during treatment; and at intervals for up to 3 years after treatment ends.Participants will have follow-up visits 1 month after treatment and then every 2 months for 6 months. Follow-up clinic visits will continue up to 3 years. Follow-ups by phone or email will continue an additional 2 years."
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "SEQUENTIAL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 27,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "120 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma",
"nctId": "NCT06344130",
"orgStudyIdInfo": {
"id": "10001859",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": null,
"id": "001859-C",
"link": null,
"type": null
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "MTD of daily re-irradiation in participants with recurrent grade 4 gliomas"
}
],
"secondaryOutcomes": [
{
"measure": "Progression free survival"
},
{
"measure": "Overall survival"
},
{
"measure": "Compliance and feasibility of administering PRO in this participant population"
},
{
"measure": "Tolerability of treatment by assessing adverse events, cognitive function, physical function, and side effect bother"
},
{
"measure": "Longitudinally describe and evaluate disease and treatment-related symptom severity and interference with daily activities"
},
{
"measure": "Meaningful change in disease and treatment-related symptoms by using anchors"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "NIH",
"name": "National Cancer Institute (NCI)"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-26"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": null
},
"conditionsModule": {
"conditions": [
"Invasive Aspergillosis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Toronto",
"contacts": [
{
"email": "[email protected]",
"name": "Shahid Husain, MD,MS",
"phone": "(416) 340-3144",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Shahid Husain, MD,MS",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Canada",
"facility": "University Health Network",
"geoPoint": {
"lat": 43.70011,
"lon": -79.4163
},
"state": "Ontario",
"status": "RECRUITING",
"zip": "M5G 2N2"
}
]
},
"descriptionModule": {
"briefSummary": "Prospective observational pilot study to evaluate the utility of breath VOCs to detect invasive aspergillosis in lung transplant recipients that are suspected of invasive fungal disease (IFD)."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CONTROL",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 45,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "UHN",
"briefTitle": "Assessment of Volatile Organic Compounds (VOC) for the Diagnosis of Invasive Aspergillosis (IA) in Lung Transplant Recipients",
"nctId": "NCT06344117",
"orgStudyIdInfo": {
"id": "MF3 UHN (IA)",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Identifying a statistical relationship between Volatile Organic Compounds detection and the diagnosis of IA by existing International Society for Heart and Lung Transplantation (ISHLT) and MSG/EORTC criteria."
}
],
"secondaryOutcomes": [
{
"measure": "Identifying a statistical relationship between the set of VOCs found in exhaled breath and the diagnosis of Aspergillus colonization as defined by ISHLT criteria"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Owlstone Ltd"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-07"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-12-12"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Baxdrostat"
},
{
"name": "Placebo"
}
]
},
"conditionsModule": {
"conditions": [
"Uncontrolled Hypertension",
"Resistant Hypertension"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Caba",
"contacts": null,
"country": "Argentina",
"facility": "Research Site",
"geoPoint": {
"lat": -34.61315,
"lon": -58.37723
},
"state": null,
"status": null,
"zip": "C1426"
},
{
"city": "Baotou",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 40.65222,
"lon": 109.82222
},
"state": null,
"status": null,
"zip": "014010"
},
{
"city": "Beijing",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 39.9075,
"lon": 116.39723
},
"state": null,
"status": null,
"zip": "100029"
},
{
"city": "Beijing",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 39.9075,
"lon": 116.39723
},
"state": null,
"status": null,
"zip": "100044"
},
{
"city": "Bengbu",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 32.94083,
"lon": 117.36083
},
"state": null,
"status": null,
"zip": "233060"
},
{
"city": "Changde",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 29.04638,
"lon": 111.6783
},
"state": null,
"status": null,
"zip": "415003"
},
{
"city": "Changsha",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 28.19874,
"lon": 112.97087
},
"state": null,
"status": null,
"zip": "410015"
},
{
"city": "Changsha",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 28.19874,
"lon": 112.97087
},
"state": null,
"status": null,
"zip": "430033"
},
{
"city": "Changzhou",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 31.77359,
"lon": 119.95401
},
"state": null,
"status": null,
"zip": "272100"
},
{
"city": "Chengdu",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 30.66667,
"lon": 104.06667
},
"state": null,
"status": null,
"zip": "610041"
},
{
"city": "Chongqing",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 29.56278,
"lon": 106.55278
},
"state": null,
"status": null,
"zip": "400010"
},
{
"city": "Chongqing",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 29.56278,
"lon": 106.55278
},
"state": null,
"status": null,
"zip": "400042"
},
{
"city": "Deyang",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 31.13019,
"lon": 104.38198
},
"state": null,
"status": null,
"zip": "618000"
},
{
"city": "Guangzhou",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 23.11667,
"lon": 113.25
},
"state": null,
"status": null,
"zip": "510100"
},
{
"city": "Ha'er Bin",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": null,
"state": null,
"status": null,
"zip": "150001"
},
{
"city": "Hangzhou",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 30.29365,
"lon": 120.16142
},
"state": null,
"status": null,
"zip": "310014"
},
{
"city": "Hefei",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 31.86389,
"lon": 117.28083
},
"state": null,
"status": null,
"zip": "230601"
},
{
"city": "Heze",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 35.23929,
"lon": 115.47358
},
"state": null,
"status": null,
"zip": "274099"
},
{
"city": "Jiujiang",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 29.70475,
"lon": 116.00206
},
"state": null,
"status": null,
"zip": "332000"
},
{
"city": "Luoyang",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 34.68361,
"lon": 112.45361
},
"state": null,
"status": null,
"zip": "471000"
},
{
"city": "Meihekou",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 42.52722,
"lon": 125.67528
},
"state": null,
"status": null,
"zip": "135022"
},
{
"city": "Nanchang",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 28.68396,
"lon": 115.85306
},
"state": null,
"status": null,
"zip": "330009"
},
{
"city": "Nanchong",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 30.79508,
"lon": 106.08473
},
"state": null,
"status": null,
"zip": "637900"
},
{
"city": "Nanjing",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 32.06167,
"lon": 118.77778
},
"state": null,
"status": null,
"zip": "210009"
},
{
"city": "Ningbo",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 29.87819,
"lon": 121.54945
},
"state": null,
"status": null,
"zip": "315020"
},
{
"city": "Panjin",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 41.121,
"lon": 122.0739
},
"state": null,
"status": null,
"zip": "124009"
},
{
"city": "Puyang",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 29.45679,
"lon": 119.88872
},
"state": null,
"status": null,
"zip": "457000"
},
{
"city": "Qiqihar",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 47.34088,
"lon": 123.96045
},
"state": null,
"status": null,
"zip": "161000"
},
{
"city": "Sanya",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 18.24306,
"lon": 109.505
},
"state": null,
"status": null,
"zip": "572000"
},
{
"city": "Shanghai",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 31.22222,
"lon": 121.45806
},
"state": null,
"status": null,
"zip": "200025"
},
{
"city": "Shanghai",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 31.22222,
"lon": 121.45806
},
"state": null,
"status": null,
"zip": "200040"
},
{
"city": "Shenyang",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 41.79222,
"lon": 123.43278
},
"state": null,
"status": null,
"zip": "110004"
},
{
"city": "Shenyang",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 41.79222,
"lon": 123.43278
},
"state": null,
"status": null,
"zip": "110016"
},
{
"city": "Taiyuan",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 37.86944,
"lon": 112.56028
},
"state": null,
"status": null,
"zip": "030024"
},
{
"city": "Tianjin",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 39.14222,
"lon": 117.17667
},
"state": null,
"status": null,
"zip": "300457"
},
{
"city": "Tianjin",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 39.14222,
"lon": 117.17667
},
"state": null,
"status": null,
"zip": null
},
{
"city": "Wuhan",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 30.58333,
"lon": 114.26667
},
"state": null,
"status": null,
"zip": "430010"
},
{
"city": "Wuhan",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 30.58333,
"lon": 114.26667
},
"state": null,
"status": null,
"zip": "430022"
},
{
"city": "Wuhan",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 30.58333,
"lon": 114.26667
},
"state": null,
"status": null,
"zip": "430060"
},
{
"city": "Xianyang",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 34.33778,
"lon": 108.70261
},
"state": null,
"status": null,
"zip": "712000"
},
{
"city": "Xianyang",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 34.33778,
"lon": 108.70261
},
"state": null,
"status": null,
"zip": "750004"
},
{
"city": "Xuzhou",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 34.18045,
"lon": 117.15707
},
"state": null,
"status": null,
"zip": "221000"
},
{
"city": "Yangzhou",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 32.39722,
"lon": 119.43583
},
"state": null,
"status": null,
"zip": "225001"
},
{
"city": "Yinchuan",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 38.46806,
"lon": 106.27306
},
"state": null,
"status": null,
"zip": "750001"
},
{
"city": "Zhengzhou",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 34.75778,
"lon": 113.64861
},
"state": null,
"status": null,
"zip": null
},
{
"city": "Zigong",
"contacts": null,
"country": "China",
"facility": "Research Site",
"geoPoint": {
"lat": 29.34162,
"lon": 104.77689
},
"state": null,
"status": null,
"zip": "643021"
},
{
"city": "Hong Kong",
"contacts": null,
"country": "Hong Kong",
"facility": "Research Site",
"geoPoint": {
"lat": 22.27832,
"lon": 114.17469
},
"state": null,
"status": null,
"zip": "00000"
},
{
"city": "Hong Kong",
"contacts": null,
"country": "Hong Kong",
"facility": "Research Site",
"geoPoint": {
"lat": 22.27832,
"lon": 114.17469
},
"state": null,
"status": null,
"zip": "0000"
},
{
"city": "Hong Kong",
"contacts": null,
"country": "Hong Kong",
"facility": "Research Site",
"geoPoint": {
"lat": 22.27832,
"lon": 114.17469
},
"state": null,
"status": null,
"zip": null
},
{
"city": "Bangalore",
"contacts": null,
"country": "India",
"facility": "Research Site",
"geoPoint": {
"lat": 12.97194,
"lon": 77.59369
},
"state": null,
"status": null,
"zip": "560 092"
},
{
"city": "Belgaum",
"contacts": null,
"country": "India",
"facility": "Research Site",
"geoPoint": {
"lat": 15.85212,
"lon": 74.50447
},
"state": null,
"status": null,
"zip": "590016"
},
{
"city": "Kanpur",
"contacts": null,
"country": "India",
"facility": "Research Site",
"geoPoint": {
"lat": 26.46523,
"lon": 80.34975
},
"state": null,
"status": null,
"zip": "208002"
},
{
"city": "New Delhi",
"contacts": null,
"country": "India",
"facility": "Research Site",
"geoPoint": {
"lat": 28.63576,
"lon": 77.22445
},
"state": null,
"status": null,
"zip": "110002"
},
{
"city": "New Delhi",
"contacts": null,
"country": "India",
"facility": "Research Site",
"geoPoint": {
"lat": 28.63576,
"lon": 77.22445
},
"state": null,
"status": null,
"zip": "110060"
},
{
"city": "Surat",
"contacts": null,
"country": "India",
"facility": "Research Site",
"geoPoint": {
"lat": 21.19594,
"lon": 72.83023
},
"state": null,
"status": null,
"zip": "395001"
},
{
"city": "Chuo-ku",
"contacts": null,
"country": "Japan",
"facility": "Research Site",
"geoPoint": {
"lat": 35.57779,
"lon": 139.71685
},
"state": null,
"status": null,
"zip": "103-0027"
},
{
"city": "Chuo-ku",
"contacts": null,
"country": "Japan",
"facility": "Research Site",
"geoPoint": {
"lat": 35.57779,
"lon": 139.71685
},
"state": null,
"status": null,
"zip": "260-0804"
},
{
"city": "Kagoshima-shi",
"contacts": null,
"country": "Japan",
"facility": "Research Site",
"geoPoint": {
"lat": 31.56667,
"lon": 130.55
},
"state": null,
"status": null,
"zip": "890-8520"
},
{
"city": "Minato-ku",
"contacts": null,
"country": "Japan",
"facility": "Research Site",
"geoPoint": {
"lat": 34.2152,
"lon": 135.1501
},
"state": null,
"status": null,
"zip": "108-0073"
},
{
"city": "Tsukuba-shi",
"contacts": null,
"country": "Japan",
"facility": "Research Site",
"geoPoint": {
"lat": 36.2,
"lon": 140.1
},
"state": null,
"status": null,
"zip": "305-0861"
},
{
"city": "Utsunomiya-shi",
"contacts": null,
"country": "Japan",
"facility": "Research Site",
"geoPoint": {
"lat": 36.56667,
"lon": 139.88333
},
"state": null,
"status": null,
"zip": "320-8580"
},
{
"city": "Yokohama-shi",
"contacts": null,
"country": "Japan",
"facility": "Research Site",
"geoPoint": {
"lat": 35.43333,
"lon": 139.65
},
"state": null,
"status": null,
"zip": "234-0054"
},
{
"city": "Yokohama-shi",
"contacts": null,
"country": "Japan",
"facility": "Research Site",
"geoPoint": {
"lat": 35.43333,
"lon": 139.65
},
"state": null,
"status": null,
"zip": "236-0004"
},
{
"city": "Daejeon",
"contacts": null,
"country": "Korea, Republic of",
"facility": "Research Site",
"geoPoint": {
"lat": 36.32139,
"lon": 127.41972
},
"state": null,
"status": null,
"zip": "35015"
},
{
"city": "Seoul",
"contacts": null,
"country": "Korea, Republic of",
"facility": "Research Site",
"geoPoint": {
"lat": 37.566,
"lon": 126.9784
},
"state": null,
"status": null,
"zip": "02841"
},
{
"city": "Seoul",
"contacts": null,
"country": "Korea, Republic of",
"facility": "Research Site",
"geoPoint": {
"lat": 37.566,
"lon": 126.9784
},
"state": null,
"status": null,
"zip": "03722"
},
{
"city": "Seoul",
"contacts": null,
"country": "Korea, Republic of",
"facility": "Research Site",
"geoPoint": {
"lat": 37.566,
"lon": 126.9784
},
"state": null,
"status": null,
"zip": "04763"
},
{
"city": "Seoul",
"contacts": null,
"country": "Korea, Republic of",
"facility": "Research Site",
"geoPoint": {
"lat": 37.566,
"lon": 126.9784
},
"state": null,
"status": null,
"zip": "05505"
},
{
"city": "Seoul",
"contacts": null,
"country": "Korea, Republic of",
"facility": "Research Site",
"geoPoint": {
"lat": 37.566,
"lon": 126.9784
},
"state": null,
"status": null,
"zip": "13620"
},
{
"city": "Iloilo City",
"contacts": null,
"country": "Philippines",
"facility": "Research Site",
"geoPoint": {
"lat": 10.69694,
"lon": 122.56444
},
"state": null,
"status": null,
"zip": "5000"
},
{
"city": "Quezon City",
"contacts": null,
"country": "Philippines",
"facility": "Research Site",
"geoPoint": {
"lat": 14.6488,
"lon": 121.0509
},
"state": null,
"status": null,
"zip": "1112"
},
{
"city": "St Petersburg",
"contacts": null,
"country": "Russian Federation",
"facility": "Research Site",
"geoPoint": {
"lat": 59.93863,
"lon": 30.31413
},
"state": null,
"status": null,
"zip": "197341"
},
{
"city": "Ankara",
"contacts": null,
"country": "Turkey",
"facility": "Research Site",
"geoPoint": {
"lat": 39.91987,
"lon": 32.85427
},
"state": null,
"status": null,
"zip": "06800"
},
{
"city": "Kahramanmaras",
"contacts": null,
"country": "Turkey",
"facility": "Research Site",
"geoPoint": {
"lat": 37.5847,
"lon": 36.92641
},
"state": null,
"status": null,
"zip": "46100"
},
{
"city": "Kayseri",
"contacts": null,
"country": "Turkey",
"facility": "Research Site",
"geoPoint": {
"lat": 38.73222,
"lon": 35.48528
},
"state": null,
"status": null,
"zip": "38039"
},
{
"city": "Kocaeli",
"contacts": null,
"country": "Turkey",
"facility": "Research Site",
"geoPoint": {
"lat": 39.62497,
"lon": 27.51145
},
"state": null,
"status": null,
"zip": "41380"
},
{
"city": "Hanoi",
"contacts": null,
"country": "Vietnam",
"facility": "Research Site",
"geoPoint": {
"lat": 21.0245,
"lon": 105.84117
},
"state": null,
"status": null,
"zip": "100000"
},
{
"city": "Ho Chi Minh",
"contacts": null,
"country": "Vietnam",
"facility": "Research Site",
"geoPoint": {
"lat": 10.82302,
"lon": 106.62965
},
"state": null,
"status": null,
"zip": "700000"
},
{
"city": "Hochiminh city",
"contacts": null,
"country": "Vietnam",
"facility": "Research Site",
"geoPoint": {
"lat": 10.82302,
"lon": 106.62965
},
"state": null,
"status": null,
"zip": "700000"
},
{
"city": "Hochiminh",
"contacts": null,
"country": "Vietnam",
"facility": "Research Site",
"geoPoint": null,
"state": null,
"status": null,
"zip": "70000"
}
]
},
"descriptionModule": {
"briefSummary": "The purpose of this study is to measure the efficacy and safety of baxdrostat in Asian participants with uHTN or rHTN. The main objective is to compare the difference in SBP change from baseline at Week 12 of treatment between participants receiving 2 mg baxdrostat or 1 mg baxdrostat tablets and participants receiving placebo tablets."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "placebo control",
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 300,
"type": "ESTIMATED"
},
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "BaxAsia",
"briefTitle": "A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Asian Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension",
"nctId": "NCT06344104",
"orgStudyIdInfo": {
"id": "D6970C00008",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Number of participants with adverse events (AEs)"
}
],
"primaryOutcomes": [
{
"measure": "Change from baseline in siSBP at Week 12"
}
],
"secondaryOutcomes": [
{
"measure": "Change from baseline in siSBP at Week 12"
},
{
"measure": "Change from RWD baseline (Week 24) in siSBP at Week 32"
},
{
"measure": "Change from baseline in the mean ambulatory 24-hour SBP at Week 12 as measured by ABPM"
},
{
"measure": "Change from baseline in the mean ambulatory 24-hour SBP at Week 12 as measured by ABPM"
},
{
"measure": "Change from baseline in siDBP at Week 12"
},
{
"measure": "Achieving siSBP < 140 mmHg at Week 12"
},
{
"measure": "Change from baseline in siDBP at Week 12"
},
{
"measure": "Achieving siSBP < 140 mmHg at Week 12"
},
{
"measure": "Change from baseline in siSBP at Week 12"
},
{
"measure": "Change from baseline in siSBP at Week 12"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "AstraZeneca"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-05-20"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-05-20"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-18"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Bupivacaine Liposome Injection"
}
]
},
"conditionsModule": {
"conditions": [
"Local Analgesia Via Infiltration"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Guangzhou",
"contacts": [
{
"email": null,
"name": "Xingrong Song",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "China",
"facility": "Guangzhou Women and Children's Medical Center",
"geoPoint": {
"lat": 23.11667,
"lon": 113.25
},
"state": "Guangdong",
"status": null,
"zip": "510000"
}
]
},
"descriptionModule": {
"briefSummary": "The study is being conducted to evaluate the safety and efficacy of bupivacaine liposome injection for local infiltration analgesia in pediatric orthopedic surgery in the real world."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "A single-arm study of liposomal bupivacaine injection",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 232,
"type": "ESTIMATED"
},
"phases": [
"PHASE4"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "17 Years",
"minimumAge": "6 Years",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients",
"nctId": "NCT06344091",
"orgStudyIdInfo": {
"id": "ZYWB-ZM-AHP-A-003",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The incidence of Treatment Emergent Adverse events (TEAE) in the cardiac and nervous system"
}
],
"secondaryOutcomes": [
{
"measure": "The cumulative amount of opioids used in 0-24 hours, 24-48 hours, 48-72 hours and 0-72 hours after administration"
},
{
"measure": "Time to first rescue analgesia of opioid"
},
{
"measure": "The proportion of patients who did not use rescue analgesia during 0-24 hours, 24-48 hours, 48-72 hours and 0-72 hours after administration"
},
{
"measure": "The proportion of patients using patient-controlled intravenous analgesia (PCIA)"
},
{
"measure": "Pain intensity score at rest after administration for children aged 6 to 7 years"
},
{
"measure": "Pain intensity score at rest after administration for children aged 8 years and older"
},
{
"measure": "Pain intensity score on movement (or cough) after administration for children aged 6 to 7 years"
},
{
"measure": "Pain intensity score on movement (or cough) after administration for children aged 8 years and older"
},
{
"measure": "Length of Stay"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Jiangsu HengRui Medicine Co., Ltd."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-10-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-09-28"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-06"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "sigmoid resection and anastomosis / stoma"
}
]
},
"conditionsModule": {
"conditions": [
"Acute Diverticulitis",
"Stoma Colostomy",
"Stoma Ileostomy"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Palermo",
"contacts": [
{
"email": "[email protected]",
"name": "francesco ferrara, medicine and surgery",
"phone": "+393343035829",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "claudio guerci",
"phone": "+393473898094",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Italy",
"facility": "Azienda ospedaliera universitaria paolo giaccone",
"geoPoint": {
"lat": 38.13205,
"lon": 13.33561
},
"state": null,
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "This study will include data collected from surgical units performing emergency surgery in Italy during 2024, with a one-year follow-up period for each patient. Data for each center will be prospectively collected through a database filled out by the Italian Society of Colorectal Surgery (SICCR) members who participate to the study. Specific data will include: WSES diverticulitis classification, procedure timing, laparoscopic/converted procedures, rate of performed protection ileostomies or colostomies, rate and timing of Hartmann reversal or stoma closure, procedures with more than two operators, procedures with expert first operator, night or weekend procedures, and patients aged over 80. Postoperative data will focus on complication rates and mortality at one, six, and twelve months."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 500,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "120 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "SIGMA-D",
"briefTitle": "Surgical Italian Guide for the Management of Complicated Acute Diverticulitis Emergency Setting (SIGMA-D). A Prospective Observational Multicenter Study on Behalf of the Italian Society of Colorectal Surgery (SICCR).",
"nctId": "NCT06344078",
"orgStudyIdInfo": {
"id": "SIGMA-d",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "adhesion to guidelines"
}
],
"secondaryOutcomes": [
{
"measure": "stoma reversal"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "NETWORK",
"name": "Societa Italiana di Chirurgia ColoRettale"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-01-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed)"
},
{
"name": "Diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed)"
},
{
"name": "Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine (adsorbed) and Haemophilus influenzae type b conjugate vaccine"
}
]
},
"conditionsModule": {
"conditions": [
"Healthy Volunteers"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Nanning",
"contacts": [
{
"email": "[email protected]",
"name": "Yi Mo",
"phone": "+86-13788686968",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "China",
"facility": "Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention",
"geoPoint": {
"lat": 22.81667,
"lon": 108.31667
},
"state": "Guangxi",
"status": "RECRUITING",
"zip": "530028"
}
]
},
"descriptionModule": {
"briefSummary": "The purpose of this study is to evaluate the safety and immunogenicity of the DTaP in 3-month-old infants."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 1584,
"type": "ESTIMATED"
},
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "3 Months",
"minimumAge": "3 Months",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants",
"nctId": "NCT06344065",
"orgStudyIdInfo": {
"id": "20220102C",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Immunogenicity results of experimental group and active control group (DTaP)"
},
{
"measure": "Immunogenicity results of experimental group and active control group (DTaP-IPV//PRP-T)"
},
{
"measure": "Immunogenicity results of experimental group"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2028-12-25"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-05-25"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-12-21"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "SP-002"
},
{
"name": "Vismodegib"
}
]
},
"conditionsModule": {
"conditions": [
"Basal Cell Carcinoma"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Phoenix",
"contacts": null,
"country": "United States",
"facility": "Research Site",
"geoPoint": {
"lat": 33.44838,
"lon": -112.07404
},
"state": "Arizona",
"status": "NOT_YET_RECRUITING",
"zip": "85006"
},
{
"city": "Lee's Summit",
"contacts": null,
"country": "United States",
"facility": "Research Site",
"geoPoint": {
"lat": 38.91084,
"lon": -94.38217
},
"state": "Missouri",
"status": "NOT_YET_RECRUITING",
"zip": "64064"
},
{
"city": "Cedar Park",
"contacts": null,
"country": "United States",
"facility": "Research Site",
"geoPoint": {
"lat": 30.5052,
"lon": -97.82029
},
"state": "Texas",
"status": "RECRUITING",
"zip": "78613"
},
{
"city": "Humble",
"contacts": null,
"country": "United States",
"facility": "Research Site",
"geoPoint": {
"lat": 29.99883,
"lon": -95.26216
},
"state": "Texas",
"status": "NOT_YET_RECRUITING",
"zip": "77346"
},
{
"city": "Longview",
"contacts": null,
"country": "United States",
"facility": "Research Site",
"geoPoint": {
"lat": 32.5007,
"lon": -94.74049
},
"state": "Texas",
"status": "NOT_YET_RECRUITING",
"zip": "75601"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this clinical trial is to evaluate the efficacy of using SP-002 in participants with locally advanced Basal cell carcinoma. The main question it aims to answer is what the objective response rate for a basal cell carcinoma tumor is following 1 or 3 cycles of SP-002 treatment given as an add-on to hedgehog pathway inhibitor therapy.Researchers will compare the objective response rate for treated Basal cell carcinoma tumors between 3 treatment Arms.* Arm 1 participants will receive daily hedgehog pathway inhibitor, and 3 cycles of SP-002 treatment.* Arm 2 participants will receive daily hedgehog pathway inhibitor, and 1 cycle of SP-002 treatment.* Arm 3 participants will receive daily hedgehog pathway inhibitor only."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 80,
"type": "ESTIMATED"
},
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "To Assess the Safety and Efficacy of SP-002 With Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma",
"nctId": "NCT06344052",
"orgStudyIdInfo": {
"id": "SP-002-004",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Objective response rate"
}
],
"secondaryOutcomes": [
{
"measure": "Duration of response"
},
{
"measure": "Progressive free survival"
},
{
"measure": "Overall survival (OS)"
},
{
"measure": "Objective Response Rate (ORR) / Complete Response (CR) / Partial Response (PR)"
},
{
"measure": "Number of subjects discontinuing treatment with SP-002 and/or vismodegib due to toxicity."
},
{
"measure": "Number of subjects with delays to SP-002 and/or vismodegib dosing due to toxicity."
},
{
"measure": "Incidence and severity of SP-002 and/or vismodegib related AEs."
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Stamford Pharmaceuticals, Inc."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2029-03-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-10"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-09-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-09"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": null,
"conditionsModule": {
"conditions": [
"Hip Fractures",
"Hip Injuries"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Aim of the study is to describe and study the patterns of floating hip injuries and assess the current management in Assiut University Hospitals Trauma Centre to help reach the best approach to plan treatment for these severe and difficult injuries."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_ONLY",
"primaryPurpose": null,
"timePerspective": "RETROSPECTIVE"
},
"enrollmentInfo": {
"count": 100,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "60 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Epidemiological Study of Floating Hip Injuries in Assiut University Hospitals",
"nctId": "NCT06344039",
"orgStudyIdInfo": {
"id": "Floating hip",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Incidence of floating hip injuries"
},
{
"measure": "Patterns of injury"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Assiut University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-05"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-05"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-04"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "ANPD001"
},
{
"name": "Custom Device"
}
]
},
"conditionsModule": {
"conditions": [
"Parkinson Disease"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Tucson",
"contacts": null,
"country": "United States",
"facility": "University of Arizona - Banner Health",
"geoPoint": {
"lat": 32.22174,
"lon": -110.92648
},
"state": "Arizona",
"status": null,
"zip": "85724"
},
{
"city": "La Jolla",
"contacts": null,
"country": "United States",
"facility": "Scripps Health",
"geoPoint": {
"lat": 32.84727,
"lon": -117.2742
},
"state": "California",
"status": null,
"zip": "92037"
},
{
"city": "Orange",
"contacts": null,
"country": "United States",
"facility": "University of California, Irvine",
"geoPoint": {
"lat": 33.78779,
"lon": -117.85311
},
"state": "California",
"status": null,
"zip": "92868"
},
{
"city": "San Francisco",
"contacts": null,
"country": "United States",
"facility": "University of California, San Francisco",
"geoPoint": {
"lat": 37.77493,
"lon": -122.41942
},
"state": "California",
"status": null,
"zip": "94143"
},
{
"city": "Manhasset",
"contacts": null,
"country": "United States",
"facility": "Feinstein Institutes",
"geoPoint": {
"lat": 40.79788,
"lon": -73.69957
},
"state": "New York",
"status": null,
"zip": "11030"
}
]
},
"descriptionModule": {
"briefSummary": "This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "Open label, dose escalation of bilateral injection of ANPD001 dopaminergic precursor cells to the putamen",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 9,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "70 Years",
"minimumAge": "50 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "ASPIRO",
"briefTitle": "Phase 1/2a Study of ANPD001 in Parkinson Disease",
"nctId": "NCT06344026",
"orgStudyIdInfo": {
"id": "ANPD001-02",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Incidence and severity of treatment emergent adverse events (Safety and Tolerability)"
}
],
"secondaryOutcomes": [
{
"measure": "\"ON\" time without troublesome dyskinesia"
},
{
"measure": "Post-injection change in Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II (Activities of Daily Living - ADL) and Part III (motor score) in the ON state (total score and scores for Parts I-IV)"
},
{
"measure": "Post-injection change in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score in the practically defined OFF state"
},
{
"measure": "Post-injection change in the 18F-DOPA uptake in the putamen"
},
{
"measure": "Incidence and severity of treatment emergent adverse events during long term follow-up (Continued Safety and Tolerability)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "California Institute for Regenerative Medicine (CIRM)"
}
],
"leadSponsor": {
"class": "INDUSTRY",
"name": "Aspen Neuroscience"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2030-04-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "ENROLLING_BY_INVITATION",
"primaryCompletionDateStruct": {
"date": "2025-10-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-01-23"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": null,
"conditionsModule": {
"conditions": [
"Delirium"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Brest",
"contacts": null,
"country": "France",
"facility": "Chu Brest",
"geoPoint": {
"lat": 48.3903,
"lon": -4.48628
},
"state": null,
"status": null,
"zip": "29609"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this observational study is to evaluate the knowledge and compliance of French intensive care units with the ABCDEF (A: Assessment, Prevention, Management of Pain, B: Both Spontaneous Awakening Trials and Spontaneous Breathing Trials, C: Choice of Sedation and Analgesia, D: Delirium Assessment, Prevention, and Management, E: Early Mobility and Exercise, F: Family Engagement and Empowerment) bundle. French ICU doctors will be asked to answer a questionnaire available online."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "CROSS_SECTIONAL"
},
"enrollmentInfo": {
"count": 341,
"type": "ACTUAL"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": null,
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The ABCDEF Bundle in Critical Care: a French National Survey Still a Long Way to go!",
"nctId": "NCT06344013",
"orgStudyIdInfo": {
"id": "29BRC24.0034 - BUNDLE ABCDEF",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "knowledge and compliance of French intensive care units with the ABCDEF"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University Hospital, Brest"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2022-07-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2022-07-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-07-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "inapplicable"
}
]
},
"conditionsModule": {
"conditions": [
"Bronchiectasis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Wuhan",
"contacts": [
{
"email": "[email protected]",
"name": "Xiaorong Wang",
"phone": "18627195231",
"phoneExt": "+86",
"role": "CONTACT"
}
],
"country": "China",
"facility": "Wuhan Union Hospital",
"geoPoint": {
"lat": 30.58333,
"lon": 114.26667
},
"state": "Hubei",
"status": null,
"zip": "430022"
}
]
},
"descriptionModule": {
"briefSummary": "Bronchiectasis is a common lung disease. The Bronchiectasis Severity Index (BSI) is a widely used assessment system. The body mass index (BMI) is a commonly used measure of nutritional status, but it has its limitations. To provide a more comprehensive assessment, the investigators also consider other nutrition-related indices such as upper arm circumference, calf circumference, skinfold thickness and grip strength. The investigators will specify the relationship between nutritional status and disease progression by measuring nutrition-related indicators and tracking participants' disease progression."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 300,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "100 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Study on Disease Progression and Nutritional Status in Bronchiectasis",
"nctId": "NCT06344000",
"orgStudyIdInfo": {
"id": "RICU20240323",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Frequency of acute exacerbations of bronchiectasis"
}
],
"secondaryOutcomes": [
{
"measure": "Deterioration of lung function"
},
{
"measure": "Severity of dyspnoea"
},
{
"measure": "Bhalla scores on CT of participants' lungs"
},
{
"measure": "Frequency of hospitalisation"
},
{
"measure": "Death"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Wuhan Union Hospital, China"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-04-15"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-04-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-15"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Physical Activity"
}
]
},
"conditionsModule": {
"conditions": [
"Metastatic Breast Cancer",
"Estrogen-receptor-positive Breast Cancer",
"Adiposity"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Aarhus N",
"contacts": [
{
"email": "[email protected]",
"name": "Signe Borgquist, MD, PhD",
"phone": "+ 45 22 62 45 25",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "May W Nielsen, Bsc.Med.",
"phone": "+45 29 90 66 05",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Denmark",
"facility": "Department of Oncology, Aarhus University Hospital",
"geoPoint": {
"lat": 56.15674,
"lon": 10.21076
},
"state": "Central Denmark Region",
"status": "RECRUITING",
"zip": "8200"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this clinical trial is to test a physical activity program in patients with metastatic breast cancer and overweight receiving endocrine-based treatment.The aim of the study is to assess the feasibility and metabolic efficacy of a 12-week physical activity program in this patient group. The hypothesis is that improving metabolic health through physical activity can optimize cancer care.Participants will randomized 2:1 to either a physical activity program or care as usual."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Continuous inclusion. Randomized 2:1 - intervention group and observational group, respectively.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 21,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity",
"nctId": "NCT06343987",
"orgStudyIdInfo": {
"id": "1-10-72-165-23",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Adherence as assessed by attendance rate"
},
{
"measure": "Metabolic efficacy assessed by change in metabolic score"
}
],
"secondaryOutcomes": [
{
"measure": "Perceived satisfaction assessed by qualitative interviews"
},
{
"measure": "Health-related quality of life as assessed by EORTC-QLQ-30"
},
{
"measure": "Cancer coping as assessed by CBI-12"
},
{
"measure": "Sleep quality as assessed by PSQI"
},
{
"measure": "Insomnia as assessed by ISI"
},
{
"measure": "Change in C-reactive protein"
},
{
"measure": "Change in leukocytes"
},
{
"measure": "Change in HbA1c"
},
{
"measure": "Change in LDL cholesterol"
},
{
"measure": "Change in HDL cholesterol"
},
{
"measure": "Change in BMI"
},
{
"measure": "Fat mass"
},
{
"measure": "Muscle mass"
},
{
"measure": "Visceral fat"
},
{
"measure": "VO2 max"
},
{
"measure": "Handgrip strength"
},
{
"measure": "Sit-rising"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Danish Cancer Society"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Aarhus University Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-03"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-09"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-12"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-02-19"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": null
},
"conditionsModule": {
"conditions": [
"Pregnancy in Diabetic",
"Diabetes Mellitus, Type 1"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Turku",
"contacts": null,
"country": "Finland",
"facility": "Turku University Hospital",
"geoPoint": {
"lat": 60.45148,
"lon": 22.26869
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this observational study is to compare fetal liver ultrasound radiomics between pregnancies complicated by type 1 diabetes and healthy controls.The main questions it aims to answer are:* Are fetal liver ultrasound radiomic features reproducible?* Does fetal liver ultrasound radiomics differ between pregnancies complicated by type 1 diabetes and healthy controls?Participants will undergo ultrasound examination to collect ultrasound data for the analyses."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CONTROL",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 60,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "45 Years",
"minimumAge": "18 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Noninvasive Evaluation of Fetal Hyperinsulinemia With Ultrasound Radiomics",
"nctId": "NCT06343974",
"orgStudyIdInfo": {
"id": "0843",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Fetal liver ultrasound texture"
}
],
"secondaryOutcomes": [
{
"measure": "Birth weight in grams"
},
{
"measure": "Birth weight centile"
},
{
"measure": "Large for gestational age (LGA)"
},
{
"measure": "Interventricular septum (IVS) width"
},
{
"measure": "Number of pregnancies with neonatal hypoglycemia"
},
{
"measure": "Rate of neonatal hypoglycemia treated with oral dextrose gel"
},
{
"measure": "Rate of neonatal hypoglycemia treated with intravenous (IV) glucose"
},
{
"measure": "Length of treatment for neonatal hypoglycemia"
},
{
"measure": "Number of neonates admitted to neonatal intensive care unit (NICU)"
},
{
"measure": "Length of NICU admission"
},
{
"measure": "Number of pregnancies with neonatal respiratory complications related to maternal diabetes"
},
{
"measure": "Number of pregnancies with neonatal hyperbilirubinemia"
},
{
"measure": "Maternal HbA1c concentration"
},
{
"measure": "Glucose management indicator (GMI)"
},
{
"measure": "Time in glycemic range (TIR)"
},
{
"measure": "Time above glucose range"
},
{
"measure": "Time below glucose range"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER_GOV",
"name": "Turku University Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-05-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Intraoperative Fluorescein Angiography"
}
]
},
"conditionsModule": {
"conditions": [
"Vascular Retinopathy of Left Eye (Disorder)",
"Vascular Retinopathy of Right Eye (Disorder)",
"Diabetic Retinopathy",
"Retinal Vein Occlusion",
"Retinal Vasculitis",
"Vitreous Hemorrhage"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The study used a new surgical technique: intraoperative fluorescence imaging,In the 1980s, some scholars proposed the concept of intraoperative fluorescein angiography.During vitrectomy, intraoperative fluorescein angiography under 3D microscope can guide the surgeon to observe the non-perfusion area and new blood vessels on the same screen for accurate retinal photocoagulation therapy.Through this technology, the primary retinal disease can be identified in time after the removal of vitreous hemorrhage during surgery, providing effective imaging evidence support for the design of further treatment."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "A total of 80 patients with vitreous hemorrhage diagnosed in Sichuan Provincial People's Hospital from January 2024 to December 2025 were selected. The number of included cases was calculated according to the minimum sample size of 200 patients with vitreous hemorrhage in our hospital, 95% confidence level and 5% confidence interval, and the calculated result was 79. The included cases were equally divided by random number method. 40 patients in the control group were given vitrectomy and other conventional operations such as retinal laser photocoagulation. In contrast group, 40 patients were given vitrectomy combined with intraoperative fluorescein angiography and other conventional operations such as retinal laser photocoagulation. The diagnosis rate of primary disease cause, observation rate of neovascularization and non-perfusion area, visual acuity, visual field, thickness of macular fovea and postoperative complications (ciliary detachment, secondary vitreous hemorrhage, neovascu",
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 80,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Intraoperative Application of Fluorescein Sodium Angiography in Vascular Retinopathy",
"nctId": "NCT06343961",
"orgStudyIdInfo": {
"id": "2024-76",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "best corrected visual acuity"
},
{
"measure": "Central retinal thickness"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Jie Zhong"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-12"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-18"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "BL-B01D1"
},
{
"name": "Eribulin"
},
{
"name": "Vinorelbine"
},
{
"name": "Gemcitabine"
},
{
"name": "Capecitabine"
}
]
},
"conditionsModule": {
"conditions": [
"HR+HER2- Breast Cancer"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Beijing",
"contacts": [
{
"email": null,
"name": "Binghe Xu",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "China",
"facility": "Cancer Hospital Chinese Academy of Medical Sciences",
"geoPoint": {
"lat": 39.9075,
"lon": 116.39723
},
"state": "Beijing",
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+HER2- breast cancer after failure of at least one prior line of chemotherapy."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 382,
"type": "ESTIMATED"
},
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer",
"nctId": "NCT06343948",
"orgStudyIdInfo": {
"id": "BL-B01D1-306",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Progression-free survival (PFS)"
}
],
"secondaryOutcomes": [
{
"measure": "Overall survival (OS)"
},
{
"measure": "Objective Response Rate (ORR)"
},
{
"measure": "Disease Control Rate (DCR)"
},
{
"measure": "Duration of Response (DOR)"
},
{
"measure": "Treatment Emergent Adverse Event (TEAE)"
},
{
"measure": "Anti-drug antibody (ADA)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Baili-Bio (Chengdu) Pharmaceutical Co., Ltd."
}
],
"leadSponsor": {
"class": "INDUSTRY",
"name": "Sichuan Baili Pharmaceutical Co., Ltd."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-05"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-04"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-05"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Linperlisib"
}
]
},
"conditionsModule": {
"conditions": [
"Indolent B-cell Lymphoma"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "This is a national multicenter, randomized controlled, open, dose-optimized Phase IV study. It is expected to enroll approximately 88 patients with relapsed/refractory indolent B-cell lymphoma. The aim is to evaluate the efficacy and safety of linperlisib in the treatment of patients with relapsed/refractory indolent B-cell lymphoma at two doses/modes of administration (clinically recommended dose/mode and optimized dose/mode)."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 88,
"type": "ESTIMATED"
},
"phases": [
"PHASE4"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma",
"nctId": "NCT06343935",
"orgStudyIdInfo": {
"id": "YY-20394-014",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Progression free survival"
}
],
"secondaryOutcomes": [
{
"measure": "Objective response rate"
},
{
"measure": "Overall survival"
},
{
"measure": "Adverse event"
},
{
"measure": "Serious adverse event"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Shanghai YingLi Pharmaceutical Co. Ltd."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-04-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-04-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-30"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "oral motor facilitation technique group"
},
{
"name": "traditional oral motor exercises group"
}
]
},
"conditionsModule": {
"conditions": [
"Cerebral Palsy (CP)"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Lahore",
"contacts": [
{
"email": "[email protected]",
"name": "Mobility Quest",
"phone": "03336596656",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Nazia Mumtaz, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Sadaf Safdar, BS",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "Pakistan",
"facility": "Mobilty Quest",
"geoPoint": {
"lat": 31.558,
"lon": 74.35071
},
"state": "Punjab",
"status": "RECRUITING",
"zip": "54000"
}
]
},
"descriptionModule": {
"briefSummary": "Cerebral palsy is a motor disorder caused by the damage to the developing brain. Feeding and swallowing difficulties are common in children with cerebral palsy (CP). Poor postural control and oral motor dysfunction results in extended feeding time, frequent coughing, choking and excessive drooling affecting their health and quality of life. The brain damage in CP is permanent that cannot be fixed however different oral motor exercises, oral facial facilitation and oral sensorimotor interventions are widely used for drool reduction and feeding difficulties in children with CP. Spastic cerebral palsy is one of most prevalent type of CP that is characterized by increased tone and stiffness of muscles. This research will be conducted to evaluate the comparative effects of oral motor facilitation technique (OMFT) and traditional oral motor exercises on drooling and feeding skills of children with spastic CP. OMFT is a complete protocol with a combination of techniques to deal with oral motor difficulties This study will be a randomized control trial. A total number of 12 children with Spastic cerebral palsy ( GMFS III-V) both male/female, between age range 3-12 and with feeding difficulties will be included in the study. Children with cerebral palsy and other co morbidities, seizures, risk of aspiration and who are on tube feeding will be excluded. Participants will be randomly allocated to two groups, either Group A (receiving OMFT) or Group B (receiving traditional oral motor exercise). Baseline scores will be recorded by using standardized tools OMAS for oral motor skill during feeding and DIS for drool severity with the consent of authors. Therapeutic sessions will be scheduled 3 days per week and 30 min a day for each group. The effects of interventions on drooling and feeding skills will be assessed after 8 and 16 weeks of sessions. Recorded data of all variables will be analyzed by using statistical package for social sciences (SPSS) for Windows Software, version 21."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Group 1 will receive exercises by using oral motor facilitation technique protocol three times a week Group 2 will receive traditional oral motor exercises three times per week",
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 10,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "10 Years",
"minimumAge": "3 Years",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Oral Motor Facilitation Technique And Traditional Exercises on Children With Cerebral Palsy",
"nctId": "NCT06343922",
"orgStudyIdInfo": {
"id": "Sadaf Riphah",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Change in Drooling"
},
{
"measure": "Change in feeding skills"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Riphah International University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-04"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-04"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-12-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Hip abductor strengthening exercise"
},
{
"name": "Intrinsic foot muscle strengthening along with conventional exercises"
}
]
},
"conditionsModule": {
"conditions": [
"Knee Osteoarthritis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Lahore",
"contacts": [
{
"email": "[email protected]",
"name": "Ayesha Anwar, DPT",
"phone": "03340003448",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Pakistan",
"facility": "THQ hospital KRK.",
"geoPoint": {
"lat": 31.558,
"lon": 74.35071
},
"state": "Punjab",
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The study will be Randomized controlled trail, Subject diagnosed with knee osteoarthritis meeting predetermined inclusion and exclusion criteria will be divided into two groups.Pre assessment will be done using pain, ROM, function, foot arches and knee alignment as subjective measurement through KOOS questionnaire, goniometer, 2D frontal plane projection, Berkemann foot prints using ink and paper ,30s chair stand test, nine step stair climb,40m fast paced walk test,Global rating of change score respectively . One group will be treated with hip abductor strengthening exercise along with conventional exercises and second group will be treated with intrinsic foot muscle strengthening exercise along with conventional exercises. Post treatment values recorded after the session.After data collection from defined study setting,data will be entered and analyzed at Riphah International University,Lahore"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 30,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "40 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Foot and Hip Abductor Strengthening in Patients With Knee Osteoarthritis.",
"nctId": "NCT06343909",
"orgStudyIdInfo": {
"id": "REC/RCR & AHS/23/0197Ayesha",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Knee Osteoarthritis Outcome Score (KOOS)"
},
{
"measure": "Berkemann foot prints"
}
],
"secondaryOutcomes": [
{
"measure": "Frontal plane projection"
},
{
"measure": "Goniometer"
},
{
"measure": "30 seconds chair stand test"
},
{
"measure": "Overall self-perception by Global Rating of Change Score"
},
{
"measure": "9 step stairs climb test."
},
{
"measure": "40-m fast-paced walk test"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Riphah International University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-06-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-06-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-11-23"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "monitorization reliability"
}
]
},
"conditionsModule": {
"conditions": [
"Sedation",
"BIS",
"Integrated Pulmonary Index"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Ankara",
"contacts": [
{
"email": "[email protected]",
"name": "tugbanur taygurt",
"phone": "+905322005632",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Turkey",
"facility": "Ankara City Hospital, Bilkent",
"geoPoint": {
"lat": 39.91987,
"lon": 32.85427
},
"state": null,
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "In this study, we aimed to investigate the predictability of possible respiratory complications and the effect of the addition of the integrated pulmonary (EPI) score to the evaluation of the patient's respiratory index status in addition to the SPO2 measurement available in standard ASA monitoring in pediatric patients undergoing interventional radiological procedures under sedoanesthesia."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "OTHER",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 68,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "18 Years",
"minimumAge": "2 Years",
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT"
]
},
"identificationModule": {
"acronym": "IPI",
"briefTitle": "Evaluation of Sedation Depth and Reliability With Integrated Pulmonary Index (IPI) Follow-up in Pediatric Radiological Interventions",
"nctId": "NCT06343896",
"orgStudyIdInfo": {
"id": "AnkaraCHBilkent-tntaygurt",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "EVALUATION OF IPI RELIABILITY IN PEDIATRIC PATIENTS"
}
],
"secondaryOutcomes": [
{
"measure": "BİS correlation with the IPI"
},
{
"measure": "pulse oximetry correlation with the IPI"
},
{
"measure": "noninvasive blood pressure"
},
{
"measure": "heart rate"
},
{
"measure": "respiratory rate"
},
{
"measure": "end tidal carbondioxide"
},
{
"measure": "apnea and hypoxia conditions that develop in the patient during anesthesia"
},
{
"measure": "postoperative recovery time"
},
{
"measure": "intraoperative total dose of medication used"
},
{
"measure": "postoperative nausea and vomiting"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Ankara City Hospital Bilkent"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-10-15"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-05"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-06-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "low-intensity focused ultrasound - low pressure"
},
{
"name": "low-intensity focused ultrasound - medium pressure"
},
{
"name": "low-intensity focused ultrasound - high pressure"
}
]
},
"conditionsModule": {
"conditions": [
"Somatic Pain"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Roanoke",
"contacts": [
{
"email": "[email protected]",
"name": "Jessica Florig, MPH",
"phone": "540-526-2261",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Wynn Legon, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Fralin Biomedical Research Institute at VTC",
"geoPoint": {
"lat": 37.27097,
"lon": -79.94143
},
"state": "Virginia",
"status": null,
"zip": "24016"
}
]
},
"descriptionModule": {
"briefSummary": "Investigating the relationship between input pressure of low-intensity focused ultrasound and an evoked potential in both eeg and fMRI."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "SEQUENTIAL",
"interventionModelDescription": "Primary cohort (safety) will be collected prior to full study collection. Primary collection will involve highest pressure application and follow-up safety scans (MRI) to be reviewed by a Neuroradiologist. Once cleared - parallel design will be utilized for eeg and fMRI cohorts. Both cohorts will receive 3 LIFU pressures randomized over 3 study visits. Electrical stimulations will be applied pre and post LIFU administration to induce somatosensory evoked potentials (SEPs).",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": "No masking, no sham. All subjects will receive all conditions, all of which are active.",
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "BASIC_SCIENCE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 25,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Investigation of Low-intensity Focused Ultrasound Pressure",
"nctId": "NCT06343883",
"orgStudyIdInfo": {
"id": "24-353",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Report of Symptoms Questionnaire"
},
{
"measure": "MRI"
}
],
"secondaryOutcomes": [
{
"measure": "EEG"
},
{
"measure": "fMRI"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Virginia Polytechnic Institute and State University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-07"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-07"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "testosterone pellet (100 mg)"
},
{
"name": "Placebo"
}
]
},
"conditionsModule": {
"conditions": [
"Menopause",
"Testosterone Deficiency",
"Estrogen Deficiency"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Estrogen and androgen deficiencies negatively impact the quality of life of women at different stages of life, especially after menopause. New modalities and new therapeutic alternatives have been researched. Parenteral administration of estradiol and testosterone could be effective to treat symptoms secondary to estrogen and androgen deficiencies and minimize these adverse events. This study evaluates the efficiency of subdermal implant-bioabsorbable use in women with menopausal symptoms associated with secondary estrogen and androgen deficiencies in women with natural menopause, premature ovarian failure or surgical menopause due to cervical cancer. Pharmacokinetic, biochemical, metabolic, thromboembolic and hormonal data will be evaluated, as well as the effects on quality of life, menopausal symptoms and sexual function after treatment."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Parallel Assignment",
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 140,
"type": "ESTIMATED"
},
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "60 Years",
"minimumAge": "18 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": "ESTIME",
"briefTitle": "Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)",
"nctId": "NCT06343870",
"orgStudyIdInfo": {
"id": "ESTIME",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Evaluate hormonal, metabolic thromboembolic and clinical effects on climacteric symptoms"
}
],
"secondaryOutcomes": [
{
"measure": "Evaluate response in quality of life and sexual function"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University of Sao Paulo General Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-04-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-01-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-31"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "self-assessment questionnaire"
}
]
},
"conditionsModule": {
"conditions": [
"Osteoarthritis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Bologna",
"contacts": null,
"country": "Italy",
"facility": "IRCCS Istituto Ortopedico Rizzoli, Clinica Ortopedica e Traumatologica II",
"geoPoint": {
"lat": 44.49381,
"lon": 11.33875
},
"state": "BO",
"status": null,
"zip": null
},
{
"city": "Milan",
"contacts": null,
"country": "Italy",
"facility": "Unità Operativa di Chirurgia della Spalla I.R.C.C.S. Ospedale Galeazzi-Sant'Ambrogio",
"geoPoint": {
"lat": 45.46427,
"lon": 9.18951
},
"state": "MI",
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The present study represents the pilot phase of the project aimed at developing anatomical site-specific self-assessment questionnaires (shoulder, knee and ankle) that can advise the subject of the need for an orthopaedic specialist examination.The pilot phase of the project involves the collection of data from questionnaires in a population of subjects who have requested an orthopaedic consultation for the anatomical site covered by the questionnaire. Each questionnaire consists of questions designed to collect information about the patient's subjective condition.The data collected from the questionnaires will be used to evaluate the statistical significance (p value) of each question in the questionnaire in relation to the outcome of the orthopaedic specialist visit. Through a multivariate logistic analysis of the answers given by the subject, it will be possible to 'weight' each answer to obtain a final value that gives an indication of an orthopaedic specialist visit."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 150,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Joint Self-Assessment Forms for Knee, Ankle and Shoulder",
"nctId": "NCT06343857",
"orgStudyIdInfo": {
"id": "CE-AVEC 878/2022/Oss/AOUFe",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Observation of the distribution of questionnaire responses for each anatomical site."
}
],
"secondaryOutcomes": [
{
"measure": "Therapeutic indication of the orthopaedic specialist for each subject participating in the study"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University Hospital of Ferrara"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-04-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "ACTIVE_NOT_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-04-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "cardiac imaging to assess left ventricular volumes and function"
}
]
},
"conditionsModule": {
"conditions": [
"Myocardial Infarction",
"Ventricular Remodeling"
]
},
"contactsLocationsModule": null,
"descriptionModule": {
"briefSummary": "Following myocardial infarction, female individuals demonstrate a poorer prognosis, characterized by elevated rates of mortality and heart failure. A primary hypothesis suggests unfavorable cardiac remodeling in women. This remodeling, defined as alterations in cardiac size and shape post-infarction, necessitates repeated non-invasive imaging for study."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "DIAGNOSTIC",
"timePerspective": null
},
"enrollmentInfo": {
"count": 1650,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "REMOVE 2",
"briefTitle": "Disparities in Myocardial Infarction Remodeling According to Gender",
"nctId": "NCT06343844",
"orgStudyIdInfo": {
"id": "49RC23_0070",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Asses left ventricular remodeling disparities between genders"
}
],
"secondaryOutcomes": [
{
"measure": "Evaluate the evolution of remodeling at Month 3"
},
{
"measure": "Assess remodeling changes between inclusion and Month 12"
},
{
"measure": "Assess the prevalence of comorbidities and their impact on the effect on the outcome: post-infarction cardiac remodeling with gender (cardiovascular risk factors, renal function, hepatic functionperipheral artery disease, way of life)"
},
{
"measure": "Explore prognostic disparities between men and women."
},
{
"measure": "Evaluate lifestyle habits up to 10 years: outcome anxiety/depression"
},
{
"measure": "Evaluate lifestyle habits up to 10 years: outcome diet score"
},
{
"measure": "Evaluate lifestyle habits up to 10 years: outcome physical activity"
},
{
"measure": "Assess the risk of remodeling based on specific parameters in female subjects: presence of endometriosis"
},
{
"measure": "Assess the risk of remodeling based on specific parameters in female subjects: presence of polycystic ovary"
},
{
"measure": "Assess the risk of remodeling based on specific parameters in female subjects: presence of uterine fibroma"
},
{
"measure": "Assess the risk of remodeling based on specific parameters in female subjects: presence of hormonal therapy"
},
{
"measure": "Assess the risk of remodeling based on specific parameters in female subjects: date of first period"
},
{
"measure": "Assess the risk of remodeling based on specific parameters in female subjects: pregnancy"
},
{
"measure": "Assess the risk of remodeling based on specific parameters in female subjects: children"
},
{
"measure": "Assess the risk of remodeling based on specific parameters in female subjects: obstetrical event"
},
{
"measure": "Assess the risk of remodeling based on specific parameters in female subjects: menopause"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER_GOV",
"name": "University Hospital, Angers"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2040-07-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2039-09-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "2-Dimensional (2-D) Photographs (Visit 1/ Follow up Visit 3-6)"
},
{
"name": "3-Dimensional (3-D) Photographs (Visit 1- 6)"
},
{
"name": "Ultrasound Soft Tissue Assessment (Visit 1/ Follow up Visit 4-6)"
},
{
"name": "Magnetic Resonance Imaging Volume Assessment (Visit 1/ Follow up Visit 4-6)"
},
{
"name": "BREAST-QTM questionnaire (Visit 1/ Follow up Visit 4-6)"
}
]
},
"conditionsModule": {
"conditions": [
"Autologous Fat Grafting"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "This is a single-arm, prospective pilot study that will objectively assess outcomes in patients electively undergoing Autologous Fat Transfer (AFT) for breast or chest wall reconstruction. Patients planning to undergo autologous fat transfer for breast or chest wall reconstruction will be enrolled prospectively. Participants will undergo standard photographs (2-D imaging) of their chest wall and torso, including the breasts, and complete a validated questionnaire (BREAST-QTM) to evaluate patient satisfaction, and quality of life, all standard of care. The 3D photographs, Magnetic resonance imaging (MRI), and Ultrasound (US) are routinely used in practice but will be performed for research purposes in this study. All imaging procedures and questionnaires will be obtained at baseline and follow-up visits 3-6."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "Patients planning to undergo autologous fat transfer for breast or chest wall reconstruction will be enrolled prospectively. Participants will undergo standard photographs (2-D imaging) of their chest wall and torso, including the breasts, and complete a validated questionnaire (BREAST-QTM) to evaluate patient satisfaction, and quality of life, all standard of care. The 3D photographs, MRI, and US are routinely used in practice but will be performed for research purposes in this study.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "OTHER",
"timePerspective": null
},
"enrollmentInfo": {
"count": 15,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Quantitative Assessment of Autologous Fat Transfer",
"nctId": "NCT06343831",
"orgStudyIdInfo": {
"id": "IRB23-1646",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Change from baseline in breast/chest wall following autologous fat grafting, measured by imaging."
}
],
"secondaryOutcomes": [
{
"measure": "Change from baseline in quality of life as measured by the BREAST-QTM survey."
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "National Institutes of Health (NIH)"
},
{
"name": "University of Houston"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "University of Chicago"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-12"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "The Compassion Project: Intervention to Reduce Empathy-Based Stress in Staff"
}
]
},
"conditionsModule": {
"conditions": [
"Reduction of Empathy-Based Stress in Healthcare Staff"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Compassion is recognising that someone is suffering and wanting to help them. Compassion fatigue is a reduction in capacity to feel compassion for others. Secondary trauma is the experience of traumatic responses to hearing about someone else's trauma. Burnout is depersonalisation, emotional exhaustion, and feeling less good at one's job. Compassion fatigue, secondary trauma and burnout can all be referred to as empathy-based stress. This is a problem for healthcare staff and their patients.Staff experiencing empathy-based stress deliver less high quality care, which can lead to serious consequences for patients. Empathy-based stress is also associated with staff sickness, which is bad for staff and costly to the United Kingdom's National Health Service (NHS).Child and adolescent mental health (CAMHS) wards are busy, high-pressure environments where families and young people are often upset, resources are stretched, and staff are managing high levels of patient risk of self-harm or suicide.The principal investigator has already reviewed research on empathy-based stress and interventions to prevent and/or reduce it in mental health ward staff. This evidence has been presented to CAMHS ward staff, managers, commissioners, patients and families and these stakeholders have co-designed an intervention for wards, to reduce empathy-based stress. The intervention aims to help staff to feel better and care better.This pilot study aims to test and improve our intervention on two CAMHS wards, measuring how useful and well-liked it is, and how feasible it would be to use it and to test it on more wards. Staff on CAMHS wards will be offered a modular intervention including psychoeducation about empathy based stress and ways of combatting it, and workplace stressor and management toolkits. NHS CAMHS ward staff and patients will be asked to complete questionnaires and a subsample of staff will be asked to complete interviews about the process of the intervention."
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "SEQUENTIAL",
"interventionModelDescription": "The study uses a repeated AB design on two ward sites to assess feasibility, acceptability and usefulness of a novel intervention for empathy-based stress in staff, and to test feasibility of this study design. It is not assessing efficacy. The extended baseline measure is the control, there is no control group",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 100,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "13 Years",
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Compassion Project: Developing an Empathy-Based Stress Intervention",
"nctId": "NCT06343818",
"orgStudyIdInfo": {
"id": "NIHR301578",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Ward-level contextual factors"
}
],
"primaryOutcomes": [
{
"measure": "Acceptability of intervention"
},
{
"measure": "Feasibility of intervention"
},
{
"measure": "Perceived usefulness of intervention"
},
{
"measure": "Feasibility of Study"
},
{
"measure": "Feasibility of gathering data on staff empathy-based stress using the Professional Quality of Life Scale at multiple timepoints"
}
],
"secondaryOutcomes": [
{
"measure": "Feasibility of assessing health economics data using a Health-related Quality of Life questionnaire"
},
{
"measure": "Process measures to assess potential mechanisms of change"
},
{
"measure": "Feasibility of gathering young person and parent/carer data on compassionate care"
},
{
"measure": "Feasibility of gathering young person and parent/carer data on experience of service"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "National Institute for Health Research, United Kingdom"
},
{
"name": "Oxford Health NHS Foundation Trust"
},
{
"name": "Central and North West London NHS Foundation Trust"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "University of Bath"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-08-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-08-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-08-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "AJ1-11095"
}
]
},
"conditionsModule": {
"conditions": [
"Primary Myelofibrosis",
"Post-Essential Thrombocythemia Myelofibrosis",
"Post-Polycythemia Vera Myelofibrosis",
"PMF",
"PPV-MF",
"PET-MF"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Tampa",
"contacts": [
{
"email": "[email protected]",
"name": "Andrew Kuykendall, MD",
"phone": "813-745-4639",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Moffitt Cancer Cancer Center",
"geoPoint": {
"lat": 27.94752,
"lon": -82.45843
},
"state": "Florida",
"status": null,
"zip": "33612"
},
{
"city": "Kansas City",
"contacts": [
{
"email": "[email protected]",
"name": "Abdulraheem Yacoub, MD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "University of Kansas Medical Center",
"geoPoint": {
"lat": 39.11417,
"lon": -94.62746
},
"state": "Kansas",
"status": null,
"zip": "66160"
},
{
"city": "Boston",
"contacts": [
{
"email": "[email protected]",
"name": "Gabriela Hobbs, MD",
"phone": "617-724-1124",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Massachusetts General Hospital",
"geoPoint": {
"lat": 42.35843,
"lon": -71.05977
},
"state": "Massachusetts",
"status": null,
"zip": "02114"
},
{
"city": "Boston",
"contacts": [
{
"email": "[email protected]",
"name": "Jacqueline Garcia, MD",
"phone": "617-632-1906",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Dana Farber Cancer Institute",
"geoPoint": {
"lat": 42.35843,
"lon": -71.05977
},
"state": "Massachusetts",
"status": null,
"zip": "02115"
},
{
"city": "Saint Louis",
"contacts": [
{
"email": "[email protected]",
"name": "Stephen Oh, MD",
"phone": "314-362-8814",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Washington University School of Medicine",
"geoPoint": {
"lat": 38.62727,
"lon": -90.19789
},
"state": "Missouri",
"status": null,
"zip": "63110"
},
{
"city": "New York",
"contacts": [
{
"email": "[email protected]",
"name": "John Mascarenhas, MD",
"phone": "212-241-8839",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Icahn School of Medicine at Mount Sinai",
"geoPoint": {
"lat": 40.71427,
"lon": -74.00597
},
"state": "New York",
"status": null,
"zip": "10029"
},
{
"city": "Charlotte",
"contacts": [
{
"email": "[email protected]",
"name": "Michael Grunwald, MD",
"phone": "980-442-4363",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Levine Cancer Institute",
"geoPoint": {
"lat": 35.22709,
"lon": -80.84313
},
"state": "North Carolina",
"status": null,
"zip": "28204"
},
{
"city": "Columbus",
"contacts": [
{
"email": "[email protected]",
"name": "Uma Borate, MD",
"phone": "614-685-9828",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "The Ohio State University Comprehensive Cancer Center",
"geoPoint": {
"lat": 39.96118,
"lon": -82.99879
},
"state": "Ohio",
"status": null,
"zip": "43210"
},
{
"city": "Houston",
"contacts": [
{
"email": "[email protected]",
"name": "Prithviraj Bose, MD",
"phone": "713-792-7747",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "MD Anderson Cancer Center",
"geoPoint": {
"lat": 29.76328,
"lon": -95.36327
},
"state": "Texas",
"status": null,
"zip": "77030"
}
]
},
"descriptionModule": {
"briefSummary": "AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of an orally administered type II JAK2 inhibitor, AJ1-11095, in subjects with primary or secondary myelofibrosis previously treated with at least one type I JAK2 inhibitor."
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "SEQUENTIAL",
"interventionModelDescription": "This dose escalation study will follow a 3+3 cohort design until the RP2D and/or MTD is determined.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 76,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)",
"nctId": "NCT06343805",
"orgStudyIdInfo": {
"id": "AJX-101",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Number of patients with treatment-emergent adverse events as assessed by CTCAE v 5.0."
},
{
"measure": "Number of patients with Dose Limiting Toxicities (DLTs)"
},
{
"measure": "To establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of AJ1-11095"
}
],
"secondaryOutcomes": [
{
"measure": "To assess clinical response to AJ1-11095 evaluated by the Total Symptom Score (TSS)."
},
{
"measure": "To assess clinical response to AJ1-11095 evaluated by spleen volume assessments."
},
{
"measure": "To assess clinical response to AJ1-11095 evaluated by spleen length assessments."
},
{
"measure": "To assess clinical response to AJ1-11095 evaluated through spleen size improvement."
},
{
"measure": "To evaluate the Area Under the Curve (AUC) of AJ1-11095"
},
{
"measure": "To evaluate the Cmax of AJ1-11095"
},
{
"measure": "To evaluate the Tmax of AJ1-11095"
},
{
"measure": "To evaluate the half-life of AJ1-11095"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Ajax Therapeutics, Inc."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-02-15"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-18"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-08-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-07-15"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "RLS-0071"
}
]
},
"conditionsModule": {
"conditions": [
"Steroid Refractory GVHD"
]
},
"contactsLocationsModule": null,
"descriptionModule": {
"briefSummary": "This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute Graft-versus-Host Disease (aGvHD) in hospitalized patients who are steroid-refractory."
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "SEQUENTIAL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 66,
"type": "ESTIMATED"
},
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "12 Years",
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "AURORA",
"briefTitle": "Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease",
"nctId": "NCT06343792",
"orgStudyIdInfo": {
"id": "RLS-0071-203",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Number of participants with treatment-related adverse events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)"
},
{
"measure": "Overall Response Rate (ORR) of RLS-0071"
}
],
"secondaryOutcomes": [
{
"measure": "Incidence of refractoriness (to RLS-0071 +/- ruxolitinib)"
},
{
"measure": "Overall corticosteroid use"
},
{
"measure": "Initiation of additional or alternative treatment(s) for aGvHD (including an increase in steroid dose to >2 mg/kg methylprednisolone equivalent)"
},
{
"measure": "Change or shift in Stage for lower GI aGvHD, liver aGvHD, skin aGvHD, or upper GI aGvHD from baseline based on MAGIC Criteria"
},
{
"measure": "Attainment of Stage 0 or 1 lower GI aGvHD, liver aGvHD, skin aGvHD, or upper GI aGvHD"
},
{
"measure": "Change or shift in overall Grade of aGvHD"
},
{
"measure": "Overall survival"
},
{
"measure": "Non-relapse mortality"
},
{
"measure": "Duration of hospital stay"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "ReAlta Life Sciences, Inc."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-09"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-04"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Deucrictibant, Placebo"
}
]
},
"conditionsModule": {
"conditions": [
"Hereditary Angioedema",
"Hereditary Angioedema Type I",
"Hereditary Angioedema Type II",
"Hereditary Angioedema Types I and II",
"Hereditary Angioedema Attack",
"Hereditary Angioedema With C1 Esterase Inhibitor Deficiency",
"Hereditary Angioedema - Type 1",
"Hereditary Angioedema - Type 2",
"C1 Esterase Inhibitor [C1-INH] Deficiency",
"C1 Esterase Inhibitor Deficiency",
"C1 Esterase Inhibitor, Deficiency of",
"C1 Inhibitor Deficiency"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Paradise Valley",
"contacts": null,
"country": "United States",
"facility": "Study Site",
"geoPoint": {
"lat": 33.53115,
"lon": -111.94265
},
"state": "Arizona",
"status": "RECRUITING",
"zip": "85258"
},
{
"city": "Walnut Creek",
"contacts": null,
"country": "United States",
"facility": "Study Site",
"geoPoint": {
"lat": 37.90631,
"lon": -122.06496
},
"state": "California",
"status": "RECRUITING",
"zip": "94598"
},
{
"city": "Madison",
"contacts": null,
"country": "United States",
"facility": "Study Site",
"geoPoint": {
"lat": 32.46181,
"lon": -90.11536
},
"state": "Mississippi",
"status": "RECRUITING",
"zip": "39110"
}
]
},
"descriptionModule": {
"briefSummary": "This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryngeal attacks, in participants ≥12 to ≤75 years of age with HAE type 1 or type 2 (HAE-1/2), a proportion of whom are using long-term prophylactic medication for HAE."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "CROSSOVER",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 120,
"type": "ESTIMATED"
},
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "12 Years",
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "RAPIDe-3",
"briefTitle": "Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema",
"nctId": "NCT06343779",
"orgStudyIdInfo": {
"id": "PHA022121-C306",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Time to onset of symptom relief, defined as Patient Global Impression of Change (PGI-C) rating of at least \"a little better\" for 2 consecutive timepoints within 12 hours post-treatment."
}
],
"secondaryOutcomes": [
{
"measure": "Proportion of study drug-treated attacks achieving PGI-C rating of at least \"a little better\" at 4 hours post-treatment."
},
{
"measure": "Time to substantial symptom relief, defined as achieving PGI-C rating of at least \"better\" for 2 consecutive timepoints within 12 hours post-treatment."
},
{
"measure": "Time to substantial symptom relief by Patient Global Impression of Severity (PGI-S)."
},
{
"measure": "Time to complete symptom resolution, defined as achieving PGI-S rating of \"none\" within 48 hours post-treatment."
},
{
"measure": "Time to End of Progression (EoP) in attack symptoms within 12 hours."
},
{
"measure": "Proportion of study drug-treated attacks requiring rescue medication within 24 hours post-treatment."
},
{
"measure": "Proportion of attacks achieving symptom resolution."
},
{
"measure": "Time to substantial symptom relief by Angioedema Symptom Rating Scale (AMRA)."
},
{
"measure": "Time to almost complete or complete symptom relief by AMRA."
},
{
"measure": "Proportion of study drug-treated attacks reaching almost complete or complete symptom relief by AMRA."
},
{
"measure": "Time to EoP in attack symptoms within 12 hours."
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Pharvaris Netherlands B.V."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-03"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-03"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-02-26"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "DNA collation and genotyping"
}
]
},
"conditionsModule": {
"conditions": [
"Dental Caries Secondary to Polymorphisms",
"Polymorphisms in Enamel Encoding Genes"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Giza",
"contacts": null,
"country": "Egypt",
"facility": "Faculty of Dentistry, October 6 University",
"geoPoint": {
"lat": 30.00808,
"lon": 31.21093
},
"state": null,
"status": null,
"zip": "12511"
}
]
},
"descriptionModule": {
"briefSummary": "A Cross-Sectional Study aims to shed light on potential genetic determinants influencing dental caries susceptibility within this demographic and significantly understanding of genetic factors associated with dental caries, particularly within the context of the Egyptian population, providing valuable insights into the genetic aspects of oral health. The research methodology involved a comprehensive examination of these polymorphic loci ENAM, AMBN, TUFT1 and KLK4 and their prevalence, employing rigorous statistical analyses to establish potential correlations between these genetic variants and susceptibility to dental caries."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CONTROL",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 204,
"type": "ACTUAL"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "22 Years",
"minimumAge": "15 Years",
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Polymorphisms in ENAM, AMBN, and KLK4 Contribute to DCS.",
"nctId": "NCT06343766",
"orgStudyIdInfo": {
"id": "RECO6U/24-2022",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Polymorphisms in genes associated with enamel formation and mineralization and dental caries susceptibility."
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Amina Fouad Farag"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-11-05"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-11-05"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-11-06"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Opioid free analgesia"
},
{
"name": "Opioid based Anesthesia"
}
]
},
"conditionsModule": {
"conditions": [
"Quality of Recovery",
"Pain, Postoperative",
"Elective Laparoscopic Cholecystectomy"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Cairo",
"contacts": [
{
"email": null,
"name": "Ahmed El-ghanam",
"phone": "201116171706",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Egypt",
"facility": "Ain Shams University",
"geoPoint": {
"lat": 30.06263,
"lon": 31.24967
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The aim of this study is to compare the quality of recovery from general anesthesia and surgery using the quality of recovery 15 item scale (QoR-15) for participant's receiving opioid-Sparing anesthesia with those receiving standard opioid-containing anesthesia in Patients undergoing a scheduled laparoscopic cholecystectomy."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 50,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Quality of Recovery After Laparoscopic Cholecystectomy Comparing Opioid Free Analgesia Versus Opioid Free Anesthesia",
"nctId": "NCT06343753",
"orgStudyIdInfo": {
"id": "FMASU MD46/2024",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Quality of recovery"
}
],
"secondaryOutcomes": [
{
"measure": "Post operative pain"
},
{
"measure": "Postoperative Hypoxia"
},
{
"measure": "Postoperative nausea and vomiting"
},
{
"measure": "Postoperative bradycardia"
},
{
"measure": "Postoperative hypotension"
},
{
"measure": "Postoperative hypertension"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Ain Shams University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-10-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-05-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "COMET-Y"
}
]
},
"conditionsModule": {
"conditions": [
"Self Esteem",
"Quality of Life"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The goal of this pilot study is to evaluate COMET-Y in 22 adolescents (11-18 years) with various mental health problems and low self-esteem. The main questions is: Does COMET-Y, parallel to care as usual (CAU), improve self-esteem?Before and after the training participants fill in questionnaires to measure self-esteem, mental health problems, resilience, quality of life, emotions and individual goals. Some of the outcomes are measured through diary methods. Youth and therapists will be assessed to evaluate feasibility and acceptability of the COMET-Y training."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "This pilot study is a pre-post study.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 22,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "18 Years",
"minimumAge": "11 Years",
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT"
]
},
"identificationModule": {
"acronym": "COMET-Y",
"briefTitle": "First Evaluation of COMET-Y",
"nctId": "NCT06343740",
"orgStudyIdInfo": {
"id": "PSY-2324-S-0136",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Self Esteem"
}
],
"secondaryOutcomes": [
{
"measure": "Domain-specific Self Esteem"
},
{
"measure": "Mental Health Problems"
},
{
"measure": "Quality of life"
},
{
"measure": "Affect"
},
{
"measure": "Resilience"
},
{
"measure": "Ecological Momentary Assessments - Global self-esteem"
},
{
"measure": "Ecological Momentary Assesments - Goal Based Outcome (GBO) tool for young people"
},
{
"measure": "Ecological Momentary Assesments - Domain-specific self-esteem"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Accare"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-04"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Egg white protein pudding"
},
{
"name": ": Ensure Plus"
}
]
},
"conditionsModule": {
"conditions": [
"Kidney Failure",
"Frailty",
"Kidney Disease, Chronic"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The goal of this clinical trial is to compare protein supplements in patients with kidney failure on dialysis. The main questions it aims to answer are:* To determine whether the supplementation of egg white protein pudding in a population of individuals with kidney failure on dialysis is feasible.* To determine whether egg white protein pudding supplementation improves serum albumin similar to other standard nutritional supplements.* To determine the effects of the egg white protein pudding on frailty measures, dietary intakes and analytes in the blood and urine. Participants will receive either the egg white pudding (experimental) or control (Ensure plus) at the end of their dialysis treatments 3-days per week for 12 weeks."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "This trial is an open-label randomized controlled parallel arm feasibility tria",
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 54,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF)",
"nctId": "NCT06343727",
"orgStudyIdInfo": {
"id": "HS25870 (H2023:026)",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Eligibility to randomization ratio"
},
{
"measure": "Weekly recruitment rate"
},
{
"measure": "Adherence to Egg pudding"
}
],
"secondaryOutcomes": [
{
"measure": "Serum albumin"
},
{
"measure": "Hand grip strength"
},
{
"measure": "Change in gait speed"
},
{
"measure": "Five rep chair stand time"
},
{
"measure": "Tandem balance time"
},
{
"measure": "Serum bicarbonate"
},
{
"measure": "Calcium"
},
{
"measure": "Urine albumin"
},
{
"measure": "chloride"
},
{
"measure": "phosphorus"
},
{
"measure": "Potassium"
},
{
"measure": "Sodium"
},
{
"measure": "HbA1c"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "University of Manitoba"
},
{
"name": "Manitoba Egg Farmers"
}
],
"leadSponsor": {
"class": "NETWORK",
"name": "Seven Oaks Hospital Chronic Disease Innovation Centre"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-07-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-05-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "FB1003"
},
{
"name": "Placebo"
}
]
},
"conditionsModule": {
"conditions": [
"Healthy Volunteers"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The purpose of this study is to evaluate safety and tolerability of FB1003 when given subcutaneously to healthy participants. Blood tests will be done to examine blood exposure, concentration and half-life of FB1003 following administrations. For each participant, the study will last up to about 12 weeks for single ascending dose part, and 18 weeks for multiple ascending dose part, including screening."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "BASIC_SCIENCE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 64,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "55 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Study of FB1003 in Healthy Subject",
"nctId": "NCT06343714",
"orgStudyIdInfo": {
"id": "FB1003-04-101",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The primary endpoint in the study is the incidence and severity of treatment emergent adverse events (TEAEs) in participants treated with FB1003 or placebo."
}
],
"secondaryOutcomes": [
{
"measure": "FB1003 serum concentrations over time"
},
{
"measure": "PK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC0-∞) of FB1003"
},
{
"measure": "Presence of anti-FB1003 antibodies over time"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "4B Technologies Limited"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-06-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-06-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-03"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Implicit motor imagery"
},
{
"name": "Explicit motor imagery"
}
]
},
"conditionsModule": {
"conditions": [
"Cerebral Palsy, Spastic"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Zonguldak",
"contacts": [
{
"email": "[email protected]",
"name": "Seda AYAZ TAŞ, Phd",
"phone": "05495458040",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Turkey",
"facility": "Kdz. Ereğli Gökkuşağı Özel Eğitim ve Rehabilitasyon Merkezi",
"geoPoint": {
"lat": 41.45139,
"lon": 31.79305
},
"state": "Ereğli",
"status": "RECRUITING",
"zip": "67300"
},
{
"city": "Bolu",
"contacts": [
{
"email": "[email protected]",
"name": "Seda Ayaz Taş, Phd",
"phone": "05495458040",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Turkey",
"facility": "Bolu Abant İzzet Baysal University",
"geoPoint": {
"lat": 40.73583,
"lon": 31.60611
},
"state": "Gölköy/ Bolu",
"status": "RECRUITING",
"zip": "14030"
},
{
"city": "Düzce",
"contacts": [
{
"email": "[email protected]",
"name": "Seda AYAZ TAŞ, Phd",
"phone": "05495458040",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Turkey",
"facility": "Düzce Gökkuşağı Özel Eğitim ve Rehabilitasyon Merkezi",
"geoPoint": {
"lat": 40.83889,
"lon": 31.16389
},
"state": "Merkez",
"status": "RECRUITING",
"zip": "81100"
}
]
},
"descriptionModule": {
"briefSummary": "The aim of this study was to investigate implicit and explicit motor imagery skills in children with spastic cerebral palsy and typically developing children. The main questions it aims to answer are:* There is a difference between the implicit motor imagery skills of children with bilateral and unilateral CP.* There is a difference between the explicit motor imagery skills of children with bilateral and unilateral CP.* There is a difference between the implicit motor imagery skills of children with cerebral palsy and typically developing children.* There is a difference between the explicit motor imagery skills of children with cerebral palsy and typically developing children."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "OTHER",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 90,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "18 Years",
"minimumAge": "6 Years",
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Investigation of Motor Imaging Skills in Children With Spastic Cerebral Palsy",
"nctId": "NCT06343701",
"orgStudyIdInfo": {
"id": "BAİBÜ-SAT4",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Explicit motor imagery -1"
}
],
"secondaryOutcomes": [
{
"measure": "Explicit motor imagery - 2"
},
{
"measure": "Explicit motor imagery - 3"
},
{
"measure": "Implicit motor imagery"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Abant Izzet Baysal University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-06-25"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-05-05"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-07-18"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "\"Assessment of Balance and Lower Extremity Gross Motor Function with and without DAFO\""
}
]
},
"conditionsModule": {
"conditions": [
"Diplegic Cerebral Palsy"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "\" Study will investigate the immediate effect of DAFO usage on balance and gross motor functions in individuals with spastic diplegic cerebral palsy. The study is planned to be conducted with children aged 4-15 who have GMFCS levels 1 and 2 and who are willing to participate along with their families at the Turkey Spastic Children Foundation Metin Sabancı Special Education and Rehabilitation Center. During the dates of the study, children who meet the inclusion criteria will be evaluated. Demographic information such as age, height, and weight will be obtained for the participating children. To classify the gross motor levels of the children, the Gross Motor Function Classification System (GMFCS), the Manual Abilities Classification System (MACS) for hand skills, the Communication Function Classification System (CFCS) for communication skills, and the Eating and Drinking Ability Classification System (EDACS) for feeding skills will be used. In addition, the Gross Motor Function Measure (GMFM-88) items D and E for assessing motor skills, the Wii Balance Board for testing balance, the Pediatric Berg Balance Scale, and the functional reach test will be utilized. The balance and gross motor functions of the included children will be assessed in two different ways: with and without DAFO. Data analysis will be conducted by a blinded statistician who is not part of the research team. IBM SPSS 26 (Statistical Package for Social Sciences) will be used for statistical analysis of the data. Normality of continuous variables will be assessed using the Kolmogorov-Smirnov test. If continuous variables follow a normal (parametric) distribution, paired sample t-tests will be conducted on pre-test and post-test data. If the data are non-parametric, Wilcoxon test will be used. Pearson chi-square test or Spearman correlation coefficient will be used to determine the relationship between variables based on assumptions. Results will be evaluated at a significance level of p \\< 0.05 with a 95% confidence interval.\""
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_ONLY",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 38,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "15 Years",
"minimumAge": "4 Years",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "\"Immediate Effect of DAFO on Gross Motor Function and Balance in Diplegic Cerebral Palsy",
"nctId": "NCT06343688",
"orgStudyIdInfo": {
"id": "BAIBU-FTR-SAT-5",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Wii Balance Board"
},
{
"measure": "\"The Gross Motor Function Measure-88 (D-E) (GMFM-88)"
},
{
"measure": "The Functional Reach Test"
},
{
"measure": "\"The Pediatric Berg Balance Scale (PBBS)"
}
],
"secondaryOutcomes": [
{
"measure": "\"The Eating and Drinking Ability Classification System (EDACS)"
},
{
"measure": "\"The Manual Abilities Classification System (MACS)"
},
{
"measure": "\"The Gross Motor Function Classification System (GMFCS)"
},
{
"measure": "\"The Communication Function Classification System (CFCS)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Abant Izzet Baysal University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-04-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-12-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-03"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "There is no intervention"
}
]
},
"conditionsModule": {
"conditions": [
"Occupational Health"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Linköping",
"contacts": [
{
"email": "[email protected]",
"name": "Anneli Peolsson, Prof., PhD",
"phone": "+46700850599",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Carlotte Wåhlin, Assoc. Prof, PhD",
"phone": "+46101036267",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Sweden",
"facility": "Occupational and Environmental Medicine Centre",
"geoPoint": {
"lat": 58.41086,
"lon": 15.62157
},
"state": null,
"status": "RECRUITING",
"zip": "581 85"
}
]
},
"descriptionModule": {
"briefSummary": "Research shows that the workplace is an important arena where much can be done to promote a sustainable working life while maintaining health. However, there is a lack of knowledge that is specific to dental care with regard to managers' and employees' perceptions of the work environment, systematic work environment management and work adaptations, as well as what measures in the workplace are necessary to create a health-promoting and sustainable work environment. There is also a lack of knowledge regarding what support employees and managers need in the systematic work environment management and what individual workplace adaptations that can work within dental care organizations."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "CROSS_SECTIONAL"
},
"enrollmentInfo": {
"count": 200,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": null,
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Systematic Health-promoting Work Environment Management in Dentistry",
"nctId": "NCT06343675",
"orgStudyIdInfo": {
"id": "Dnr 2024-00620-01",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Background data"
},
{
"measure": "Semi-structured individual interview study with managers, sub-study 2"
}
],
"primaryOutcomes": [
{
"measure": "Work Ability Single Item Scale (WAS)"
},
{
"measure": "Work Ability physical demands"
},
{
"measure": "Work Ability mental demands"
},
{
"measure": "Sick leave"
}
],
"secondaryOutcomes": [
{
"measure": "Structured Multidisciplinary Work Evaluation Tool (SMET)"
},
{
"measure": "Satisfaction with work"
},
{
"measure": "Global Health"
},
{
"measure": "Perceived stress"
},
{
"measure": "Health problems related to work"
},
{
"measure": "Pain during last 7 days"
},
{
"measure": "Psychological safety"
},
{
"measure": "Work environment problems"
},
{
"measure": "Health related problems"
},
{
"measure": "Questions about workplace improvements, work adjustments, and support in the workplace"
},
{
"measure": "Work adjustment and discomfort"
},
{
"measure": "Support and meaning in work"
},
{
"measure": "Sustainable work life"
},
{
"measure": "Systematic work environment management and safety"
},
{
"measure": "Targeted questions to managers"
},
{
"measure": "Work environment responsibility and measures"
},
{
"measure": "Work environment management support and education"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER_GOV",
"name": "Linkoeping University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-05"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "MERAKI_ABI"
}
]
},
"conditionsModule": {
"conditions": [
"Acquired Brain Injury"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Serra",
"contacts": [
{
"email": "[email protected]",
"name": "Miguel Fombuena, PhD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Selene Valero-Moreno, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Isabel Bellver Vercher",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Ana Alegre Soler",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "José Jorge Botella Trellis, Dr.",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Cristina Rocío Espejo Fernández, Dra.",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "María Carmen Badía Picazo, Dra.",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "Spain",
"facility": "Hospital Dr. Moliner",
"geoPoint": {
"lat": 39.68333,
"lon": -0.43333
},
"state": "Valencia",
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The study aims to analyse the impact of music therapy-based treatment on the comfort and well-being of patients with acquired brain injury (ABI). To achieve this objective, it is proposed to validate and implement a music therapy-based assessment and treatment protocol. The protocol will be tested in a pilot sample to improve adaptation to the disease and promote integration with the usual health measures of patients with ABI. Implementing a group treatment programme based on music therapy applied to patients with ABI."
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 80,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "Meraki_ABI",
"briefTitle": "Group Music Therapy for Acquired Brain Injury",
"nctId": "NCT06343662",
"orgStudyIdInfo": {
"id": "Meraki_Acquired Brain Injury",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Change in Discomfort ( Baseline (3 Assessments), Pre- Post)"
}
],
"secondaryOutcomes": [
{
"measure": "Barthel Index"
},
{
"measure": "Pfeiffer Short Form Mental State Questionnaire, SPMSQ"
},
{
"measure": "Charlson Comorbidity Index (CCI),"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University of Valencia"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-07"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-15"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-07"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Visual"
},
{
"name": "Auditory"
}
]
},
"conditionsModule": {
"conditions": [
"Pelvic Pain"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Valencia",
"contacts": null,
"country": "Spain",
"facility": "University of Valencia",
"geoPoint": {
"lat": 39.46975,
"lon": -0.37739
},
"state": null,
"status": null,
"zip": "46010"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this clinical trial is to compare the response of Explicit Motor Imagery interventions in patients suffering Persistent Pelvic Pain. The main question it aims to answer is:• Does the modality of application of Explicit Motor Imagery, either through visual or auditory stimuli, influence the response in patients suffering Persistent Pelvic Pain?Participants will receive an online Explicit Motor Imagery program either through visual inputs or auditory inputs. They will be instructed to follow the program en register their response.Researchers will compare visual Explicit Motor Imagery and auditory Explicit Motor Imagery to see if different inputs generate different responses in patients suffering Persistent Pelvic Pain."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 49,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Explicit Motor Imagery in Persistent Pelvic Pain",
"nctId": "NCT06343649",
"orgStudyIdInfo": {
"id": "CEUMA 187-2023-H",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Numerical Rating Scale"
},
{
"measure": "Pain Vigilance and Awareness Questionnaire"
}
],
"secondaryOutcomes": [
{
"measure": "Movement Imagery Questionnaire-Revised"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University of Valencia"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-11-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-23"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-11-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-11-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "VG-3927"
},
{
"name": "Placebo"
}
]
},
"conditionsModule": {
"conditions": [
"Healthy"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Miami",
"contacts": null,
"country": "United States",
"facility": "Clinical Pharmacology of Miami",
"geoPoint": {
"lat": 25.77427,
"lon": -80.19366
},
"state": "Florida",
"status": null,
"zip": "33014"
}
]
},
"descriptionModule": {
"briefSummary": "A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927 in Healthy Adults"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "SEQUENTIAL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 90,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "55 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Phase 1 Study of VG-3927 in Healthy Adults",
"nctId": "NCT06343636",
"orgStudyIdInfo": {
"id": "VG3927-02.101",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Adverse Events"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Vigil Neuroscience, Inc."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "ENROLLING_BY_INVITATION",
"primaryCompletionDateStruct": {
"date": "2024-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-09-27"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "myomucosal resection and direct closure"
},
{
"name": "superiorly based flap"
}
]
},
"conditionsModule": {
"conditions": [
"Velopharyngeal Insufficiency"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Minya",
"contacts": null,
"country": "Egypt",
"facility": "Faculty of medicine",
"geoPoint": {
"lat": 28.10988,
"lon": 30.7503
},
"state": null,
"status": null,
"zip": "61511"
}
]
},
"descriptionModule": {
"briefSummary": "Patients were classified into two groups. Group (A) patients included fifty patients had velopharyngeal insufficiency and were surgically corrected by the superiorly based pharyngeal flap. Group (B) patients included fifty patients had velopharyngeal insufficiency and were surgically corrected with myomucosal resection and direct closure of the posterior pharyngeal wall"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 150,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "10 Years",
"minimumAge": "4 Years",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Superiorly Based Pharyngeal Flap Versus Myomucosal Resection and Direct Closure",
"nctId": "NCT06343623",
"orgStudyIdInfo": {
"id": "fac.med.2018.15",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Improvement in the speech outcome"
}
],
"secondaryOutcomes": [
{
"measure": "obstructive sleep apnea"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Minia University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2022-10-16"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2022-10-16"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2018-10-12"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Active product"
},
{
"name": "Placebo"
}
]
},
"conditionsModule": {
"conditions": [
"Minimal Erythema Dose"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Ljubljana",
"contacts": [
{
"email": "[email protected]",
"name": "Katja Zmitek, PhD",
"phone": "002831700",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Katja Žmitek, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Tina Pogačnik, MSc",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Petra Keršmanc, MSc",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Sara Jereb, Msc",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "Slovenia",
"facility": "VIST - Faculty of Applied Sciences, Institute of Cosmetics",
"geoPoint": {
"lat": 46.05108,
"lon": 14.50513
},
"state": null,
"status": "RECRUITING",
"zip": "1000"
}
]
},
"descriptionModule": {
"briefSummary": "This is a double-blind, randomized, placebo-controlled interventional study of the effect of multiple-dose dietary intake on minimal erythema dose and other skin parameters."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 54,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "21 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "VIST-TO-UV",
"briefTitle": "The Effect of 8-week Dietary Intake of Novel Food Supplement on Minimal Erythema Dose",
"nctId": "NCT06343610",
"orgStudyIdInfo": {
"id": "VIST TO-UV 01-2024",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Change of minimal erythema dose"
}
],
"secondaryOutcomes": [
{
"measure": "Change of redness formation"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "VIST - Faculty of Applied Sciences"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-10"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-07"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": null,
"conditionsModule": {
"conditions": [
"Esophageal Cancer"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Richardson",
"contacts": [
{
"email": "[email protected]",
"name": "Crystee Cooper, DHEd",
"phone": "214-947-1280",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Zaid Haddadin, MS",
"phone": "2149471280",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Dhiresh Jeyarajah, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Methodist Richardson Medical Center",
"geoPoint": {
"lat": 32.94818,
"lon": -96.72972
},
"state": "Texas",
"status": "RECRUITING",
"zip": "75082"
}
]
},
"descriptionModule": {
"briefSummary": "This is a retrospective analysis to assess if high-volume hospital facilities experience greater or lesser rates of incidence in patients with esophageal cancer than low-volume facilities."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "RETROSPECTIVE"
},
"enrollmentInfo": {
"count": 30,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Volume Outcome Relationships and Effects",
"nctId": "NCT06343597",
"orgStudyIdInfo": {
"id": "037.HPB.2020.R",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Esophageal Cancer resection in patients in high volume (more than 5 esophagectomy performed per year) and low volume (less than 5 esophagectomy performed per year) hospital facilities"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Methodist Health System"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-06-15"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-06-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2020-06-15"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Study will conducted over a six-month period using a quasi-experimental Pre-test/Post-test design using Stamm's (2009) ProQOL Scale."
}
]
},
"conditionsModule": {
"conditions": [
"Burnout"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Mansfield",
"contacts": null,
"country": "United States",
"facility": "Methodist Mansfield Medical Center",
"geoPoint": {
"lat": 32.56319,
"lon": -97.14168
},
"state": "Texas",
"status": null,
"zip": "76063"
}
]
},
"descriptionModule": {
"briefSummary": "For leadership positions with only a handful of staff under their direct chain of command, this may not be all-consuming and detrimental to work-life balance. But for NMs with upwards of 100 direct reports, this can make for a never-ending stream of contact points. This study will implement several communication and behavioral strategies to determine how using provided smartphone tools impact work-life balance and professional burnout."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 6,
"type": "ACTUAL"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Are Personal Smartphones Hurting Work-Life Balance for Nurse Managers?",
"nctId": "NCT06343584",
"orgStudyIdInfo": {
"id": "023.NUR.2021.M",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "• Impact of smartphone tool utilization will be measured using a pre-study survey and post-study survey using the Professional Quality of Life (ProQOL) Scale (Stamm, 2009)."
}
],
"secondaryOutcomes": [
{
"measure": "• Participants in Group 1 will self-report on the post-study survey (Appendix D1) the number of tools implemented during the study duration."
},
{
"measure": "• Participants in Group 1 will self-report on the post-study survey (Appendix D1) the frequency of tool utilization during the study duration using a Likert scale."
},
{
"measure": "• Participants in Group 2 will self-report on the post-study survey (Appendix D2) using the ProQOL Scale."
},
{
"measure": "• Responses to the post-study survey from participants in Group 2 will be compared to participants in Group 1 to determine if utilizing a separate work smartphone during business hours has a greater improvement on work-life balance and burnout."
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Methodist Health System"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2022-05-06"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2022-05-06"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2021-07-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": null,
"conditionsModule": {
"conditions": [
"Cochlear Implants"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "This retrospective study aims at analysing data from clinical routine as anonymized data sets. The study aims at analysing clinical data from MED-EL Cochlear Implant (CI) recipients using a FLEX electrode array."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "RETROSPECTIVE"
},
"enrollmentInfo": {
"count": 2000,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": null,
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "LOTOS",
"briefTitle": "Longitudinal Outcomes in MED-EL Cochlear Implant Recipients Using a FLEX Electrode",
"nctId": "NCT06343571",
"orgStudyIdInfo": {
"id": "MED-EL_CRD_2022_12",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Evaluate short and long term longitudinal clinical performance data from MED-EL CIs to assess their clinical effectiveness and safety."
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "MED-EL Elektromedizinische Geräte GesmbH"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-08"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-08"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Questionnaires, clinical scales and instrumental tests"
}
]
},
"conditionsModule": {
"conditions": [
"Multiple Sclerosis",
"Parkinson Disease",
"Peripheral Neuropathy",
"Rare Diseases",
"Healthy",
"Healthy Aging"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Milano",
"contacts": [
{
"email": "[email protected]",
"name": "Antonio Caronni, MD, PhD",
"phone": "02 619111",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Italy",
"facility": "IRCCS Istituto Auxologico Italiano",
"geoPoint": {
"lat": 45.46427,
"lon": 9.18951
},
"state": "Milan",
"status": "RECRUITING",
"zip": null
},
{
"city": "Milano",
"contacts": null,
"country": "Italy",
"facility": "IRCCS Istituto Neurologico Carlo Besta",
"geoPoint": {
"lat": 45.46427,
"lon": 9.18951
},
"state": null,
"status": "ACTIVE_NOT_RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "Rare and very rare neurological diseases primarily or exclusively affect the nervous system with a prevalence of \\< 5 out of 10'000 and 100'000 people, respectively. Besides these, there are undiagnosed neurological diseases: neurological conditions without a diagnosis after completing a full diagnostic examination.Rare, very rare, and undiagnosed neurological diseases are complicated and progressive and often cause variegated motor signs, impairments, and syndromes.Balance and gait are frequently affected in these conditions, already at the clinical examination. These balance and gait impairments limit activities and cause an increased risk of falling. Falls can eventually result in injuries, even severe.There are only a few studies about these diseases, likely because of their rarity. Hence, the clinical presentation and the course of rare and very rare diseases are poorly known or even unknown. Essential information for these conditions' diagnosis, prognosis, treatment and rehabilitation is missing.MaNeNeND is an observational study underway at the Fondazione IRCCS Istituto Neurologico \"Carlo Besta\" (Milano) aimed at detailing the clinical and biological features of very rare and undiagnosed neurological diseases.Research questions:1. Do patients with rare (Ra), very rare (V) and undiagnosed (U) neurological diseases suffer a balance and gait impairment?2. Is there a correlation between the clinical and instrumental severity of the balance and gait impairment in RaVU neurological diseases?3. Are instrumental measures more sensitive in detecting balance and gait impairments in patients affected by a RaVU neurological disease than the clinical measures?4. Do the balance and gait impairments in RaVU neurological diseases worsen in time?The current project aims at diagnosing, quantifying and detailing the balance and gait impairment in rare, very rare and undiagnosed neurological diseases.To this aim, questionnaires, clinical scales and instrumental tests will be administered to these patients to collect a wide range of balance and gait measures.These measures will also integrate those collected with MaNeNeND to provide a more detailed description of patients with rare, very rare and diagnosed neurological diseases.Participants will complete two questionnaires: the Dizziness Handicap Inventory - short form (DHI-sf, an ordinal score of self-perceived balance) and the Modified Fatigue Impact Scale (MFIS, an ordinal score of self-perceived fatigue).Moreover, a clinician will administer the Mini Balance Evaluation Systems Test (Mini-BESTest, an ordinal score of balance), the 10 m walking test (for measuring the gait speed and other gait parameters) and the Timed Up and Go test (an instrumental measure of mobility and balance). Walking and the Timed Up and Go tests will be recorded with a trunk-worn inertial measurement unit.Finally, participants will be asked to complete an instrumental upright stance and gait assessment, the first consisting of standing on posturographic plates and the second of walking on a treadmill equipped with force sensors. When walking on the treadmill, an optoelectronic system will also record the position in time of limbs and trunk.The quantification of the severity of the balance and gait impairment of the patients suffering a rare, very rare or undiagnosed neurological disease will highlight these persons' therapeutic and rehabilitative needs.Comparing the balance and gait impairment of rare, very rare and undiagnosed diseases with those of multiple sclerosis, Parkinson's disease and peripheral neuropathy will highlight if the formers' balance and gait impairment has unique characteristics that could help ease the diagnosis of these uncommon conditions.The longitudinal measurements on rare, very rare and undiagnosed diseases will be paramount to identifying prognostic factors.In addition, the data collected in the current study will be crucial for future studies, for example, for estimating the sample size in clinical trials."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CONTROL",
"primaryPurpose": null,
"timePerspective": "CROSS_SECTIONAL"
},
"enrollmentInfo": {
"count": 200,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "GALVANISE",
"briefTitle": "Gait and Balance Impairment in Rare and Very Rare Neurological Diseases",
"nctId": "NCT06343558",
"orgStudyIdInfo": {
"id": "24C302",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Balance (Mini-BESTest)"
},
{
"measure": "Balance (Timed Up and Go test)"
},
{
"measure": "Gait speed"
},
{
"measure": "Gait analysis - kinematic - stride length"
},
{
"measure": "Gait analysis - kinematic - duration"
},
{
"measure": "Gait analysis - kinematic - width of the base of support"
},
{
"measure": "Gait analysis - kinematic - dorsal ankle angle"
},
{
"measure": "Gait analysis - dynamic - reaction force"
},
{
"measure": "Gait analysis - dynamic - ankle power"
},
{
"measure": "Gait analysis - dynamic - energy"
},
{
"measure": "Posturography - static - centre of pressure position"
},
{
"measure": "Posturography - static - centre of mass position"
},
{
"measure": "Posturography - dynamic - centre of pressure position"
},
{
"measure": "Posturography - dynamic - centre of mass position"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "IRCCS Istituto Neurologico Carlo Besta"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Istituto Auxologico Italiano"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-05-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-05-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-05-30"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Standard of Care"
},
{
"name": "Rehabilitation"
}
]
},
"conditionsModule": {
"conditions": [
"Acute Respiratory Failure"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "To evaluate, through a randomized clinical trial in groups/clusters (stepped wedge), the impact of specific bundles for disability prevention and early rehabilitation, focused on 3 domains (ICU, Ward and post-discharge), on health-related quality of life and other long- and short-term outcomes in critically ill patients affected by hypoxemic acute respiratory failure with suspected COVID-19."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "CROSSOVER",
"interventionModelDescription": "Cluster crossover randomized trial",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 2000,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "Rehab",
"briefTitle": "Evaluation of the Impact of Rehabilitation Strategies and Early Discharge After Respiratory Failure",
"nctId": "NCT06343545",
"orgStudyIdInfo": {
"id": "Rehab_PROADI",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Quality of life"
}
],
"secondaryOutcomes": [
{
"measure": "Mortality"
},
{
"measure": "Days alive and free of hospital"
},
{
"measure": "Rehospitalization"
},
{
"measure": "Return to work"
},
{
"measure": "Anxiety and Depression"
},
{
"measure": "New disability"
},
{
"measure": "Disability"
},
{
"measure": "Clinical Status"
},
{
"measure": "Cognitive impairment"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Hospital Israelita Albert Einstein"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-07-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "SXC-2023"
},
{
"name": "SXC-2023 Placebo"
}
]
},
"conditionsModule": {
"conditions": [
"Cocaine Use Disorder"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Overland Park",
"contacts": [
{
"email": "[email protected]",
"name": "Debra J Kelsh, MD",
"phone": "913-696-1601",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Debra J Kelsh, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Altasciences Clinical Kansas, Inc.",
"geoPoint": {
"lat": 38.98223,
"lon": -94.67079
},
"state": "Kansas",
"status": null,
"zip": "66212"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this clinical trial is to determine whether there are any interactions between the study drug and cocaine. Researchers will compare a treatment group and a placebo group to see if they experience any effects when administered cocaine after taking the treatment/placebo."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 20,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "59 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "SXC-2023 Cocaine Interaction Study",
"nctId": "NCT06343532",
"orgStudyIdInfo": {
"id": "NIDA-SXC-Ph1b-001",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Determine Safety and Tolerability of Oral SXC-2023 Co-administered with Intravenous Cocaine by Collecting Vital Signs and Adverse Events"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Promentis Pharmaceuticals, Inc."
},
{
"name": "Altasciences Company Inc."
},
{
"name": "Technical Resources International, Inc."
}
],
"leadSponsor": {
"class": "NIH",
"name": "National Institute on Drug Abuse (NIDA)"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-12"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Echocardiography"
}
]
},
"conditionsModule": {
"conditions": [
"Shock"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Shocked patients require prompt and accurate assessment of their hemodynamic status to guide appropriate management. Echocardiography is a valuable tool for assessing cardiac function, while laboratory parameters such as mixed venous oxygen saturation and arterial blood lactate provide insights into tissue perfusion and oxygen metabolism. This study aims to compare echocardiographic findings, including cardiac index, speckle tracking parameters, and tissue Doppler indices, with laboratory findings in the evaluation of hemodynamic monitoring in shocked patients."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_ONLY",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 60,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Echocardiographic and Laboratory Findings in Hemodynamic Monitoring of Shocked Patients",
"nctId": "NCT06343519",
"orgStudyIdInfo": {
"id": "Shocked Patients Monitoring",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Change in Shock Status After Fluid Therapy Based on Echocardiographic Assessment of Fluid Responsiveness"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Assiut University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-05"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-03"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Grassroots Ankle Flex"
}
]
},
"conditionsModule": {
"conditions": [
"Physical Therapy Modality"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Bozeman",
"contacts": [
{
"email": "[email protected]",
"name": "Corey Pew, PhD",
"phone": "406-994-6769",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Neuromuscular Biomechanics Laboratory",
"geoPoint": {
"lat": 45.67965,
"lon": -111.03856
},
"state": "Montana",
"status": "RECRUITING",
"zip": "59717"
}
]
},
"descriptionModule": {
"briefSummary": "Ankle range of motion is an important degree of freedom for performing activities of daily living. Limited range of ankle motion has been related to Achilles tendonitis, lower limb injury, and abnormal gait leading to overuse injury. While stretching and massage can help increase range of motion the amount and frequency of manual manipulation needed to affect range of motion is not accessible to an individual in their home. A new device has been developed to allow deep stretching of the ankle and surrounding muscles to help increase ankle dorsiflexion. This device can be used in an individual's home, without assistance, allowing more frequent stretching without increased visits to physical therapy. The goal of this study is to determine the effect of using this device during a course of treatment to improve ankle dorsiflexion in individuals with decreased ankle range of motion."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 10,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Ankle Dorsiflexion Changes With Assisted Stretching Device",
"nctId": "NCT06343506",
"orgStudyIdInfo": {
"id": "2023-929-EXPEDITED",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Ankle Range of Motion"
}
],
"secondaryOutcomes": [
{
"measure": "Ankle Strength"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Montana State University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-04"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-06-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-10-30"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Normal saline heated up to 50 °C"
}
]
},
"conditionsModule": {
"conditions": [
"Rhinosinusitis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Rawalpindi",
"contacts": null,
"country": "Pakistan",
"facility": "Benazir Bhutto Hospital",
"geoPoint": {
"lat": 33.6007,
"lon": 73.0679
},
"state": "Punjab",
"status": null,
"zip": "46000"
}
]
},
"descriptionModule": {
"briefSummary": "Control of bleeding is very important during endoscopic sinus surgery. Saline heated up to 50°C causes dilatation of vessels and edema without nasal mucosa necrosis. It also promotes the clotting cascade so helps in having a bloodless procedure.This randomized controlled trial was conducted on 60 patients divided into two groups (30 each). Group A was the interventional group in which patients were irrigated with saline of 50°C during surgery. Group B was the control group where room temperature saline was used. Operative field was assessed using the Boezaart score, duration of surgery and bleeding in ml.KEY WORDS:* Chronic rhinosinusitis (CRS)* Endoscopic sinus surgery* Boezaart score"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 60,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": null,
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Effect of Hot Saline Irrigation on the Operative Field During Endoscopic Sinus Surgery",
"nctId": "NCT06343493",
"orgStudyIdInfo": {
"id": "JALTAF",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Boezaart Score"
}
],
"secondaryOutcomes": [
{
"measure": "Bleeding in ml"
},
{
"measure": "Duration of Surgery"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Rawalpindi Medical College"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-12-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-06-16"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | {
"largeDocumentModule": {
"largeDocs": [
{
"date": "2023-05-16",
"filename": "Prot_SAP_000.pdf",
"hasIcf": false,
"hasProtocol": true,
"hasSap": true,
"label": "Study Protocol and Statistical Analysis Plan",
"size": 142077,
"typeAbbrev": "Prot_SAP",
"uploadDate": "2024-03-29T12:12"
},
{
"date": "2023-06-16",
"filename": "ICF_001.pdf",
"hasIcf": true,
"hasProtocol": false,
"hasSap": false,
"label": "Informed Consent Form",
"size": 48384,
"typeAbbrev": "ICF",
"uploadDate": "2024-03-24T04:58"
}
]
}
} |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Labour Induction"
}
]
},
"conditionsModule": {
"conditions": [
"Labor Onset and Length Abnormalities"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Abakaliki",
"contacts": null,
"country": "Nigeria",
"facility": "Alex Ekwueme Federal University Teaching Hospital",
"geoPoint": {
"lat": 6.32485,
"lon": 8.11368
},
"state": "Ebonyi",
"status": null,
"zip": "480001"
},
{
"city": "Abakaliki",
"contacts": null,
"country": "Nigeria",
"facility": "Federal Teaching Hospital, Abakaliki",
"geoPoint": {
"lat": 6.32485,
"lon": 8.11368
},
"state": "Ebonyi",
"status": null,
"zip": "480001"
}
]
},
"descriptionModule": {
"briefSummary": "Intravenous oxytocin titration has a prime position as a choice agent for induction of labour following term PROM as it has been shown to be efficacious for such purpose. Recent evidence however has shown that misoprostol is associated with better outcomes and merits evaluation in our environment. This study compared the efficacy of misoprostol and oxytocin for induction of labour in parturients with term Prelabour Ruptuture of Membranes."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 120,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "44 Years",
"minimumAge": "15 Years",
"sex": "FEMALE",
"stdAges": [
"CHILD",
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Misoprostol Versus Oxytocin for Induction of Labour in Parturients With Spontaneous Rupture of Fetal Membranes at Term",
"nctId": "NCT06343480",
"orgStudyIdInfo": {
"id": "SMVOT2024CT",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Mean induction delivery interval"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER_GOV",
"name": "Federal Teaching Hospital Abakaliki"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2021-11-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2021-08-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2020-09-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Generic Volar Locking Plate"
},
{
"name": "Conventional Volar Locking Plate"
}
]
},
"conditionsModule": {
"conditions": [
"Distal Radius Fractures"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Saint Paul",
"contacts": null,
"country": "United States",
"facility": "Regions Hospital",
"geoPoint": {
"lat": 44.94441,
"lon": -93.09327
},
"state": "Minnesota",
"status": null,
"zip": "55101"
}
]
},
"descriptionModule": {
"briefSummary": "Across orthopedics, the investigators will be using the generic volar locking plates for patients undergoing open reduction and internal fixation (ORIF) of the distal radius using a block schedule, meaning one month we the generic implants and one month we use conventional implants from the surgeon's brand of choice. At the end of each month the health system will switch which type of implants (generic vs. conventional) they will use at their facilities. From a quality perspective each patient will be monitored both short and long term for complication and reoperation. This will be done through chart review."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Surgeons alternated between using generic implants and conventional implants in their distal radius fracture patients over the course of six months.",
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": "Patients underwent the standard surgical consent, however the specific plate vendor that was used, was not specified by the physician.",
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 101,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Do Generic Volar Locking Plates Provide Similar Outcomes at a Reduced Cost?",
"nctId": "NCT06343467",
"orgStudyIdInfo": {
"id": "A17-376",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "90-day reoperation rate"
},
{
"measure": "90-day readmission rate"
},
{
"measure": "90-day mortality rate"
}
],
"secondaryOutcomes": [
{
"measure": "Implant Cost"
},
{
"measure": "Tourniquet Time"
},
{
"measure": "Estimated Blood Loss"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "HealthPartners Institute"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-04-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-04-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-11-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | {
"largeDocumentModule": {
"largeDocs": [
{
"date": "2022-08-16",
"filename": "Prot_SAP_000.pdf",
"hasIcf": false,
"hasProtocol": true,
"hasSap": true,
"label": "Study Protocol and Statistical Analysis Plan",
"size": 218626,
"typeAbbrev": "Prot_SAP",
"uploadDate": "2024-03-14T00:31"
}
]
}
} |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Digital Interocclusal Record In Different Head Positions"
}
]
},
"conditionsModule": {
"conditions": [
"Occlusion"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Ankara",
"contacts": null,
"country": "Turkey",
"facility": "Hacettepe University",
"geoPoint": {
"lat": 39.91987,
"lon": 32.85427
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this clinical trial is to learn about different head position's effect on occlusal contacts during digital interocclusal record. The main question aims to answer is:• Are different head positions in physiological limits can be affected the occlusal contact during interocclusal record? Participants will be asked to stand in three different physiological head positions (neutral, forward and backward) which are common in daily routine. In these positions, after maxillary and mandibular arch scans three different interocclusal records will be taken. Also for assessment of these records in digital occlusal analysis module (oJMA, zebras), three different oJMA record will be taken.Researchers will compare neutral, forward and backward head positions to see if there are any difference in number, density and location of occlusal contacts."
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "DIAGNOSTIC",
"timePerspective": null
},
"enrollmentInfo": {
"count": 36,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The Effect of Different Head Positions on Occlusal Contacts During Digital Interocclusal Bite Registration",
"nctId": "NCT06343454",
"orgStudyIdInfo": {
"id": "2023/04-03(KA-22111)",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Number of Occlusal Contacts"
},
{
"measure": "Density of Occlusal Contacts"
},
{
"measure": "Location of Occlusal Contacts"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Hacettepe University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-03-03"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2024-01-27"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-10-25"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | {
"largeDocumentModule": {
"largeDocs": [
{
"date": "2023-04-17",
"filename": "Prot_SAP_000.pdf",
"hasIcf": false,
"hasProtocol": true,
"hasSap": true,
"label": "Study Protocol and Statistical Analysis Plan",
"size": 212403,
"typeAbbrev": "Prot_SAP",
"uploadDate": "2024-03-29T04:39"
},
{
"date": "2023-04-17",
"filename": "ICF_001.pdf",
"hasIcf": true,
"hasProtocol": false,
"hasSap": false,
"label": "Informed Consent Form",
"size": 97067,
"typeAbbrev": "ICF",
"uploadDate": "2024-03-29T04:39"
}
]
}
} |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "intraoral scan"
},
{
"name": "open tray impression"
}
]
},
"conditionsModule": {
"conditions": [
"Edentulous Jaw"
]
},
"contactsLocationsModule": null,
"descriptionModule": {
"briefSummary": "To compare the accuracy of digital impression and conventional impression for complete-arch implant-supported fixed prosthesis"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 22,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "70 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Accuracy of Two Methods of Making Impressions for Complete-arch Implant Supported Fixed Prosthesis",
"nctId": "NCT06343441",
"orgStudyIdInfo": {
"id": "SH9H-2024-T29-2",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Grade of framework passive fit"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-31"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": null
},
"conditionsModule": {
"conditions": [
"Neuroendocrine Neoplasm"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Milan",
"contacts": [
{
"email": null,
"name": "Francesca Spada, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Italy",
"facility": "European Institute of Oncology",
"geoPoint": {
"lat": 45.46427,
"lon": 9.18951
},
"state": null,
"status": "RECRUITING",
"zip": "20141"
}
]
},
"descriptionModule": {
"briefSummary": "The 2017 World Health Organization (WHO) introduced a new category of high-grade, well-differentiated neuroendocrine neoplasms (NENs) that called neuroendocrine tumors (NETs) G3 in pancreatic NENs classification and, then, in 2019, for all gastro-entero-pancreatic (GEP) tract NENs.The new classification made it possible to separate NETs G3 from high-grade, poorly-differentiated, NENs that are called neuroendocrine carcinomas (NECs).However, in clinical practice, we observed that several clinical, pathological and radiological differences are arising among NET G3 patients, suggesting that a multiparametric definition of NET G3 is needed."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 40,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "TAPIOCA",
"briefTitle": "Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients",
"nctId": "NCT06343428",
"orgStudyIdInfo": {
"id": "IEO 1519",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Immunohistochemical characteristics analysis"
}
],
"secondaryOutcomes": [
{
"measure": "Review of the functional imaging"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "European Institute of Oncology"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-07-19"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-07-19"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2021-07-19"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "GAIT-assisted training"
},
{
"name": "STEP-assisted training"
}
]
},
"conditionsModule": {
"conditions": [
"Traumatic Brain Injury",
"Disorders of Consciousness"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Glostrup",
"contacts": [
{
"email": "[email protected]",
"name": "Christina Kruuse, Professor",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Vibeke Wagner, MSc",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Denmark",
"facility": "Department of brain and spinal cord injury",
"geoPoint": {
"lat": 55.6666,
"lon": 12.40377
},
"state": "Greater Copenhagen",
"status": "RECRUITING",
"zip": "2600"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this randomised cross-over feasibility trial is to investigate two intensive robot-assisted training therapies in the early rehabilitation phase after traumatic brain injury and disorders of consciousness. The main questions it aims to answer are:* Is the protocol feasible concerning inclusion in the study?* Is the protocol feasible concerning protocol completion? Participants will randomly be assigned to either five days of robot-assisted gait training (GAIT), two days of pause, then five days of robot-assisted step training (STEP) or vice versa.The investigators will explore and compare safety events, physiological measures and physical activity levels, behavioural measures, and functional disability outcomes. Further, the investigators report intervention and technical parameters in detail."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "CROSSOVER",
"interventionModelDescription": "AB - BA",
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": "Assessors are blinded to allocation for the following exploratory clinical outcome scales: \"Disability Rating Scale\" and \"Coma Recovery Scale-Revised\".Data analyses are blinded by coding and blinding the groups (groups A and B) for the statistical analyses. After the analysis, two separate conclusions will be written before lifting the blinding and revealing the results.",
"whoMasked": [
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "OTHER",
"timePerspective": null
},
"enrollmentInfo": {
"count": 17,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Robot-assisted Training After Traumatic Brain Injury and Disorders of Consciousness",
"nctId": "NCT06343415",
"orgStudyIdInfo": {
"id": "H-23052844",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Disability Rating Scale (DRS)"
},
{
"measure": "Coma Recovery Scale-Revised (CRS-R) and level of consciousness"
},
{
"measure": "Early Functional Abilities (EFA)"
},
{
"measure": "Functional Independence Measure (FIM)"
},
{
"measure": "Physical activity intensity"
},
{
"measure": "Mean arterial pressure (MAP)"
},
{
"measure": "Heart Rate Variability (HRV)"
},
{
"measure": "Behavioural Outcome"
}
],
"primaryOutcomes": [
{
"measure": "Inclusion Rate"
},
{
"measure": "Completion Ratio of protocols"
}
],
"secondaryOutcomes": [
{
"measure": "Exploratory Safety Outcomes"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Christina Kruuse"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-07-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-17"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-04-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-16"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "BBO-8520"
},
{
"name": "Pembrolizumab"
}
]
},
"conditionsModule": {
"conditions": [
"Non-small Cell Lung Cancer",
"Metastatic Non-Small Cell Lung Cancer",
"NSCLC",
"KRAS G12C",
"Metastatic Lung Cancer",
"Advanced Lung Carcinoma"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Cleveland",
"contacts": null,
"country": "United States",
"facility": "Cleveland Clinic",
"geoPoint": {
"lat": 41.4995,
"lon": -81.69541
},
"state": "Ohio",
"status": "RECRUITING",
"zip": "44195"
},
{
"city": "Nashville",
"contacts": null,
"country": "United States",
"facility": "SCRI Oncology Partners",
"geoPoint": {
"lat": 36.16589,
"lon": -86.78444
},
"state": "Tennessee",
"status": "RECRUITING",
"zip": "37203"
},
{
"city": "Fairfax",
"contacts": null,
"country": "United States",
"facility": "NEXT Oncology",
"geoPoint": {
"lat": 38.84622,
"lon": -77.30637
},
"state": "Virginia",
"status": "RECRUITING",
"zip": "22031"
},
{
"city": "Melbourne",
"contacts": null,
"country": "Australia",
"facility": "Peter MacCallum Cancer Centre",
"geoPoint": {
"lat": -37.814,
"lon": 144.96332
},
"state": "Victoria",
"status": "RECRUITING",
"zip": "3051"
}
]
},
"descriptionModule": {
"briefSummary": "A first in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-8520, a KRAS G12C (ON) inhibitor, single agent and in combination with pembrolizumab in patients with advanced non-small cell lung cancer"
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "SEQUENTIAL",
"interventionModelDescription": "Phase 1a: sequential/parallel, Phase 1b: parallel",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 160,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer",
"nctId": "NCT06343402",
"orgStudyIdInfo": {
"id": "TBBO8520-101",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "TheRas",
"id": "ONKORAS-101",
"link": null,
"type": "OTHER"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Adverse Events"
},
{
"measure": "Dose-limiting toxicities (DLTs)"
}
],
"secondaryOutcomes": [
{
"measure": "To evaluate preliminary antitumor activity of BBO-8520"
},
{
"measure": "To evaluate preliminary antitumor activity of BBO-8520"
},
{
"measure": "Overall Survival (OS)"
},
{
"measure": "To characterize the pharmacokinetics (PK) of BBO-8520"
},
{
"measure": "To characterize the pharmacokinetics (PK) of BBO-8520"
},
{
"measure": "To characterize the pharmacokinetics (PK) of BBO-8520"
},
{
"measure": "To characterize the pharmacokinetics (PK) of BBO-8520"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "TheRas, Inc"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2028-02"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-22"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-08"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "serum creatinine"
}
]
},
"conditionsModule": {
"conditions": [
"Acute Kidney Injury in Patients With Liver Cirrhosis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Sohag",
"contacts": [
{
"email": null,
"name": "Magdy M Amin, professor",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Egypt",
"facility": "Sohag University Hospital",
"geoPoint": {
"lat": 26.55695,
"lon": 31.69478
},
"state": null,
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "In our locality, limited studies have discussed AKI in patients with liver cirrhosis and its outcome, therefore we aim to highlight the incidence, patterns, risk factors, and outcomes of acute kidney injury in patients with liver cirrhosis at Sohag University Hospital."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CONTROL",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 200,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Acute Kidney Injury in Patients With Liver Cirrhosis",
"nctId": "NCT06343389",
"orgStudyIdInfo": {
"id": "Soh-Med-24-03-14MS",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Incidence of acute kidney injury in cirrhotic patients in Sohag University Hospital"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Sohag University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-04"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-10"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Biopsy"
},
{
"name": "Biospecimen Collection"
},
{
"name": "Bone Marrow Aspiration"
},
{
"name": "Bone Marrow Biopsy"
},
{
"name": "Computed Tomography"
},
{
"name": "Cyclophosphamide"
},
{
"name": "Echocardiography"
},
{
"name": "EGFRt/19-28z/IL-12 CAR T-lymphocytes"
},
{
"name": "Fludarabine Phosphate"
},
{
"name": "Leukapheresis"
},
{
"name": "Multigated Acquisition Scan"
},
{
"name": "Positron Emission Tomography"
}
]
},
"conditionsModule": {
"conditions": [
"Recurrent Chronic Lymphocytic Leukemia",
"Recurrent Diffuse Large B-Cell Lymphoma",
"Recurrent Follicular Lymphoma",
"Recurrent High Grade B-Cell Lymphoma",
"Recurrent Mantle Cell Lymphoma",
"Recurrent Transformed Chronic Lymphocytic Leukemia",
"Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",
"Refractory Chronic Lymphocytic Leukemia",
"Refractory Diffuse Large B-Cell Lymphoma",
"Refractory Follicular Lymphoma",
"Refractory High Grade B-Cell Lymphoma",
"Refractory Mantle Cell Lymphoma",
"Refractory Transformed Chronic Lymphocytic Leukemia",
"Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Buffalo",
"contacts": [
{
"email": "[email protected]",
"name": "Francisco J. Hernandez-ILizaliturri",
"phone": "716-845-1642",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Francisco J. Hernandez-ILizaliturri",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Roswell Park Cancer Institute",
"geoPoint": {
"lat": 42.88645,
"lon": -78.87837
},
"state": "New York",
"status": null,
"zip": "14263"
}
]
},
"descriptionModule": {
"briefSummary": "This phase I trial tests the safety, side effects, and best dose of genetically engineered cells called EGFRt/19-28z/IL-12 CAR T cells, and to see how they work in treating patients with hematologic malignancies that makes a protein called CD19 (CD19-positive) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Chimeric Antigen Receptor (CAR) T-cell Therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. To improve the effectiveness of the modified T cells and to help the immune system fight cancer cells better, the modified T cells given in this study will include a gene that makes the T cells produce a cytokine (a molecule involved in signaling within the immune system) called interleukin-12 (IL-12). The researchers think that IL-12 may improve the effectiveness of the modified T cells, and it may also strengthen the immune system to fight cancer. Giving EGFRt/19-28z/IL-12 CAR T cells may be safe and tolerable in treating patients with relapsed or refractory CD19+ hematologic malignancies."
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 36,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies",
"nctId": "NCT06343376",
"orgStudyIdInfo": {
"id": "I-3641523",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "CTRP (Clinical Trial Reporting Program)",
"id": "NCI-2024-01818",
"link": null,
"type": "REGISTRY"
},
{
"domain": "Roswell Park Cancer Institute",
"id": "I-3641523",
"link": null,
"type": "OTHER"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Incidence of adverse events"
},
{
"measure": "Maximal tolerated dose (MTD) of EGFRt/19-28z/IL-12 chimeric antigen receptor T-cells"
}
],
"secondaryOutcomes": [
{
"measure": "Incidence of complete remission (CR)/complete remission with incomplete count recovery (CRi)"
},
{
"measure": "Incidence of CR/CRi + partial response (PR) (ORR)"
},
{
"measure": "Event free survival"
},
{
"measure": "Overall survival"
},
{
"measure": "Progression-free survival"
},
{
"measure": "Modified T-cell persistence"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Roswell Park Cancer Institute"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2029-04-15"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-04-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-15"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Early discharge protocol"
}
]
},
"conditionsModule": {
"conditions": [
"Mitral Regurgitation",
"Tricuspid Regurgitation",
"Mitral Repair",
"Heart Failure"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Oxford",
"contacts": [
{
"email": "[email protected]",
"name": "Sam Dawkins, MBBS MRCP BSc DPhil",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United Kingdom",
"facility": "John Radcliffe Hospital",
"geoPoint": {
"lat": 51.75222,
"lon": -1.25596
},
"state": "Oxfordshire",
"status": "RECRUITING",
"zip": "OX3 9DU"
}
]
},
"descriptionModule": {
"briefSummary": "Mitral regurgitation (MR) and tricuspid regurgitation (TR) are common causes of breathlessness, fluid retention and other heart failure symptoms, which lead to reduced quality of life and frequent hospitalisation. These conditions are particularly prevalent in older adults with many of these patients being at high risk for surgical intervention due to frailty and comorbidities, leaving them with few treatment alternatives.Transcatheter edge-to-edge repair (TEER) procedures have increasingly been used to improve the severity of both MR and TR, offering patients symptomatic relief and reductions in heart failure hospitalisation at low procedural risk. There is considerable geographic variation in protocols to assess these patients prior to the procedure and also in length of hospital stay. The standard of care in the UK, and particularly in Oxford, emphasises fewer investigations before the TEER procedure and shorter length of hospital stay.This prospective, observational cohort study will examine the safety and feasibility of this practice."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 100,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "EARLY-Edge",
"briefTitle": "Early Discharge After Mitral and Tricuspid Edge-to-edge Repair: an Assessment of Feasibility and Safety",
"nctId": "NCT06343363",
"orgStudyIdInfo": {
"id": "318352",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Proportion of patients discharged 'early' after edge -to-edge repair"
},
{
"measure": "All - cause rehospitalisation after completion of procedure"
},
{
"measure": "All cause death after completion of procedure"
}
],
"secondaryOutcomes": [
{
"measure": "Hospital length of stay"
},
{
"measure": "Proportion of patients requiring intensive care unit care"
},
{
"measure": "Safety outcomes a. Major adverse events at the time of the procedure b. Major adverse events (procedure/device related) up to 30 days"
},
{
"measure": "Symptomatic improvement"
},
{
"measure": "Heart failure hospitalisation"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Edwards Lifesciences"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Oxford University Hospitals NHS Trust"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-05"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "OPTDR01 software application"
}
]
},
"conditionsModule": {
"conditions": [
"Diabetic Retinopathy",
"Diabetes"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "San Diego",
"contacts": [
{
"email": "[email protected]",
"name": "Marie Inocentes",
"phone": "619-501-0371",
"phoneExt": "310",
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Precision Research Institute",
"geoPoint": {
"lat": 32.71533,
"lon": -117.15726
},
"state": "California",
"status": null,
"zip": "92114"
}
]
},
"descriptionModule": {
"briefSummary": "In the United States, only 62% of the 37 million people with diabetes receive annual screening exams for diabetic retinopathy. One of the goals of the US Department of Health and Human Services Healthy People 2030 campaign is to increase diabetic retinopathy screening rates to 70.3%. Research indicates that low screening rates are associated with a variety of factors, including income levels, race and lack of access to care. Furthermore, because diabetic retinopathy frequently presents asymptomatically, non-adherence to screening results in postponed disease detection and a higher probability of vision loss. Currently, it is estimated that 9 million adults in the US are affected by diabetic retinopathy, and 1.8 million suffer from vision-threatening diabetic retinopathy. Importantly, the rates of vtDR vary greatly by race, with Hispanic individuals at 7.14% and Black individuals at 8.66%, compared to 3.55% in White individuals. Despite these alarming figures, the disease can be managed and vision loss can often be averted with early disease detection, thus highlighting the importance of increasing screening rates.A clear need exists for a diabetic retinopathy screening tool that can be deployed in primary care settings, addressing the shortage of specialist care and making screening more accessible to underserved populations. OPTDR01 will directly address these issues by providing accessible, high quality screening for diabetic retinopathy. OPTDR01 will automatically detect more than mild diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopathy (vtDR) in diabetic adults who have not previously been diagnosed with mtmDR or vtDR."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_ONLY",
"primaryPurpose": null,
"timePerspective": "CROSS_SECTIONAL"
},
"enrollmentInfo": {
"count": 75,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "22 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "OPTDR01 Feasibility for Automated Diabetic Retinopathy Detection",
"nctId": "NCT06343350",
"orgStudyIdInfo": {
"id": "OPTDR01P",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Enrollment rate of eligible participants at clinical site"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Optain Health"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-12-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-10-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Evaluation of DMFT index, CPI scores, salivary pH and flow rate in pregnant and non-pregnant woman"
}
]
},
"conditionsModule": {
"conditions": [
"Pregnancy Related",
"Dental Caries",
"Periodontal Diseases",
"Saliva Altered"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Mentese",
"contacts": null,
"country": "Turkey",
"facility": "Fatma Yilmaz",
"geoPoint": null,
"state": "Mugla",
"status": null,
"zip": "48000"
}
]
},
"descriptionModule": {
"briefSummary": "The aim of this study was to evaluate the effects of pregnancy on salivary pH, flow rate, caries experience and periodontal status.The main questions it aims to answer are:* Does pregnancy affect caries experience and periodontal status?* Does pregnancy affect salivary pH and flow rate?* Is there a difference between pregnant and non-pregnant woman with respect to caries experience, periodontal status, salivary pH and flow rate?* Is there a difference among first, second and third trimester with respect to caries experience, periodontal status, salivary pH and flow rate?"
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "FACTORIAL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": "The individual who evaluates the salivary pH and flow rate.",
"whoMasked": [
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "DIAGNOSTIC",
"timePerspective": null
},
"enrollmentInfo": {
"count": 198,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "35 Years",
"minimumAge": "18 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The Effects of Pregnancy on Oral Health",
"nctId": "NCT06343337",
"orgStudyIdInfo": {
"id": "MSKUDİSCLİNİCALTRİALS_FYİLMAZ.",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The effects of pregnancy on caries experience"
},
{
"measure": "The effects of pregnancy on periodontal status."
},
{
"measure": "The effects of pregnancy on salivary pH."
},
{
"measure": "The effects of pregnancy on salivary flow rate."
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Muğla Sıtkı Koçman University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-04-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-04-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-05-20"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Web-based education"
}
]
},
"conditionsModule": {
"conditions": [
"Noninvasive Ventilation",
"COPD"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Konya",
"contacts": null,
"country": "Turkey",
"facility": "Health Sciences University Konya Beyhekim Training and Research Hospital",
"geoPoint": {
"lat": 37.87135,
"lon": 32.48464
},
"state": "Selçuklu",
"status": null,
"zip": "42060"
}
]
},
"descriptionModule": {
"briefSummary": "Home use of the NIV device, which is used to manage respiratory failure, one of the most disturbing symptoms due to COPD, will continue to increase. There is a need for studies evaluating the effectiveness of the use of WEB-based training programs in making patients and their families independent in the use of this device. This study will produce evidence for this effect and contribute to the awareness of healthcare professionals working in this field. The WEB-based training module to be developed aims to increase compliance with NIV in patients using NIV at home for a long time and to manage symptoms such as insomnia that may develop due to NIV."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "HEALTH_SERVICES_RESEARCH",
"timePerspective": null
},
"enrollmentInfo": {
"count": 80,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "50 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Effect of Web-Based Adaptation and Insomnia Severity in Individuals Using Noninvasive Ventilators at Home",
"nctId": "NCT06343324",
"orgStudyIdInfo": {
"id": "2023/012",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "insomnia severity index"
},
{
"measure": "Expected behavioral changes in the individual survey"
}
],
"primaryOutcomes": [
{
"measure": "Patient Identifiable Characteristics Form"
}
],
"secondaryOutcomes": [
{
"measure": "S³-NIV Questionnaire"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "KTO Karatay University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-04-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "ENROLLING_BY_INVITATION",
"primaryCompletionDateStruct": {
"date": "2024-02-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-01-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "EB103"
}
]
},
"conditionsModule": {
"conditions": [
"B-Cell Non-Hodgkin's Lymphoma (NHL)",
"Lymphoma, Non-Hodgkins",
"Lymphomas Non-Hodgkin's B-Cell",
"Non-Hodgkin Lymphoma",
"Non-Hodgkin's Lymphoma",
"Large B-Cell Lymphoma",
"Lymphoma, Non-Hodgkin's, Adult",
"Lymphoma",
"Refractory Non-Hodgkin Lymphoma",
"Relapsed Non-Hodgkin Lymphoma",
"Lymphoma, Non-Hodgkin",
"HIV Associated Lymphoma",
"CNS Lymphoma",
"High-grade B-cell Lymphoma",
"Refractory B-Cell Non-Hodgkin Lymphoma"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will include a dose escalation phase followed by an expansion phase."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SEQUENTIAL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 21,
"type": "ESTIMATED"
},
"phases": [
"PHASE1",
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "Starlight-1",
"briefTitle": "T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)",
"nctId": "NCT06343311",
"orgStudyIdInfo": {
"id": "EBUS22CD19AR100",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "To assess the Dose Limiting Toxicities of EB103."
},
{
"measure": "Incidence rates of Treatment-Emergent Adverse Events of EB103."
},
{
"measure": "Incidence rates Treatment-Emergent Laboratory Abnormalities reported for EB103."
},
{
"measure": "To determine the Recommended Phase II Dose (RP2D) of EB103."
}
],
"secondaryOutcomes": [
{
"measure": "To assess the Overall Response Rate of EB103 in our study subject population."
},
{
"measure": "To assess the Disease Control Rate of EB103 in our study subject population."
},
{
"measure": "To assess the Duration of Response of EB103 in our study subject population."
},
{
"measure": "To assess the Progression-Free Survival rate of EB103 in our study subject population."
},
{
"measure": "To assess the Event-Free Survival rate of EB103 in our study subject population."
},
{
"measure": "To assess the Overall Survival rate of EB103 in our study subject population."
},
{
"measure": "To characterize the pharmacokinetic (PK) profile of EB103 by measuring the peak exposure (Cmax)."
},
{
"measure": "To characterize the pharmacokinetic (PK) profile of EB103 by measuring the time to reach peak exposure (Tmax)."
},
{
"measure": "To characterize the pharmacokinetic (PK) profile of EB103 by measuring the partial area under the curve (pAUC)."
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Eureka Therapeutics Inc."
}
],
"leadSponsor": {
"class": "INDUSTRY",
"name": "Estrella Biopharma, Inc."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-18"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-15"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "MANP"
},
{
"name": "Placebo Matched control"
}
]
},
"conditionsModule": {
"conditions": [
"Difficult to Control Hypertension"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 132,
"type": "ESTIMATED"
},
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension",
"nctId": "NCT06343298",
"orgStudyIdInfo": {
"id": "ES_MANP_2001",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Differential Outcomes in African-American Subject versus Non-African American Subjects"
},
{
"measure": "Metabolic biomarkers - Glucose"
},
{
"measure": "Metabolic biomarkers - Insulin"
},
{
"measure": "Metabolic biomarkers - HbA1C"
},
{
"measure": "Lipid biomarkers - HDL"
},
{
"measure": "Lipid biomarkers - LDL"
},
{
"measure": "Lipid biomarkers - TG"
}
],
"primaryOutcomes": [
{
"measure": "Change from baseline in mean daytime SBP derived from 24-hour ABPM at approximately Day 42."
},
{
"measure": "Incidence and severity of Adverse events through 4- weeks post end of treatment."
},
{
"measure": "Incidence and severity of Serious Adverse Events through 4- weeks post end of treatment."
},
{
"measure": "Incidence and severity of Treatment Emergent Adverse Events through 4- weeks post end of treatment."
}
],
"secondaryOutcomes": [
{
"measure": "Change in Clinic sitting systolic blood pressure"
},
{
"measure": "Pharmacokinetics - Cmax"
},
{
"measure": "Pharmacokinetics - Tmax"
},
{
"measure": "Anti-drug Antibody"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Mayo Clinic"
},
{
"name": "PPD"
}
],
"leadSponsor": {
"class": "INDUSTRY",
"name": "E-Star BioTech, LLC"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-08-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-10"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-07-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-07-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Encora Therapeutics Tremor Reduction Device"
}
]
},
"conditionsModule": {
"conditions": [
"Essential Tremor"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Cambridge",
"contacts": [
{
"email": "[email protected]",
"name": "Kristi Winterfeldt, MSHS",
"phone": "763-248-1210",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Taylor Robertson",
"phone": "7814221105",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Kristi Winterfeldt, MSHS",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Fatta Nahab, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Encora Therapeutics",
"geoPoint": {
"lat": 42.3751,
"lon": -71.10561
},
"state": "Massachusetts",
"status": "RECRUITING",
"zip": "02139"
}
]
},
"descriptionModule": {
"briefSummary": "This study is designed to demonstrate the safety and tolerability of the Encora Therapeutics Tremor Mitigation Device in subjects with upper limb tremor caused by Essential Tremor."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "SEQUENTIAL",
"interventionModelDescription": "Three different arms in a randomized order",
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": "Randomization schedule maintained by non-Clinical personnel",
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 30,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "22 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "ULTRE",
"briefTitle": "Upper Limb Tremor Reduction in Essential Tremor Patients",
"nctId": "NCT06343285",
"orgStudyIdInfo": {
"id": "20231215",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "The Essential Tremor Rating Scale (TETRAS) #2.4"
},
{
"measure": "TETRAS #2.6"
},
{
"measure": "TETRAS #2.8"
},
{
"measure": "Patient Global Impression of Severity (PGI-S)"
},
{
"measure": "Clinician Global Impression of Severity (CGI-S)"
},
{
"measure": "Tremor power as measured by accelerometer"
}
],
"primaryOutcomes": [
{
"measure": "Tolerability"
},
{
"measure": "Safety"
}
],
"secondaryOutcomes": [
{
"measure": "Bain & Findley Activity of Daily Living (BF-ADL) #2"
},
{
"measure": "BF-ADL #4"
},
{
"measure": "BF-ADL #17"
},
{
"measure": "BF-ADL #21"
},
{
"measure": "Patient Global Impression of Change (PGI-C)"
},
{
"measure": "Clinician Global Impression of Change (CGI-C)"
},
{
"measure": "Tremor power as measured by gyroscope"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Encora, Inc."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-06"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-05"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-01-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "EAA supplementation"
},
{
"name": "Isocaloric placebo"
}
]
},
"conditionsModule": {
"conditions": [
"Advanced Gastrointestinal Cancers"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Pavia",
"contacts": [
{
"email": "[email protected]",
"name": "Alessandra Ferrari",
"phone": "0382.503689",
"phoneExt": "+39",
"role": "CONTACT"
},
{
"email": null,
"name": "Salvatore Corallo",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Italy",
"facility": "IRCCS Policlinico San Matteo",
"geoPoint": {
"lat": 45.19205,
"lon": 9.15917
},
"state": null,
"status": "RECRUITING",
"zip": "27100"
}
]
},
"descriptionModule": {
"briefSummary": "LEGO is single center double-blind randomized trial aimed at testing the efficacy of an essential ammino acid (EAA) supplementation in improving the absolute count of peripheral lymphocytes and the tolerance to chemotherapy in patients with advanced gastrointestinal malignancies not candidates to immune check-point inhibitors containing regimens."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 54,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Lymphocyte Enhancement in Gastroenteric Oncology",
"nctId": "NCT06343272",
"orgStudyIdInfo": {
"id": "LEGO",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Exit from lymphopenia"
}
],
"secondaryOutcomes": [
{
"measure": "The change in the % of lymphocytes over time"
},
{
"measure": "The proportion of patients with G3-G5 toxicity"
},
{
"measure": "The percentage of chemotherapy dose administered compared to that expected for the patients."
},
{
"measure": "plasma aminoacids composition chang during treatment"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "University of Pavia"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Fondazione IRCCS Policlinico San Matteo di Pavia"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-02-28"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-12-22"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-03-22"
},
"studyFirstPostDateStruct": {
"date": "2024-04-02"
}
}
} | false | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.